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ABSTRACT
Obesity has reached epidemic proportions in recent years. The World Health Organi-
zation estimated in 2008 that 1.4 billion people were overweight of whom 500 million
were obese. Obesity associates with a wide range of conditions, such as cardiovascu-
lar diseases, cancer, diabetes, and neurological disorders, and causes approximately
2.8 million deaths each year. Many studies have established that obesity strongly
impacts the normal function of the immune system: it dysregulates production of
inflammatory and anti-inflammatory cytokines, alters numbers of immune cells, and
causes an overall weaker immune response. Developing therapies that aim to im-
prove the immune response is crucial in order to increase the quality of life of obese
subjects and to reduce their ever-increasing healthcare-related costs.
The long-term objective of this work is to contribute to the development of
therapies that can increase the immune response in obese macrophages. In particular,
v
gene modifications adjusting the response to infection in obese macrophages closer to
that of lean macrophages are desired. To this end, the present work focused on the
Toll-like Receptors (TLRs), which play an essential role in the detection of pathogens
and the initiation of both innate and acquired immune responses.
Genes essential to the transmission of the infection signal were first identified
using a model of the TLR signaling pathways. These genes provided the basis for re-
constructing a gene regulatory network that not only accounts for information coming
from the TLRs, but also regulates key reactions within the pathways. The topology
and regulatory functions of this network were identified by applying novel compu-
tational techniques to time-series gene-expression datasets. The TLR signaling and
gene-regulatory networks were then integrated to develop a modeling framework for
macrophage that predicts the time behavior of several markers for infection. Finally,
formal verification techniques were used to demonstrate that the model satisfies sev-
eral properties characteristic of the response to infection in macrophage. The work
detailed in this dissertation offers a suitable platform for developing and testing bi-
ological hypotheses that aim to improve responses to infection.
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1Chapter 1
Introduction
1.1 Motivation
Excessive consumption of high energy food in conjunction with low physical
activity have resulted in overweight and obesity to reach epidemic proportions in
the recent years. The World Health Organization (WHO) estimated that 1.5 billion
adults were overweight in 2008 [1]. In addition, nearly 43 million children under
the age of five were overweight in 2010. In the United States, obesity is becoming
a major public health issue with approximately two thirds of the population being
overweight of whom half are obese (Fig. 1.1) [2]. The Body Mass Index (BMI) offers a
crude diagnostic tool for obesity. The BMI corresponds to the ratio of an individual’s
weight (in kilograms) by the square of his or her height (in meters). A BMI over 25
kg/m2 or 30 kg/m2 is associated with overweight and obesity, respectively (Tab. 1.1).
Further tests are usually performed to declared obesity.
The increased amount of body fat, or adipose tissue, resulting from obesity has
many detrimental effects on one’s health. Obesity increases the risk factors of type
II diabetes [3], atherosclrosis [4], asthma [5], cancer [6], periodontal disease [7], and
depression [8]. It also accentuates exciting neurological [9], urologic [10], orthopedic
[11], and pulmonary conditions [12].
The primary role of adipose tissue is the storage of body fat. In the recent years,
studies showed that adipocytes, the cells that primarily compose adipose tissue, have
a major endocrine function that affects various metabolic and signaling pathways
2Overweight and obesity among adults  
NOTE: Overweight but not obese is body mass index (BMI) greater than or equal to 25 but less than 30; grade 1 obesity is BMI greater 
than or equal to 30 but less than 35; grade 2 obesity is BMI greater than or equal to 35 but less than 40; grade 3 obesity is BMI greater 
than or equal to 40.  
SOURCE: CDC/NCHS, Health, United States, 2012, Figure 11. Data from the National Health and Nutrition Examination Survey. 
Fig. 1.1: Overweight and obesity trends in the United States. Figure taken
from [2]
Classification BMI (kg/m2)
Underweight < 18.5
Normal range 18.5 - 24.9
Overweight 25 - 29.9
Obese ≥ 30
class I 30 - 34.9
class II (severe obesity) 35 - 39.9
class III (morbid obesity) ≥ 40
Table 1.1: Body Mass Index classification
3[13, 14, 15, 16, 17]. These cells secrete a variety of mediators and cytokines, known
as adipokines, which can notably dysregulate the immune system when produced in
abnormal quantities [13, 18, 19, 17] Many studies have described the effects of obe-
sity on the immune system [20, 21, 18]. The excessive amount of pro-inflammatory
markers produced by adipocytes maintains a chronic inflammatory state in adipose
tissues. The inflammatory process interferes with the normal activation of resident
macrophages into M1 or M2 macrophages, which induces a weaker immune response.
Note that the entire mechanism by which obesity affects the immune response is not
fully understood.
Developing therapies that aim to improve the immune response is crucial in or-
der to increase the quality of life of obese subjects and to reduce their ever-increasing
healthcare-related costs. To this end, we focussed on the Toll-like Receptors (TLRs),
which play an essential role in the detection of pathogens and in the initiation of
both innate and acquired immune responses. Our goal was to use the TLR pathways
to create a framework capable of modeling the response to infection in macrophage.
TLRs are a class of proteins that are part of a bigger family known as Pat-
tern Recognition Receptors (PRRs), and are one of the most evolutionary con-
served group of proteins found in both the animal and plant kingdoms [22]. PRRs
are deeply involved in the immune response by recognizing specific moieties of
Pathogen-Associated Molecular Patterns (PAMPs) from bacterial and viral origins
(e.g. proteins, lipoproteins, or nucleic acids), or Danger-Associated Molecular Pat-
terns (DAMPs) from the host. PRRs can be categorized into two groups: endocytic
PRRs, which enable the endocytosis of pathogens by phagocytes [23], and signaling
PRRs, such as the TLRs, which enable intra- and inter-cellular communication [24].
4Ligand Receptor Localization
Peptidoglycan TLR1, TLR2, TLR6 Plasma membrane
Lipoproteins TLR1, TLR2, TLR6 Plasma membrane
dsDNA TLR3 Intracellular membrane
LPS TLR4 Plasma membrane
Flagellin TLR5 Plasma membrane
ssRNA TLR7, TLR8 Intracellular membrane
unmethylated CpG TLR9 Intracellular membrane
Table 1.2: TLR ligands and their respective receptors
TLRs are composed of three domains: 1) an extracellular domain that contains
a leucine-rich repeat, which enables the receptor to detect and to bind to its specific
ligand; 2) a transmembrane domain specifying the localization of the receptor: the
plasma membrane (TLR1, TLR2, TLR4, TLR5, and TLR6) or intracellular mem-
branes (TLR3, TLR7, TLR8, and TLR9); and 3) an intracellular Toll/IL-1 receptor
(TIR) homologous domain that recruits adaptor proteins, such as MyD88 or TICAM
[25, 26], and initiates a signaling cascade leading to the activation of Transcription
Factors (TFs). Plasma membrane receptors recognize exogenous compounds, such as
proteins, while intracellular membrane receptors bind to nucleic acids (Tab. 1.2). The
host usually fails to detect self RNA and DNA but their recognition can contribute
to autoimmune diseases.
The triggering of the TLRs induces the inflammatory process and adaptive im-
mune response. Reactive Oxygen Species (ROS) and inflammatory cytokines, such
as Il-6 and Tnf-α, help eliminating pathogens. However, an excessive amount of
these molecules may provoke septic shocks and be lethal for the host [27, 28, 29].
The specificity of the immune response depends on which adaptor is recruited by the
TLRs. All adaptors contain a TIR domain that bind to the intracellular domain of
the TLRs. Two main pathways are involved: the MyD88-dependent pathway and the
MyD88-independent pathway. The MyD88-dependent pathway recruits MyD88 and
5induces the production of inflammatory cytokines. The death domain of MyD88 re-
cruits IRAK proteins, which with TRAF6 activates TAK1 and the IKK complex,
hence activating NF-κB. This pathway also leads to the activation of Mitogen-
activated protein kinases (MAPK). TIRAP is another adaptor that function similarly
to MyD88. The MyD88-independent pathway can also lead to activate NF-κB and
MAPK when MyD88 is deficient. The activation is done by recruiting the TRIF
adaptor also called TICAM-1. TLR3 binds directly with TRIF, while TLR4 requires
the help of another adaptor, TICAM-2.
In this dissertation, we first identified genes essential to the transmission of the
infection signal using a stoichiometric model of the TLR signaling pathways, the
ihsTLR v1.0 model [30]. These genes provided the basis for reconstructing a gene
regulatory network that not only accounts for information coming from the TLRs,
but also regulates key reactions within the pathways. We identified the topology
and regulatory functions of this network by applying novel computational techniques
to time-series gene-expression datasets. We then proceeded to integrate the TLR
signaling and gene-regulatory networks to develop a modeling framework for the re-
sponse to infection in macrophage that predicts the time behavior of several markers
for infection. Finally, We applied formal verification techniques to demonstrate that
the model satisfies several properties characteristic of the response to infection in
macrophage. The work detailed in this dissertation offers a suitable platform for
developing and testing biological hypotheses that aim to improve responses to infec-
tion.
61.2 Related Work
Many approaches have focused on integrating transcriptome and proteome data
to stoichiometric models of metabolic pathways. The GIMME algorithm presented
by Becket and Palsson uses transcriptome data (e.g. gene expression levels) to gen-
erate consistency scores, used to determine which reactions are disabled in specific
experimental conditions [31]. Alternatively, the E-Flux algorithm proposed by Col-
ijn et al. sets upper limits to reaction fluxes according to models derived from the
observed data [32]. Shlomi et al. detailed in iMAT a methodology to use transcrip-
tome and proteome data in Mixed Integer Linear Programming (MILP) problems to
construct tissue-specific metabolic networks [33, 34].
Further improvements in modeling biochemical pathways arose by integrating
networks of different origins. Shlomi et al. integrated gene regulatory events in the
form of Boolean rules to produce a more comprehensive model of the metabolic
pathways of Escherichia coli (E. coli) [35]. Goelzer et al. used a similar approach
to reconstruct the genetic- and metabolic-regulatory networks of the central carbon
metabolism of Bacillus subtilis [36]. Covert et al. integrated an Ordinary Differen-
tial Equation (ODE) model of signal transduction pathways to the stoichiometric
model of the E. coli central carbon metabolism [37]. Lee et al. used stoichiometric
modeling to account for signaling pathways in Saccharomyces cerevisiae and pro-
posed a framework for the dynamic modeling of metabolic, signaling, and regulatory
networks [38]. An other approach from Biggs and Papin consisted in integrating
an agent-based model and a stoichiometric model to analyze the formation of Pseu-
domonas aeruginosa biofilms [39].
Integrating experimental data and networks has given rise to networks that are
now specific to various cell types [33, 40, 41, 42, 43], or species [44]. These models
broaden the spectrum of Systems Biology by enabling the analysis of interactions
7between different cells types [45] and species [41].
1.3 Contributions and Challenges
The main contribution of this dissertation is the creation of a modeling frame-
work for the response to infection in macrophage (Fig. 1.2). This task presented
many challenges. The response to infection is a complex biological system that is
affected by many metabolic, signaling, and gene networks. An accurate model must
integrate information from these pathways, which evolves at various time-scales.
The modeling framework, described in Chapter 4, allows for the simulation of
the response to an infection in macrophage (Fig. 1.2). The framework integrates
information coming from the TLR pathways and from a Gene Regulatory Network
(GRN). Briefly, the simulation proceeds as follows. The current state of the gene net-
work (i.e. the expression levels of the genes in the network) determine the constraints
of some of the reactions in the TLR pathways (see Sec. 4.3.2). A flux distribution is
obtained according to these constraints and allows to determine if any TF present in
the TLR model is activated (see Sec. 4.3.1). Active TFs will modify the expression
levels of their respective targets. The model of the GRN is then used to update
gene expression levels (see Sec. 4.2), which will be used at a further iteration of the
framework.
The work presented in this thesis has been used for the publication of five
articles: two pier-reviewed journal publications [46, 47], and three pier-reviewed full
conference publications appearing in the proceedings [48, 49, 50]. An additional
journal publication is also in preparation.
8Fig. 1.2: Overview of the modeling framework. The procedure starts by
initializing the biomass and the concentrations of each external metabolite. At each
iteration, the gene expression levels (or protein expressions) constrain some of the
reactions of the signaling network. The infection signal is then processed by the
updated signaling network, which may activate some TFs. The activated TFs change
the expression of some of the genes in the gene regulatory network. The model of the
regulatory network is then used to update the expression levels of a future iteration.
91.3.1 Time Scale Differences
Signaling and gene-regulatory networks evolve at a different time scale (Fig. 1.2).
Indeed, signaling reactions, as metabolic reactions, are relatively fast (in the order
of milliseconds to seconds) compared to gene dynamics, which typically last in the
order of hours [51, 52].
We modeled each network separately to take into account the time scale differ-
ences. We also employed different classes of models depending of the time scale. We
modeled the signaling pathways using a stoichiometric representation (see Sec. 2.1.1),
which is particularly suitable to model a high number of reactions evolving at a fast
time scale with unknown kinetic rates. We decided to represent the gene-regulatory
network using a piecewise affine (PWA) dynamical system (see Sec. 3.1.2). This type
of models gives good approximations of complex polynomial systems while remaining
simple to construct and to evaluate.
Having separated the signaling and gene networks, we had to define methods
that interfaced the two networks in order to produce a final modeling framework (see
Sec. 4.3).
1.3.2 Stoichiometric Analysis of Mammalian Systems
We used the ihsTLR v1.0 of the TLR signaling pathways [30] as a basis for our
signaling network. Using a model that was already developed was a clear advantage.
In addition, many methods have been implemented to analyze and use stoichiometric
models [53, 54].
The typical approach to obtain a flux distribution from stoichiometric models
is to use Flux Balance Analysis (FBA) (see Sec. 2.1.2). Briefly, the essence of FBA
lies in the definition of an objective function, which is used to solve an optimization
problem. This objective, commonly referred to as the “biomass function”, represents
10
the set of chemical compounds that the cell need to synthesize in order to grow
and divide. This paradigm is largely accepted when studying bacteria, which have
typically evolved to outgrow their competitors as quickly as possible [55, 56, 31].
When dealing with more complex organisms, such as vertebrates and plants,
the usage of the biomass function is, in our opinion, no longer applicable. The
cells’ sole objective is no longer to divide, but heavily depends on the cell type,
developmental stage of the host, and environmental factors. Moreover, defining a
“growth” functions for macrophages is inappropriate since these cells do not divide.
Macrophages, along with the remaining cells involved in the immune system, derive
from the differentiation of cell lines originating from hematopoietic stem cells.
These observations led us to use the ihsTLR v1.0 model in a non-classical way
in order to avoid introducing a bias using an inaccurate objective function in the
FBA problem. In order to obtain the flux distribution necessary for our simulation,
we decided to randomly sample the (convex) space of feasible solution defined by the
TLR model (see Eq. (2.5)).
Many algorithms have been developed to sample convex regions [57, 58], and
have been applied to stoichiometric models [59, 60, 61] (see Sec. 4.1.2). However,
past studies have focused on relatively small networks, and few attempts at opti-
mizing their usage to large-scale models, such as the ihsTLR v1.0 model, have been
published.
1.3.3 Construction of a Gene Regulatory Network
Contrary to the TLR signaling pathways, no GRN involved with the TLR path-
way was available. This led us to reconstruct a custom GRN specifically focussed
towards the regulation these pathways.
Identification of GRNs remains a challenge in the field of Systems Biology.
GRNs have been modeled with Bayesian networks [62, 63], Boolean networks [64],
11
probabilistic Boolean networks [65], and ordinary differential equations [37, 66].
These methods usually rely on an important amount of data that can be time- and
money-wise very expensive to obtain.
The approach we employed, and which was developed by our collaborators, uses
time-series expression data to reconstruct a network topology (see Sec. 3.1.1) [67].
The regulatory interactions are modeled as continuous, nonnegative, and monotonic
(CNM) functions and are obtained as a by-product of the identification procedure
(see Sec. 3.1.2) [68].
The methods detailed in [67, 68] are essentially based on model invalidation,
rather than model identification. The exact procedure to reconstruct a regulatory
network remains open for discussion and we defined in this work new methodologies
to reconstruct accurate gene networks from experimental data.
1.3.4 Algorithmic Efficiency
One of the main challenge of the work presented in this dissertation was the
algorithmic efficiency of the methods we employed (see Sec. 4.5). Many of the meth-
ods we used were previously described and implemented, but few were functional for
large-scale networks. Using the original algorithms would have required months of
computation time. A deep knowledge of the different algorithms was necessary in
order to find ways to improve their efficiency.
The sampling algorithm we employed had only been used for sampling relatively
small networks (in the hundreds of reactions), compared to the ihsTLR v1.0 model
which contains a few thousands reactions. In addition, our framework requires to
sample the feasible space of the signaling network at every iteration of the simulation.
Our simulation framework originally spent about a day per iteration when using the
originally developed sampling algorithm. Some of our simulations containing 120
iterations would have required 4 months of computation before completion, compared
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to the 2 days we currently require. An example of the optimizations we did was
to avoid saving intermediate sample points. This simple change led to reduce the
computation time of a simulation by 10 hours.
In addition, we performed hardware optimizations parallel to software optimiza-
tions. The HyNeSs lab acquired a cluster to reduce the computation time of several
lab projects. Codes could not necessarily run on our cluster without prior modifi-
cations. Many changes were necessary in order to run our code, and to make an
efficient usage of cluster computing.
1.3.5 Organization of the Dissertation
The remainder of this dissertation is organized as follows. First, in Chapter 2,
we describe our analysis of the TLR signaling pathways. Control reactions were
obtained using the concept of Minimal Cut Set (MCS). We studied epistatic inter-
actions between modules of the TLR pathways. We expended the MCS to Essential
Gene Sets (EGSs) to obtain genes controlling essential reactions of these pathways.
In Chapter 3, we detail the construction of a GRN from the control genes we pre-
viously identified. The procedure we employed uses time-series gene-expression data
to identify the topology of a gene network that is consistent with the observed data.
Regulatory functions were generated in order to obtain a mathematical model for the
regulatory network. In Chapter 4, we describe the integration of the signaling and
regulatory networks in order to create a framework modeling the response to infec-
tion in macrophage. We used formal verification techniques to demonstrate that the
framework produces results characteristic of infection responses. In Chapter 5, we
use our framework to model the response to a Porphyromonas gingivalis (P. gingi-
valis) infection. We show that the simulations match experimental observations and
identify properties that the model satisfies. Finally, in Chapter 6, we summarize the
13
work presented in this dissertation and offer concluding remarks and potential future
directions.
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Chapter 2
Analysis of the Toll-Like Receptor
Signaling Pathways
Many studies have established the significant role Toll-like Receptors (TLRs)
play within the immune system: detection of pathogenic particles [69], signal trans-
duction [26], and activation of Transcription Factors (TFs) [70]. For some infections,
recent works have shown that the TLRs provoke deleterious side effects to the host by
increasing cytokine concentrations. They have established that mice deficient in one
of the TLRs had a better response to infection: TLR4−/− for Citrobacter rodentium
[27], TLR2−/− for Porphyromonas gingivalis [29], and TLR3−/− for Phlebovirus [28].
Targeting a TLR enables to decrease cytokine concentrations leading to an increased
survival rate. These results demonstrate that regulating cytokine production may
be a good strategy to improve responses to infections. One has to keep in mind that
the deletion of a TLR has an overall negative effect on the host on the long term.
Polymorphisms in the TLRs significantly increase the susceptibility to opportunistic
infections [71], emphasizing the key role the TLRs play in the immune system. It
is not clear, however, how targeting other components of the TLR pathways can
improve the responses to infections.
The ihsTLR v1.0 model is a stoichiometric representation of the human TLR
signaling pathways that follows six outputs: AP-1, CREB, IRF3, IRF7, Reactive
Oxygen Species (ROS), and NF-κB (Table 2.1) [30]. These compounds play a major
role in the response to infection. AP-1 is involved in proliferation and differentiation,
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Output name Description
AP-1 Binding of the Jun/Fos dimer to the AP-1 site
AP-1(2) Binding of the Jun/Jun dimer to the AP-1 site
CREB Binding of CREB to the CRE site
IRF3 Binding of phosphorylated IRF3 to the ISRE site
IRF7 Binding of phosphorylated IRF7 to the ISRE site
NF-κB Dissociation of the NF-κB/IκBα complex
NF-κB(2) Dissociation of the NF-κB/IκBβ complex
ROS Formation of the NADPH oxidase complex, the p47phox subunit
being phosphorylated three times
ROS(2) Formation of the NADPH oxidase complex, the p47phox subunit
being phosphorylated eight times
Table 2.1: Output reactions of the ihsTLR v1.0 model
and activates both pro- and anti-apoptotic responses [72]. CREB responds to growth
factor signals and regulates cell survival and proliferation [73]. IRF3 and IRF7 are
activated during viral infections and are critical for the activation of Type I IFN [74].
NF-κB plays a role in both innate and adaptive immune responses by regulating B-
and T-cells development, and is involved in the inflammatory response [75]. ROS,
which is the only output not being a TF, are highly reactive chemicals containing
oxygen. ROS regulate signal transduction pathways at small dose, provoke oxidative
damage at high dose, and are actively involved in wound healing processes [76].
Stoichiometric modeling have been extensively used to study metabolic [55, 56,
77, 78, 79, 80, 61, 81, 82, 83, 84, 85, 86, 87, 88, 31, 33, 89, 90, 91, 92, 40, 93, 94,
95, 96, 97, 43] and signaling pathways [51, 52, 38, 30, 98]. Alternatively, signal
transduction pathways have been modeled by Petri nets [99] and Boolean logic [100].
The stoichiometric reaction format has led to the development of various methods,
such as Extreme Pathway (EP) analysis [101], Flux Balance Analysis (FBA) [56], and
computation of Minimal Cut Set (MCS) [102]. An MCS for an objective reaction is a
minimal set of reactions whose knockout disables that function. This notion is helpful
for studying robustness and epistasis relationships in complex networks. FBA can
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easily generate MCS by testing all knockout combinations in a network, however, this
approach becomes computationally challenging for large-scale networks. EP analysis
can bypass this difficulty and has successfully been applied to the Escherichia coli
(E. coli) and human metabolic models [88, 91].
Contributions
In this chapter, we generated MCS for the ihsTLR v1.0 model. We encountered
2,669 MCS showing that each output uses different components of the TLR network.
We partitioned the model in modules, which group reactions having similar functions.
We determined which modules the MCS targeted, allowing to identify epistatic re-
lations between components of the network. It appeared from our analysis that the
TLRs were not the primary targets of the MCS, implying the TLR pathways are
better manipulated by disabling targets downstream of the TLRs. We extended the
MCS to the notion of Essential Gene Sets (EGSs). EGS are sets of genes whose dele-
tion ensures the knockout of an output. We assessed the impact of these deletions
over the network, in term of species, reactions, and modules perturbed. We gener-
ated more than 10,000 EGS for both human and mouse. The EGS provide valuable
information when designing knockout experiments by identifying gene deletions that
have minimal impact on the network. They also identify essential genes that have a
key role in the activation of a particular output of the TLR pathways.
The results in this Chapter were used for the publication of a first author journal
paper [46].
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2.1 Background
2.1.1 Stoichiometric Modeling
A network containing m species and r reactions is modeled by a stoichiometric
matrix, usually denoted as S ∈ Rm×r. Each entry Si,j, i ∈ M, j ∈ R, where M
and R are the sets of all species and reactions, respectively, corresponds to the
stoichiometric coefficient of species i in reaction j. This number is negative for
substrates, and positive for products. A flux value vj is associated to each reaction.
Fluxes represent the flow of biomaterial “flowing” through reactions. The collection
of individual fluxes is denoted as v ∈ Rr. The concentration of the chemical species
in the model is represented as c ∈ Rm. Under the stoichiometric formalism, the
variation in time of species concentrations is given by:
c˙ = Sv. (2.1)
Thermodynamics constraints (e.g. irreversibility, maximum capacity) are modeled
by assigning lower and upper bounds to v:
αj ≤ vj ≤ βj , j ∈ {1, . . . , r}. (2.2)
Recent genome-scale stoichiometric models contains in the order of thousands
of chemical species and reactions [41, 103, 43].
2.1.2 Flux Balance Analysis
FBA is a method commonly used to study stoichiometric models [56, 80, 86, 31].
FBA has the advantage of not requiring kinetic parameters, which are particularly
difficult to obtain experimentally. A simplification of Eq. (2.1) has been proposed
to account for the fact that metabolic and signaling reactions evolve at a much
faster rate than gene dynamics [56, 51, 52]. This simplification, known as the quasi-
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steady state assumption, transforms Eq. (2.1) and defines the conservation of mass
constraints:
Sv = 0. (2.3)
The essence of FBA lies in the definition of a “biomass” reaction (the flux
through this reaction is usually denoted by µ) that models the growth of the cell.
A flux distribution through all the reactions in the network can be easily found by
maximizing µ under the constraint that the fluxes are feasible. Computationally,
this leads to a Linear Programming (LP) problem. The maximal growth assumption
is reasonable in bacteria, where it can be assumed that cells tend to grow as fast
as possible [55, 36]. Biomass functions, and objective functions in general, are hard
to formulate in the case of multicellular organisms where cellular objectives depend
primarily on the cell type.
FBA has been successfully applied to study the metabolic and signaling path-
ways of many organisms and has provided results matching experimental observations
[56, 31].
2.1.3 Minimal Cut Sets
Initially defined for metabolic networks, a cut set for an objective reaction is a
set of reactions whose knockout disables that function [102]. Formally, C is a cut set
for an objective reaction j in model S if and only if vj is producible in the wild type
(i.e. ∃v ∈ K such that vj > 0) and
vC = 0→ vj = 0, ∀v ∈ K, (2.4)
where K is the space of feasible solution (also known as feasible space) of S:
K = {v ∈ Rr|Sv = 0,α ≤ v ≤ β}. (2.5)
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A cut set is considered minimal if none of its subset is a cut set for the objective
(Fig. 2.1). MCS can be generated in a “brute force” way by performing all knockout
combinations and by testing (e.g. using FBA) if the maximum flux through the ob-
jective reaction is zero. This method becomes rapidly infeasible for large networks
and MCS of high cardinality. Alternatively, MCS can be constructed as minimal hit-
ting sets of EPs [102], which are the generators of the polyhedral cone from Eq. (2.5).
A hitting set for an objective reaction j is a set that intersects all j-containing EPs.
This method has previously been employed to study epistasis in the E. coli and
human metabolism [88, 91].
2.2 Identifying Control Reactions
2.2.1 Generating Minimal Cut Sets
As detailed in Sec. 2.1.1, we represent a mass-balanced signaling network in-
volving m species and r reactions with a stoichiometric matrix S ∈ Rm×r. The
stoichiometric matrix comprises the biochemical reactions occurring within the TLR
pathways: receptor/ligand binding, phosphorylation cascades, activation of TFs. We
consider all reactions to be irreversible (i.e. 0 ≤ v ≤ β) by breaking all reversible
reactions into two irreversible ones. The ihsTLR v1.0 model originally comprised
781 species involved in 963 reactions. We extended the model to 1,956 reactions to
account for irreversibility and sink reactions.
Chemical reactions occurring in signaling networks (e.g. phosphorylation, trans-
port, etc) take less than 1 sec, while transcriptional regulation and receptor internal-
ization take on the order of 102 sec [51, 52]. This difference in time scales justifies
the quasi-steady state assumption from Eq. (2.3) and suggested by Li [30], under
which the fast signaling dynamics are assumed in steady state. All 14 inputs I of
the ihsTLR v1.0 model (Table S3 from [30]) were considered active, i.e. vI ≥ 0,
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where vI is the vector of all vj , j ∈ I. The inputs are 11 TLRs (TLR1 through
TLR11), IL1R1, NOD1, and NOD2. Nine output reactions are defined in the model
(Tab. 2.1). An output j is considered producible if and only if
∃v ∈ K s.t. vj > 0, (2.6)
where K is the feasible cone of S, as defined in Eq. (2.5).
We generated MCS using the algorithm detailed by Imielinski and Belta [88].
In summary, to compute MCS for a target reaction j, the algorithm performs three
main steps: (1) generation of EP for an “over-approximation” cone K¯ that includes
the feasible flux cone K, (2) computation of minimal hitting sets for reaction j in K¯,
and (3) reduction of the above sets to minimality. As proved in [88], the sets obtained
at (3) are guaranteed to be MCS for reaction j in K. However, the approach is not
complete, in the sense that it might miss some MCS. The over-approximation flux
cone K¯ of the model yielded 1,598,509 EPs. We computed hitting sets for each
output reaction and reduced them to minimality. We obtained a total of 2,669 MCS
for all outputs (Tab. 2.2). The number of MCS greatly varies across outputs: it
ranges from 6 for NF-κB(2) to 1,042 for IRF7.
2.2.2 Partitioning Reactions into Modules
We grouped the reactions of the ihsTLR v1.0 into distinct modules. Reactions in
the same module generally have the same function or lead to the same end product.
These functions usually consist in activating a specific protein or in transmitting
a stimulus to another part of the network. The modules determine a partition of
the set of all reactions (see Fig. 2.1 for a module partition of a toy network). We
derived 34 modules from the map of the TLR network (Fig. S1 from [30]). This map
clusters biologically related reactions that share substrates or products. Tab. 2.3 and
21
Output MCS Cardinality Signatures Module hit
AP-1 189 1-7 10 7
AP-1(2) 185 1-7 9 7
CREB 510 1-8 18 9
IRF3 22 1-3 6 5
IRF7 1,042 1-8 18 8
NF-κB 351 1-5 10 5
NF-κB(2) 6 1-3 1 1
ROS 138 1-6 21 13
ROS(2) 226 1-5 20 12
Total 2,669 1-8 68 24
Table 2.2: Basic statistics about the MCS. The cardinality of an MCS is defined
as the number of reactions present in the MCS. Its signature corresponds to the list
of modules (cf. Tab. 2.3) that are targeted by the MCS. The table lists the number
of distinct signatures obtained for each output reaction, as well as the total number
of targeted modules.
Appendix A provide the list and a description of the modules hit by MCS. Ten of
the 34 modules are never targeted by any MCS: Akt, Caspase 9, Cytoplasmic MAPK
substrates, FADD, IL-1, IL-1 cascade, IKK, NOD, PKR, and SIGIRR.
Three hypotheses are made. First, reactions in these modules may not be
included in any EP, rendering them “unusable” in a cut set. The analysis of the
partial flux cone shows, however, that the reactions in these modules are present in
at least 1 EP. Second, these modules may not be essential for the activation of the
outputs. Third, too many reactions from these modules may need to be targeted
simultaneously to observe an effect. This last hypothesis reflects a limitation of the
algorithm, which did not detect MCS of more than 8 reactions.
2.2.3 Analysis of Affected Pathways
The mapping of reactions to modules enabled to determine the signature of each
MCS (see Fig. 2.1 for a graphical illustration of this concepts in a small network). The
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Fig. 2.1: Schematic representation of a signaling network. The left part of the
figure shows a toy model of a signaling network. Nodes and edges represent species
and reactions, respectively. The network contains two inputs (top incoming arrows)
and two outputs (bottom outgoing arrows). The set of reactions is partitioned in four
modules (A, B, C, and D). Each crossed reaction belongs to an MCS for output O
(only 4 MCS are shown for simplicity). Each color denotes a different MCS. Targeting
simultaneously the two red-crossed reactions disables O. This MCS describes an
epistatic relation between modules A and B. The upper-right diagram represents the
profile of output O, i.e. the collection of distinct signatures obtained from the MCS.
The profile displays distributions showing the frequency of each signature (top) and
how many times each module is hit by an MCS (right). In our example, the first
signature is obtained twice (red and blue MCS). Module A is hit three times: twice by
the first signature and once by the second one. The lower-right diagram represents
the MCS Module Cardinality (MMC) distribution of O, which shows the number
of MCS targeting i module(s) simultaneously (i = 1, 2). The targeted modules are
color coded in relative proportion. Among all the MCS of cardinality 2, half of the
targeted reactions belong to module A.
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Module Function
AP-1 Binding of AP-1 complex to AP-1 site
Btk Activation of Btk
Calcium dependent cas-
cade
Activation of calcium/calmodulin-dependent protein
kinase
Common metabolites Transport of metabolites into the cytoplasm
CREB Binding of CREB to CRE site
Cytoplasm-Nucleus
transport
Transport of various species into the nucleus
Early endosome Degradation and recycling of receptors
GSK3β Activation of GSK3β
IFN genes Binding of IFN with the ISRE site
KSR1 Activation of the MAPK pathway
Ligands Import of ligands in the system
Lipids Lipids phosphorylation
MAPK Transmission of stimuli
MAP3K7 Transmission of stimuli
MyD88 Transmission of stimuli from the TLRs
NF-κB Dissociation of NF-κB from IκB
NF-κB phosphorylation Activation of NF-κB
PDK1 Activation of PDK1
PKCζ Activation of PKCζ
Rho GTPases Activation of GTPases
ROS production Formation of the NADPH oxidase complex
Thioredoxin Oxidation and reduction of thioredoxin
TICAM Transmission of stimuli from the TLRs and activation
of IRF3
TLR Binding of ligands with the TLRs
Table 2.3: Modules of the TLR network. Function of the modules involved in
the TLR network [30]. Only modules hit by MCS are shown. A short description of
these modules is available in Appendix A.
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signature of an MCS is the list of modules it targets, i.e. the modules containing
reactions hit by the MCS. We obtained one signature per MCS. We were able to
reduce the 2,669 MCS to 68 distinct signatures indicating that most of them target
the same combinations of modules (Tab. 2.2). We define as the profile of an output
the set of distinct signatures obtained for that output. We generated profiles for
each output (Fig. 2.2). In addition to presenting the signatures, the profiles display
distributions showing the number of times each signature is encountered (top) and
how many times each module is hit by an MCS (right). These distributions emphasize
the most frequent signatures and the modules that are targeted the most, respectively
(cf. Fig. 2.1). The AP-1(2) and NF-κB(2) profiles are not shown in Fig. 2.2. The AP-
1(2) profile is identical to the AP-1 one, without the 7-th signature. The NF-κB(2)
profile is composed of only one signature targeting the NF-κB module.
Each reaction in a MCS belongs to a module and some of these reactions may
belong to the same module. Hence, an MCS may target the same module through
different reactions. We define the MMC as the number of modules an MCS hits.
Fig. 2.3 shows the MMC distribution for the outputs. Each distribution describes
how many MCS target n modules simultaneously for a given output (n ≤ 4 for all
MCS). In addition, the colors describe which modules are targeted, as well as their
relative importance. The distributions enable to immediately identify modules that
are targeted alone (e.g. Common metabolites, ROS production, TICAM ) and the
ones that are targeted with other modules (e.g. PDK1 for ROS, Early endosome for
IFR7, or MyD88 for AP-1 and AP-1(2)).
Since the TLRs are the inputs of the TLR network, one would expect that they
control the outputs. Among the 2,669 MCS, only 183 targeted directly one of the
TLRs. Even though the TLRs are critical in the response to infection, it appears that
disabling them is inefficient to accurately control the network’s outcome. Searching
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Fig. 2.2: Profiles obtained for seven of the output reactions: AP-1, CREB, IRF3, IRF7, NF-κB, ROS,
and ROS(2). Each vertical line represents a distinct signature, i.e. the list of modules hit by an MCS. The profiles also
display distributions showing the number of times each signature is encountered (top) and how many times each module
is hit by an MCS (right). These distributions emphasize the most frequent signatures and the modules that are targeted
the most, respectively (cf. Fig. 2.1). Profiles of AP-1(2) and NF-κB(2) are omitted. The AP-1(2) profile is identical to
the AP-1 one, without the 7-th signature. The NF-κB(2) profile is composed of a single signature targeting the NF-κB
module.
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Fig. 2.3: Distributions of the MMC. An MCS may target the same module through different reactions. The MMC
represents the number of distinct modules an MCS hits. The bars in each plot represents the number of MCS targeting
simultaneously n modules (n = {1, 2, 3, 4}). No MCS targets more than 4 modules at a time. The colors describe which
modules are targeted, as well as their relative importance. For n ≥ 2, the distributions do no show which combinations
of modules are hit together (see Fig. 2.2 for this information).
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for targets downstream of the TLRs appears to be a better strategy to efficiently shut
down a desired pathway. This observation may seem contradictory to previous works
showing that the deletion of the TLRs perturbed reactions within these pathways.
These studies, however, analyzed the TLR pathways for specific infections. Here,
the MCS ensure the suppression of an objective regardless of which set of TLRs is
triggered, which makes MCS non-specific to a particular infection. The low frequency
of the TLRs appearing in the MCS may also be due to redundancies in the TLR
pathways, already highlighted by Li et al. [30]. In their study, the authors showed
that some outputs of the TLR network (i.e. NF-κB, CREB, AP-1, and ROS) are
activated by at least 11 different receptors. Hence, knocking out one TLR will not
affect these outputs since the remaining receptors can potentially activate them.
One would need to disable all the TLRs to ensure that the outputs can no longer
be activated. This extreme solution has also the biological disadvantage of disabling
all TLR pathways, making the host highly susceptible to infection. It is difficult to
establish clear consequences of TLR knockouts on the network. We can only perform
this analysis for IRF7. The MCS confirmed that the knockout of TLR7, TLR8, and
TLR9 shuts down IRF7 activation, which disables the transcription of Type I IFN
genes [74], and interferes with the differentiation of monocytes to macrophages [104].
As suggested in [30], metabolites seem to play a crucial role in signal transduc-
tion. Most of the outputs can be disabled by only targeting the Common metabolite
module, which perturbs the normal exchange of metabolites between the extracellu-
lar and cytoplasmic compartments. Interestingly, no other module has such effect,
highlighting the pivotal role of metabolite transfers. In many cases, perturbations of
cytoplasmic transports are associated with the targeting of the Cytoplasm-Nuclear
Transport module (Fig. 2.2). This result emphasizes again the major role metabolites
play in signal transduction pathways. Nonetheless, as the Cytoplasm-Nuclear Trans-
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port module is never targeted on its own, it appears that the most critical reactions
in these pathways occur within the cytoplasm.
2.3 Identifying Control Genes
We define an EGS as a set of genes whose deletion renders a predefined output
non-producible. EGS can be seen as the gene version of MCS. Instead of providing
reactions, EGS procure the list of genes whose knockout stops the production of
an objective, which is a valuable information when designing knockout experiments.
We can clearly disable genes in an EGS (e.g. with siRNA), and the corresponding
objective reaction, unlike reactions in an MCS (Fig. 2.4). Gene knockouts are also
more optimal than reaction knockouts. EGS summarize MCS since a common gene
may be able to disable multiple reactions. Finally, EGS identify essential genes that
have a key role in the activation of a particular output of the TLR model. Even
though genes have much slower dynamics than reactions in the TLR model, we
do not perform any dynamical analysis of these pathways with the EGS. Transient
behaviors of the network do not affect the producibility of the outputs.
2.3.1 Mapping Proteins to Genes
We constructed EGS iteratively for each MCS of all outputs. For each reaction
in an MCS, we first identified combinations of genes whose deletion disabled that
reaction. This was done by searching genes coding for proteins used in that reaction.
We initially had to identify these genes in human and mouse through searches in the
literature and in the Entrez Gene and MGI databases (Appendix B). Similar sets of
rules, usually called Gene-Protein-Reaction (GPR) associations, are present in many
metabolic models [86], but were absent from the ihsTLR v1.0 model.
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The ihsTLR v1.0 model is based on human pathways. The TLRs and their
pathways are however highly conserved across species and especially among verte-
brates [105]. Since human and mouse share 90% of their genome [106], we generated
GPR associations for the two organisms. Moreover, most data translation to human
comes from mouse. We recognize that there are some significant differences between
the human and mouse TLR pathways, notably in the TLR10 pathway [107]. This
particular pathway was however not involved in the MCS we encountered, therefore
limiting the inconsistencies in the mouse results. We were able to assign 341 and 335
genes to 570 and 567 species of the model in human and mouse, respectively (Ap-
pendix B). The discrepancy in the number of relationships and genes is explained by
different numbers of isoenzymes or subunits in both species.
2.3.2 Extension to Essential Gene Sets
Several combinations of genes may exist as different gene deletions can have the
same effect over a reaction. We denote as Gj the set of all combinations for reaction
j. Once we obtained the sets Gj for all reactions in an MCS, we took their Cartesian
product to construct EGS for the corresponding objective reaction. In the example
from Fig. 2.4, deleting A or B stops R1 (G1 = {(A), (B)}) and deleting C stops
R2 (G2 = {(C)}). We obtain EGS for RX by taking the Cartesian product of G1
and G2: EGSRX = {(A,C), (B,C)}. Note that the sets Gj cannot be constructed
for every reaction; at least one of the reaction substrates must be coded by a known
gene. If at least one reaction cannot be disabled by gene deletion than no EGS can
be generated. As MCS, EGS are considered to be minimal, i.e. no subset of an EGS
is itself an EGS. We consider an EGS for a set of outputs as a set of genes whose
deletion renders all the corresponding outputs non-producible.
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Fig. 2.4: Identification of Essential Gene Sets. Species X is produced by two
distinct reactions: R1 and R2. These reactions require proteins P1 and P2 to be
expressed, respectively. The proteins can be used as enzymes or substrates. P1 is a
dimer coded by genes A and B, while P2 is coded by gene C. Species X is no longer
produced if both P1 and P2 are absent. Hence, the deletion of genes A and C, or B
and C renders reaction RX non-producible.
We used the MCS to generate initially 42 and 44 EGS for human and mouse,
respectively. The number of EGS is similar since all the proteins of the network have
homologs in both organisms.
Only AP-1(2) failed to produce EGS targeting specifically this output. This is
easily explained as disabling AP-1(2) requires to knock out the Jun protein. This
protein is however essential for the formation of the Jun/Fos complex (i.e. AP-1,
cf. Tab. 2.1). Hence, EGS found for AP-1(2) hit AP-1 as well. Since the ROS/ROS(2)
and NF-κB/NF-κB(2) outputs are also closely related, many of the EGS for one of
the outputs disable the other one.
Genes in the EGS are part of the MyD88-dependent pathway (e.g. MyD88,
TRAF6, TLR7, TLR8, TLR9), MyD88-independent pathway (e.g. TICAM1, TBK1,
IKK%), and the Mitogen-activated protein kinases (MAPK) pathways (e.g. MAPK8,
MAP2K4, MAP2K7). The initial EGS we computed contain in general a small num-
ber of genes (see Appendix C). Disregarding the evident EGS, most of the remaining
EGS contain no more than 3 genes (∼80%). It is experimentally difficult to knock out
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more than two genes at a time. Even with this limitation, ∼68% of the non-evident
EGS remain experimentally usable.
We used the 42 and 44 initial EGS to generate a second set of EGS capable of
disabling any combination of outputs. Combining the initial EGS gave us a total of
10,377 and 11,577 gene sets targeting any desired set of outputs in human and mouse,
respectively. In addition, we computed the species, reaction, and module impacts of
each EGS, i.e. the number of species, reactions, and modules disabled after deletion
of the EGS. These values estimate the global impact of the EGS. We enumerated the
801 EGS that target the power set of outputs with minimal impact in both species
(Appendix D). The minimal EGS target a specific set of outputs while affecting a
minimum number of species, reactions, and modules.
2.3.3 Validation of Control Genes
We validated the genes in EGS by searching the literature (see Appendix C).
In both species, 16 EGS involved genes directly coding for the outputs and required
no further validation (i.e. “evident” EGS). We were also able to confirm a total of
12 EGS through literature searches. In summary, we were able to find evidence to
validate ∼66% of all EGS.
2.4 Remarks
The TLR network is a complex set of signaling reactions which upon triggering
leads to the activation of various TFs and release of cytokines. These cytokines,
which coordinate the response to infection, also provoke collateral damage when
reaching too high levels. Several studies have shown that the knockout of particular
TLRs were beneficial for hosts undergoing specific infections, as it reduces cytokine
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concentrations [28, 27, 29]. It is not clear, however, how targeting other components
of the TLR pathways can improve the responses to infections.
We studied the ihsTLR v1.0 model [30] and generated 2,669 MCS for all out-
puts of the network. The MCS were organized into 68 distinct signatures, revealing
epistatic relationships in the network (Fig. 2.2 and 2.3). Epistasis was not examined
at the reaction level, but rather at the module level. We focused our attention on the
sub-systems of the network whose joint perturbation disabled an output. Epistatic
relationships reveal the major functions needed to ensure the production of the out-
puts. For example, IRF3 production is shut down by perturbing the transmission of
the stimuli from the TLRs via the TICAM adaptor molecules, while ROS produc-
tion is stopped by disabling the activation of both PDK1 and PKCζ . Fig. 2.3 shows
how the network is being used for each output. Based on the output, different sets
of modules are targeted. This difference in module composition suggests that each
output uses different pathways of the network.
Gene deletions can be performed to ensure the knockout of the outputs of the
TLR network. Adequate combinations of genes, which we provide with the EGS,
enable to target a specific set of outputs. Using the MCS, we generated 10,377 and
11,577 EGS for human and mouse, respectively. Since we considered a human TLR
network, discrepancies may arise in the mouse EGS. This limiting factor is attenuated
as the MCS did not involved any human specific pathway. The EGS identify essential
genes for the activation of the network’s outputs (Appendix D). For example, TBK1
and IKK% seem to be essential for the activation of IRF3 and IRF7, while PDK1 and
PKCζ appear to be key in the production of ROS.
To the best of our knowledge, this study is the first attempt to use MCS for
studying a signaling network in the form of a stoichiometric model. MCS have
initially been developed for the study of metabolic networks. Their application to
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the E. coli and human metabolic networks have given interesting results [102, 88, 91].
Even though MCS were not intended for signaling networks, their usage on such
networks gives promising results. Indeed, our validation of the EGS (derived from
the MCS) showed that about 80% of them concord with biological observations.
This validation process indicates that the usage of MCS on the ihsTLR v1.0 model
provides results that are biologically relevant.
Li et al. defined DIOS pathways based on a pairing of inputs and outputs [30].
In our study, MCS and EGS are output-specific. However, we can compare the
two approaches based on which output is controlled by the DIOS pathways. By
using FBA, the authors only provided single reactions controlling a pathway. We
analyzed EPs to determine sets of reactions, or MCS, disabling a particular output
and to study epistasic relationship between components of the system. We obtained
MCS containing up to 8 reactions. Obtaining similar results with FBA would be
computationally very expensive for large scale networks, such as the ihsTLR v1.0
model. In addition to control reactions we also provided (sets of) control genes,
i.e. the EGS. In addition, Li et al. focused on single DIOS pathways, while we also
describe gene sets capable of disabling multiple outputs.
We observed similarities with the essential reactions listed in Table S6 from
[30]. Our EGS list that the evident knockout of IRF3 is capable of disabling the
production of this output. IRF3 is also involved in all the essential reactions of the
IRF3 DIOS pathway. A similar results is observed with IRF7. Four out of the 5
essential reactions in the ROS production DIOS pathway are listed in our MCS. Our
EGS list that the knockout of IKKα, IKKβ, and IKKγ disables the NF-κB output.
These genes are the subunits of the IKK complex, which is involved in essential
reactions of the RIP1, NOD1, NOD2, and RIP2/TRIP6/TRAF2 DIOS pathways
(two reactions in each pathway). These 4 DIOS pathways each control NF-κB [30].
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Interestingly, we obtain similar results even after increasing the number of reactions
in the model.
Surprisingly, none of the MCS targeted the IKK module. The NF-κB and NF-
κB(2) outputs can however be disabled by targeting this module, which activates the
IKK complex. IKK is a protein kinase formed of three subunits that phosphorylates
IκB, the inhibitory proteins of NF-κB [108]. Members of the IκB family bind to NF-
κB to form an inactive complex. Two IκB proteins are present in the model: IκBα
and IκBβ, which correspond to the NF-κB and NF-κB(2) outputs, respectively. After
phosphorylation by IKK, the NF-κB/IκB complex rapidly dissociates, leaving NF-
κB free for activation. The phosphorylation of IKK occurs in the model through 11
independent reactions. However, the MCS algorithm failed to generate MCS with
more than 8 reactions, hence being unable to produce some targeting IKK. One can
argue that preventing the phosphorylation of IKK in vivo would require to shut down
at least 11 different reactions each using a different enzymatic complex, which may
not be an easy task. A simpler way to prevent IKK phosphorylation would be to
disable the formation of the complex by knocking out one of its three subunits. This
solution was not detected since the reaction leading to the formation of IKK is absent
from the ihsTLR v1.0 model. Adding this reaction would have certainly provided us
with more MCS for the NF-κB outputs, thus increasing the number of EGS. Being
able to generate MCS of higher cardinality represents an improvement that would
greatly benefit the analysis of stoichiometric reconstructions. However, we would like
to emphasize that MCS already give us access to information other techniques are
unable to provide.
An additional limitation arises from the ihsTLR v1.0 model itself. This model
is derived from the map of the TLR pathways developed by Oda and Kitano [30,
109]. However, this map does not exhaustively describe the pathways present in the
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immune system. Consequently, some crosstalk pathways, which may be affecting the
producibility of the network’s outputs, are potentially missing from the ihsTLR v1.0
model. Some EGS found from our computational results may prove to be irrelevant in
vivo due to these missing components. Moreover, since the model is human centered,
the mouse results must be interpreted with additional caution, although most of the
TLR pathways are conserved between human and mouse. Finally, a non-uniform
gene nomenclature makes it difficult to exhaustively construct the GPR associations.
We also want to emphasize that transient behaviors of the network do not affect the
producibility of the outputs.
A valuable piece of information that we provide along with the EGS is the impact
they have. In metabolic networks, the lethality of a gene deletion can be assessed by
checking whether it disables the production of a biomass component. The ihsTLR
v1.0 model does not include such an objective function. Moreover, this approach is
relevant for the study of unicellular organisms, but for more complex organisms, the
producibility of the biomass is only necessary, but not sufficient for survival. This
motivated us to compute several estimates for the impact of the deletion of an EGS:
the species, reaction, and module impacts (Appendix D). We define these impacts
as the number of species, reactions, and modules, respectively, that are no longer
producible or affected upon deletion of all the genes in an EGS. The three estimates
allow us to evaluate the global impact of gene deletions. We determined which EGS
have the “minimal” impact on the network based on the three impact values. Among
all the EGS that knock out the same set of outputs, we first identified the ones that
disabled either the minimum number of species (i.e. Es), reaction (i.e. Er), or module
(i.e. Em). Then, taking the intersection Es∩Er ∩Em gave us the EGS with minimal
impact. If this intersection is empty then no “minimal” EGS can be found. Species,
reaction, and module impacts were computed for every EGS to identify which ones
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had a minimal impact of the network. These EGS target a specific set of outputs while
affecting the minimum number of species, reactions, and modules. We enumerated
801 EGS that targeted the power set of outputs with minimal impact, in both human
and mouse (Appendix D). Note that a minimal impact does not guarantee that the
knockout will not be lethal for the cell. Linking the TLR network with a metabolic
network could provide an answer to such a question. The integration of multiple
systems is an efficient way to improve biological predictions of computational models
[35, 38, 37].
Searching essential reactions or genes (i.e. MCS or EGS) for an objective has
two applications. Firstly, this information can be used to disable the objective.
Secondly, it can identify key elements to maintain in order to conserve the objective.
Given the current literature, we can conjecture on the effect of disabling any of the
outputs of the TLR network. NF-κB is involved in a multitude of cellular processes:
inflammation, T- and B-cells development, hematopoeitic cells survival, nitric oxide
regulation, and lymphoid organogenesis [75]. Moreover, NF-κB is involved in the
activation of other TFs present in the network. Hence, knocking out NF-κB may
provoke serious repercussions on the host. In this case, the EGS identify deletions
to avoid at all cost, or sets of genes that should not be targeted simultaneously in
order to preserve the activity of NF-κB. The knockout of AP-1 dysregulates cell-cycle
and proliferation, and interferes with lymphoid cells development [72]. Here again,
disabling AP-1 risks to provoke some unwanted consequences such as oncogenesis.
Among all the outputs, ROS may be the one whose disabling causes the least side
effects as it is the only one that is not a TF. As a matter of fact, the oxidative
burst generated by ROS provokes collateral damage to the host by itself [76]. Hence,
blocking the formation of the NADPH oxidase complex would protect the organism
from such damage, while depriving it of the positive effects of the burst.
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Chapter 3
Reconstruction of a Regulatory Gene
Network
Gene regulatory network identification is one of the main challenges in Systems
Biology and is related to the problem of identifying how a group of genes interact
based on their expression activities [110, 111]. As gene regulatory networks play a
fundamental role in the regulation of biological processes, gene network identification,
also termed reverse engineering, is a crucial step in understanding these processes.
Identification of Gene Regulatory Networks (GRNs) is a difficult problem for the
following reasons: 1) the size of the network can be very large; 2) The measurements
are noisy; 3) although it is possible to have a large quantity of data (genome-wide)
for each snapshot, the number of snapshots is typically small. This is because ob-
taining a large number of snapshots is highly impractical, due to logistical and cost
considerations; and 4) the dynamics of the GRNs are highly nonlinear.
There are several families of methods for identification of GRNs from gene
expression data [112]. Within the systems and control community, identification of
GRNs is usually done by modeling networks as dynamical systems [113].
For certain model structures (e.g. linear systems), with the availability of gene
expression measurements, the network can in principle be reconstructed by inverting
the data. However, as the measurements are noisy, the reconstructed network tends
to be populated with spurious interconnections (i.e. false positives). This concern
motivates sparse identification that aims at getting a network model with as few
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connections as possible without losing the fitness to the data [110, 114, 115]. Identi-
fication of GRNs in general and sparse identification of GRNs in particular are quite
active research areas. For example, de Jong et al. developed a method for identifi-
cation of GRNs using the structure of piecewise affine dynamical systems [116, 117].
Papachristodoulou et al. developed a model for identification of sparse networks us-
ing Hill functions to describe the dynamics of gene-gene interactions [118]. Work
by Julius et al. aimed at identifying sparse networks based on genetic perturba-
tion data, assuming that the dynamics can be described (locally) as a linear system
[119, 120, 121]. Recent work by Yuan et al. [122, 123] investigated handling sparsity
by using Akaike information criterion. A different approach was taken by Chang and
Tomlin [124], where compressive sensing is used to identify a sparse linear model.
Contrary to the Toll-like Receptor (TLR) signaling network used in Chapter 2,
no GRN regulating these pathways was available. We thus proceeded to the con-
struction of a custom network involved in the regulation of the TLR pathways. This
reconstruction is based on the tool developed by our collaborators and described in
[67] and [68] (see Sec. 3.1.1). Briefly, a regulation hypothesis H is formed by defining
the set of regulators for a target gene g. Regulators can either activate or repress
their target gene g. The regulation hypothesis is evaluated by testing the feasibil-
ity of a Linear Programming (LP) problem (see [68]). In practice, this is done by
solving the Quadratic Programming (QP) problem in Eq. (3.7), which returns an
error ε describing how well the input data explains the hypothesis defined in H. By
checking all possible regulation hypotheses, one can select the hypothesis returning
the minimum error.
Testing the entire set of regulation hypotheses formed by all mouse genes is how-
ever computationally impractical (see Fig. 3.1 for numbers of regulation hypotheses
according to the number of candidate genes). First, every gene has to be tested as an
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Agonist
Associated
TLR
Description
PAM3CSK4 (PAM) TLR2 synthetic mimic of bacterial lipopeptides
polyinosine-polycytidylic
acid (poly(I:C))
TLR3 viral-like double-stranded RNA
lipopolysaccharide (LPS) TLR4
purified component from Gram-negative
Escherichia coli
gardiquimod TLR7 small-molecule
CpG TLR9 synthetic single-stranded DNA
Table 3.1: TLR agonists used by Amit et al. , 2009. Each agonist triggers a
specific TLR and was used to initiate an immune response in mouse immune cells
[125].
activator and a repressor, essentially doubling the number of regulators. Second, the
number of regulation hypotheses grows exponentially with the number of regulators
considered in each hypothesis. To solve this problem, we limited ourselves to regu-
lation hypotheses containing a maximum of 3 regulators. In addition, we selected a
subset of genes from mouse that were used in our procedure. The genes we identified
in Chapter 2, namely the genes involved in the Essential Gene Sets (EGSs), provided
the basis for reconstructing a GRN.
The data we used in conjunction with the reconstruction algorithm consists of
gene expression levels published by Amit et al. [125]. This dataset contains the time
course expression levels of genes from mouse immune cells. These cells were exposed
to five different TLRs agonists, each triggering a specific TLR, yielding five distinct
time series. The list of agonists used for each experiment is detailed in Tab. 3.1.
Contributions
In this Chapter, we present the reconstruction of a GRN containing 131 genes
involved in the TLR pathways. We started the procedure by defining sets of 258
candidates genes. The control genes we identified in Chapter 2 provided the basis for
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Fig. 3.1: Number of regulation hypotheses. The number of regulation hypothe-
ses grows exponentially with the number of candidate genes used to form regulation
hypotheses and with the number of regulators in each hypothesis.
this reconstruction. Using the identification tools detailed in [67, 68] with time series
expression data published in [125], we defined a methodology to identify a candidate
network topology among all possible ones. Our identification procedure uses a par-
simonious approach where the simplest regulatory interactions are tested first. We
then proceeded to generate regulatory functions for each of the genes present in the
network using the experimental data. We propose two procedures that aim at opti-
mizing the regulatory functions obtained after the topology identification. The first
method refines the domains of the regulatory functions, while the second technique
uses a gradient descent method to explore the space of regulatory functions. We val-
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idated the network model we obtained by verifying that simulated and experimental
gene trajectories were comparable.
The results in this Chapter were used for the publication of two pier-reviewed
full conference papers (one first author paper) [48, 50].
3.1 Background
3.1.1 Identifying a Network Topology
Assume that the GRN we are working with consists of a set of genes G. The
dynamics of the gene expression xg of every gene g ∈ G are modeled as the following
discrete-time model:
xg(n + 1)− xg(n) = −λgxg(n) + fg
(
xg1(n), . . . , x
g
Rg(n)
)
, ∀g ∈ G, (3.1)
where λg ≥ 0 is the decay parameter of gene g (degradation component), fg is the
regulatory function of gene g (production component), and xg1(n), . . . , x
g
Rg(n) are
the expression activities of the Rg regulatory genes of g at time n. To simplify the
notations, the regulatory set of gene g is defined asGRg ! {x
g
1, . . . , x
g
Rg}. The problem
of identifying a GRN summarizes to identifying λg, GRg , and fg for each gene g ∈ G
from experimental data.
The procedure detailed in [67, 68] uses time-series gene-expression data to re-
construct a GRN. If the data is composed of N time points, then the time differential
expression qg,n of gene g is defined as:
qg,n ! xg,n+1 − xg,n, ∀n ∈ {1, . . . , N − 1}. (3.2)
Therefore, for the data to fit the model, the following relation must hold:
qg,n = −λgxg,n + fg(x
g
1,n, . . . , x
g
Rg ,n). (3.3)
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The only assumption made over the regulatory function is that they must be
in the form of a continuous, nonnegative, and monotonic (CNM) function. These
assumptions are very general and can model any type of regulatory function [67, 68].
Requiring monotonicity is in line with the fact that most, if not all, known mathe-
matical models for gene regulation use monotonic functions. If fg is monotonically
increasing or decreasing in xgk, then the k-th regulator of gene g is considered an
activator or repressor, respectively. The set of regulators GRg can be split into two
disjoint sets:
GRg = G
R+
g ∪G
R−
g , (3.4)
where GR+g and G
R−
g are the sets of activators and repressors of g, respectively.
A regulation hypothesis Hg for gene g states that GRg := G
R+
g ∪G
R−
g is the set
of regulators of g. Given a regulation hypothesis Hg = (GR+g , G
R−
g ), the vector of
expression levels of all regulatory genes at time n is denoted xgR,n. The vectors of
expression levels of all activators and repressors are denoted xg+,n and x
g
−,n, respec-
tively.
The regulation hypothesis Hg is equivalent to the existence of some λg ≥ 0, and
a CNM function fg(,, ◦) that is monotonically increasing in the variables in , and
monotonically decreasing in the variables in ◦, such that
qg,n = −λgxg,n + fg(x
g
+,n, x
g
−,n), ∀n ∈ {0, . . . , N − 1}. (3.5)
The validity of the regulation hypothesis Hg is equivalent to the feasibility of a LP
problem involving xgR,n, ∀n ∈ {0, . . . , N − 1} and xg,n, ∀n ∈ {1, . . . , N} (see [68] for
the exact formulation of this LP).
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Given a regulation hypothesis Hg = (GR+g , G
R−
g ), the partial ordering
.Hg ⊂ R
|GRg | × R|G
R
g | is defined as:
xgR,n .Hg x
g
R,k :⇔


xg+,n ≤ x
g
+,k
xg−,n ≥ x
g
−,k
(3.6)
SHg := {(n, k) ∈ {0, . . . , N − 1}
2 | xgR,n .Hg x
g
R,k}.
In addition to formulating the necessary and sufficient conditions for the validity
of the regulation hypothesis, a QP optimization problem is defined to quantify how
far the data is from satisfying the regulation hypothesis Hg. The Frobenius norm of
εg (denoted as ‖εg‖F below) quantifies this distance:
min ‖εg‖F subject to (3.7)
qg,n = −λgxg,n + qˆg,n + εg,n, ∀n ∈ {0, . . . , N − 1},
λg ≥ 0,
qˆg,n ≥ 0, ∀n ∈ {0, . . . , N − 1},
qˆg,n ≥ qˆg,k, ∀(n, k) ∈ SHg ,
with λg, εg,n, and qˆg,n, n ∈ {0, . . . , N − 1} as the optimization variables.
In theory, ‖εg‖F = 0 if and only if the regulation hypothesis Hg is valid [68].
In practice, ‖εg‖F > 0 because of measurement noise and/or unmodelled external
variables in the network. A regulation hypothesis Hg is accepted if ‖εg‖F is small
enough, or if it is the smallest among competing hypotheses.
The exact procedure for reconstructing a regulatory network remains open for
discussion and we define in this work new methodologies to identify candidate net-
work topologies from experimental data.
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3.1.2 Constructing Regulatory Functions
Once a regulation hypothesis Hg is accepted with ‖εg‖F small enough, a reg-
ulatory function fg can be constructed by interpolating the solution qˆg,n from the
optimization problem given in Eq. (3.7) [68]. There is not a unique way to do this,
and Cooper et al. presented a multi-affine interpolation technique for this purpose
[68].
Suppose that we form a candidate network of G genes by proposing the reg-
ulation hypotheses H1, . . . ,HG. That is, we define the (graph of the) network by
specifying the regulators for each gene. Following the reasoning for individual genes
above, this set of hypotheses is valid if and only if there exist:
(C1) A regulation function F = (f1, f2, . . . , fG) that is continuous, non-negative,
and monotonic in the sense that is required by the regulation hypothesis. That is
if the regulation hypotheses state that the k-th regulator is an activator of gene g,
then fg is monotonically increasing w.r.t. x
g
k, etc.
(C2) Some non-negative λ1, . . . ,λG, such that for all g ∈ {1, . . . , G} and n ∈
{0, . . . , N − 1}:
qg,n ! xg,n+1 − xg,n = −λgxg,n + fg
(
xg1,n, . . . , x
g
G,n
)
. (3.8)
3.2 Selecting Genes of Interest
Testing the entire set of regulation hypotheses formed by all mouse genes is
computationally impractical (Fig. 3.1). We started our network identification proce-
dure by defining sets of candidate genes. Keeping in mind that the GRN we wished
to construct had to include 1) genes regulated by the output Transcription Factors
(TFs) of the ihsTLR v1.0 model and 2) genes controlling the TLR pathways, we
defined candidates genes by following two approaches. First, we manually defined a
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Core Set (CS) of genes from the control genes identified in Chapter 2 and by con-
sidering marker genes for infections (i.e. genes allowing us to follow the state of the
infection response). Second, we defined Predicted Sets (PSs) of genes based on au-
tomated searches through bioinformatics databases. The idea behind the definition
of these two sets is that genes in CS will be included in the GRN, and that genes in
PS will be added only if they allow the identification of new regulatory interactions.
3.2.1 Manual Selection
We defined as CS the set of genes that have to be included in the GRN. This
set contains some of the control genes we identified in Chapter 2. In addition to
the control genes, we included marker genes for infection: Tnf-α, Il-1β, Il-6, Ccl4,
and Ccr2. These genes are typically used to follow the progression of responses to
infection [126, 127]. CS contained 28 genes in total (see Appendix E for the list of
genes).
3.2.2 Automated Selection
In addition to CS, we defined PS as a set of genes that can potentially be
included in the GRN. Contrary to the genes in CS, genes in PS are added only if
they are involved in a regulation hypothesis. This allowed to extend the set of genes
in the network, without crowding it with unnecessary genes. In addition, we defined
several PS sets in order to extend the network starting from genes that are most
likely involved with the TLR pathways.
PS sets were obtained by searching the Gene Ontology (GO) database [128].
This database gathers manually curated annotations of gene products known as GO
terms. GO terms describe broad categories, from precise information about protein
localization or domains, to more general knowledge about biological activities and
involved pathways.
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We defined two PS sets, namely PS1 and PS2, composed of genes that contained
“Toll-like” or “immune” in at least one of their GO terms, respectively. We decided
to define two groups of genes in order to separate genes that are “very likely” to
interact with the TLRs pathways (i.e. PS1), from genes with less defined connections
to these pathways (i.e. PS2). Our analysis of the GO database yielded 27 and 170
genes belonging to PS1 and PS2, respectively (see Appendix E).
3.3 Identifying the Topology of a TLR-Regulating Network
The identification algorithm from [67, 68] and described in Sec. 3.1.1 uses time
course expression data to identify a set of regulatory genes that regulates the expres-
sion level of a target gene. We denote the mapping of a set of regulatory genes to
a target gene g as a regulation hypothesis. Regulation hypotheses are accepted or
rejected by testing the feasibility of a LP problem that tests whether a discrete time
model of the following form can be constructed from the data:
xˆg(n+ 1) = xˆg(n) + fg(Rg(n))− λgxˆg(n), (3.9)
where Rg(n) is the expression levels at time n of the regulators of gene g, fg is the
regulatory function of g, modeled as a piecewise affine (PWA) function, and λg is
the decay rate of g. In practice, the QP problem defined in Eq. (3.7) is solved and
returns the error εg between the inferred time course and the experimental data. A
regulatory set can be obtained by solving this QP problem for every combination of
genes, and keeping the hypothesis with the smallest error.
We addressed the problem of identifying the best regulation hypothesis using a
parsimonious approach. For each gene in CS, we first tested regulation hypotheses
formed by a single gene in CS. If none were accepted, we then proceeded to test all
hypotheses formed by pairs of genes in CS, and then triplets of genes in CS. We did
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not test any regulation hypothesis formed by more than three genes in an attempt to
limit the computation time. If we tested and rejected all hypotheses using only genes
in CS, we then proceeded to test regulation hypotheses formed by genes in {CS ∪
PS1}, again starting with hypotheses containing first one, then two, and finally three
genes. If no hypothesis was accepted, we then formed regulation hypotheses using
genes in {CS ∪ PS1∪ PS2}. Genes from PS1 or PS2 that are part of a regulation
hypothesis were included in the GRN. Similarly, we attempted to identify the best
regulation hypothesis for these genes. Defining several PS sets allows to first test
genes that likely interact with the TLR pathways (i.e. with “Toll-like” in their GO
term). If no regulation hypothesis was accepted then genes with a looser connection
(i.e. with “immune” in their GO term) were considered.
We proposed two methods to identify the best regulation hypothesis for a target
gene: 1) by using a single time-series gene expression dataset (Sec. 3.3.1) and 2) by
using multiple time-series gene expression datasets (Sec. 3.3.2).
3.3.1 Using Time-Series Gene Expression Data
The basis for identifying the topology of a regulatory network is to determine
the set of regulatory genes (or regulation hypothesis) that control the expression of
each gene in the network. The method we developed to identify the best regulation
hypothesis is described in Alg. 1. Briefly, this algorithm attempts to identify a
regulatory set GRg for a target gene g. The set G
R
g contains at most rmax genes, all
taken from a set of candidate genes GR. The algorithm uses Eq. (3.9) and a time
series expression dataset D to identify potential regulatory sets.
An initial set of regulation hypotheses H is obtained by generating all combi-
nations of nReg genes in GR(line 6) (nReg ≤ 3 in practice). Each gene can be used
as an activator or a repressor. Some of these regulation hypotheses are irrefutable
(line 7) (see [67] for more details) or have been tested during a previous iteration of
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Algorithm 1 Regulatory Set Identification
Input: Maximum number of regulatory genes rmax,
target gene g,
set of candidate regulatory genes GR ⊂ G,
dataset D,
maximum error εthres
Output: Regulation hypothesis Rg,
Regulatory set GRg
1: nReg = 0
2: Missing = True
3: GRg = ∅
4: while nReg ≤ rmax and Missing do
5: nReg = nReg + 1
6: H = regulation hypotheses with nReg regulators taken from GR targeting g
7: Hg = irrefutable hypotheses in H
8: HT = hypotheses in H that have already been tested
9: H = H\(Hg ∪HT )
10: for all regulation hypothesis Hk ∈ H do
11: Obtain εk by solving Eq. (3.7) using data D
12: if εk > εthres then
13: H = H\Hk
14: end if
15: end for
16: if H 4= ∅ then
17: Retrieve the hypothesis Rg ∈ H with smallest error εmin
18: GRg = genes in Rg
19: Missing = False;
20: end if
21: end while
22: return Rg, GRg
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the identification procedure (line 8) and are removed from H (line 9). The remaining
hypotheses are each tested with Eq. (3.7) (line 11), which returns an error εk for each
hypothesis Hk. If this error is bigger than the input maximum tolerated error εthres
(line 12), then the current hypothesis is removed from H (line 13). After testing all
regulation hypotheses, the algorithm checks whether the set H is empty or not. If H
is empty, then the next family of regulation hypotheses are tested, i.e. the ones with
nReg+1 regulators. If H is not empty, then the algorithm searches for the hypothesis
with the smallest error (line 17) and retrieves the genes forming it (line 18). The
algorithm works in a incremental procedure in order to save computation time. Reg-
ulatory sets containing one gene are tested first. If all hypotheses are rejected, then
the algorithm proceed to test regulatory sets containing two genes, then three genes.
The algorithm stops when all sets of rmax genes have been tested or if a regulatory
set has been identified (line 4).
This identification of regulatory set is iteratively used over each gene in the
network to reconstruct the topology of the GRN. The procedure is described in
Alg. 2. The algorithm takes as input rmax, the maximum number of regulatory
genes used to form a regulation hypothesis, G, the set of genes considered for the
reconstruction (this set can be divided into separate groups Gk, k ∈ {0, . . . ,Gmax}),
D, the dataset used for the reconstruction, and εthres, the maximum error allowed
for a regulation hypothesis. The algorithm starts by including in the network all
the genes in G0 (G0 = CS in practice) (line 1). The algorithm will run until a set
of regulatory genes has been identified for every gene in the network (line 2). Until
then, it selects a random gene for which regulators are missing and attempts to
identify a regulatory set for this gene (line 3). This is done by first defining the set
GR of genes to consider as candidate regulators. Candidate genes are taken from the
Gk sets where k ∈ {0, . . . , nset} (line 7). nset is initially set to 0 (line 4). GR, the
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Algorithm 2 Network Reconstruction
Input: Maximum number of regulatory genes rmax,
genes G =
⋃Gmax
k=0 Gk,
dataset D,
maximum error εthres
Output: Gene network with genes in GN ,
topology T ,
regulation function fg, ∀g ∈ GN
1: GN = G0
2: while regulation function missing for at least one gene do
3: Select a gene g ∈ GN with missing regulatory function
4: nset = 0
5: Missing = 1
6: while nset ≤ Gmax or Missing do
7: GR =
⋃nset
k=0 Gk
8: Try to identify a regulation hypothesis Rg and regulatory set GRg using Alg. 1
with:
- maximum number of regulatory genes rmax
- target gene g
- set of candidate regulatory genes GR
- dataset D
- maximum error εthres
9: if regulatory set GRg 4= ∅ then
10: Generate a regulation function fg compatible with Rg
11: Missing = 0
12: end if
13: nset = nset + 1
14: end while
15: GN = GN ∪GRg
16: end while
17: return GN , topology T , and individual regulation functions fg, g ∈ GN
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target gene g, the data D, rmax, and εthres are used as inputs for Alg. 1 (line 8). If
a regulatory set GRg is found (line 9), then a regulatory function is generated such
that it complies with the accepted hypothesis (line 10). If no set has been identified
(i.e. GRg = ∅), then the algorithm tries to identify regulatory genes using the sets Gk
where k ∈ {0, . . . , nset + 1} (line 13). This search ends when all sets Gk have been
used or if a regulation hypothesis have been found (line 6). Genes in GRg are included
in the network (line 15). At the end of the reconstruction procedure, the algorithm
returns a GRN composed of genes in GN , a topology T , and regulatory functions fg
for all genes g in GN (line 17).
3.3.2 Using Multiple Time-Series Gene Expression Datasets
We propose here to identify a regulatory interaction using more than one time-
series expression dataset. An interaction that is independently accepted by multiple
datasets will have its overall confidence increased. Most of the procedure detailed in
Alg. 2 remains unchanged. The main change lies in the method used to identify the
best regulation hypothesis. We used here Alg. 3 instead of Alg. 1. This algorithm
tests each regulation hypothesis against all available datasets and searches for the
hypothesis that consistently has a small error. We used all five datasets present in the
study from Amit et al. [125]. In general, we rejected an hypothesis whose returned
errors were high in at least three of the five datasets.
Alg. 3 requires the same inputs as Alg. 1 (i.e. maximum number of regulators
rmax, target gene g, set of candidate regulators GR, and maximum error tolerated
εthres) in addition to d datasets Dj, j ∈ {1, . . . , d}, and dmin, the minimum number of
datasets required to accept an hypothesis. Lines 1 through 10 in Alg. 3 are identical
to the ones from Alg. 1. The main difference between the two algorithms lies in the
fact that in Alg. 3 each regulation hypothesis Hk ∈ H is tested using several datasets
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Algorithm 3 Regulatory Set Identification with Multiple Datasets
Input: Maximum number of regulatory genes rmax,
target gene g,
set of candidate regulatory genes GR ⊂ G,
d datasets Dj , j ∈ {1, . . . , d},
maximum error εthres,
minimum number of dataset for consensus dmin
Output: Regulation hypothesis Rg,
Regulatory set GRg
1: nReg = 0
2: Missing = True
3: Rg = ∅
4: while nReg ≤ rmax and Missing do
5: nReg = nReg + 1
6: H = Regulation hypotheses with nReg regulators taken from GR targeting g
7: Hg = irrefutable hypotheses in H
8: HT = hypotheses in H that have already been tested
9: H = H\(Hg ∪HT )
10: for all regulation hypothesis Hk ∈ H do
11: Valid = 0
12: for all datasets Dj, j ∈ {1, . . . , d} do
13: Obtain εk using data Dj and Eq. (3.7)
14: if εk ≤ εthres then
15: Valid = Valid + 1
16: end if
17: end for
18: if Valid< dmin then
19: H = H\Hk
20: end if
21: end for
22: if H 4= ∅ then
23: Retrieve the hypothesis Rg ∈ H with smallest average error εmin
24: GRg = genes in Rg
25: Missing = False;
26: end if
27: end while
28: return Rg, GRg
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(line 12). An error εk is obtained using each dataset Dj with Eq. (3.7) (line 13) and
a temporary variable saves the number of datasets for which the current regulation
hypothesis is accepted (lines 14 and 15). If this number is below the input threshold
(line 18), then the hypothesis is removed from H (line 19). Similarly to lines 17
and 18 from Alg. 1, the algorithm searches for the regulation hypothesis that has,
on average, the smallest error throughout the tested datasets (line 23), retrieves the
genes from this hypothesis (line 24), and then returns them.
We used this procedure to reconstruct the topology of a GRN regulating the
TLR pathways (Fig. 3.2). We initiated the procedure by including all 28 genes
from CS in our network. The reconstruction procedure extended the network by
including 103 genes from the PS sets, yielding a network of 131 genes. The network
comprises 366 regulatory interactions: 187 positive (i.e. activators) and 179 negative
(i.e. repressors) interactions.
3.4 Constructing a Mathematical Model for Gene Regula-
tion
There is not a unique way to create a regulatory function fg for gene g by inter-
polating the solution qˆg,n of the optimization problem in Eq. (3.7). Cooper et al. pre-
sented an multi-affine interpolation technique for this purpose [68]. Here, we want
to exploit the non-uniqueness of the interpolation. That is, we formulate a cost cri-
terion that aims to fit the model predictions and the experimental time-series data,
and optimize this cost criterion while we find the regulation function. We propose
two methods that aim at fine tuning an initial model of the regulation function. Both
methodologies diminish our cost criterion and yield an optimized model that predicts
more accurate gene dynamics.
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Fig. 3.2: Topology of the reconstructed gene regulatory network. Positive
interactions (i.e. activators) are represented with red edges. Negative interactions
(i.e. repressors) are represented with green edges.
55
If F and λ1, . . . ,λG, are given, we can define an error quantity that measures
the )2 distance between the experimental gene expression time series data and the
gene expression time series generated by the model as follows:
ε2!(F ,λ1, . . . ,λG) !
G∑
g=1
N+1∑
n=0
(xg,n − xˆg,n)
2 , (3.10)
where the model prediction xˆg,n is defined recursively as follows.
xˆg,0 = xg,0, (3.11a)
xˆg,n+1 = xˆg,n − λgxˆg,n + fg (xˆ1,n, . . . , xˆG,n) , (3.11b)
for all g ∈ {1, . . . , G}, and n ∈ {0, . . . , N − 1}.
The problem of finding the regulatory functions that best fit the time series data
in the )2 sense, given the regulation hypotheses R1, . . . ,RG, can then be formulated
as follows:
min ε2!(F ,λ1, . . . ,λG) subject to (3.12)
F conforms with R1, . . . ,RG,
λ1, . . . ,λG ≥ 0,
with F , λ1, . . . ,λG as the optimization variables. By “conforming with R1, . . . ,RG”
we mean that F is continuous, nonnegative, and has the monotonicity property as
dictated by R1, . . . ,RG.
Note the optimization “variable” F assumes its value in a function space. Also,
we can observe that the feasible set in (3.12) is a cone, which is a convex set. Note
that (3.12) differs from (3.7) in the sense that (3.12) uses the model recursively to
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propagate the prediction from the initial state. If we were to replace (3.11b) with
xˆg,j+1 = xg,j − λgxg,j + fg (x1,j , . . . , xG,j) , (3.13)
then (3.12) would be equivalent to (3.7). Similarly to the observation made after
(3.7), ε2!(F ,λ1, . . . ,λG) = 0 if and only if the regulation hypotheses R1, . . . ,RG are
valid. Although the feasible set in (3.12) is convex, the cost function is generally
not, making (3.12) a non-convex optimization problem in general. We present here
techniques that we developed to approximate the solution of (3.12).
In order to find the best regulation function F that minimizes ε2!(F ,λ1, . . . ,λG)
in (3.12), we optimized the generation of the individual CNM functions fg that
compose F . If Gene g has Rg regulators, then its regulation function is modeled
as a piecewise multi-affine function fg : RRg → R. We define a grid Gg in the RRg
space, whose vertices map to the boundaries of the domains of the affine pieces of fg
(Fig. 3.3). We assign a regulation value to each vertex, corresponding to the values of
the regulation function at these specific locations in RRg . Optimizing fg translates
to finding the best sets of vertices and regulation values such that fg accurately
predicts the experimental data. Our optimization procedures start from an initial
regulation function obtained by solving problem (3.7) for the chosen set of regulatory
genes. The vertices of Gg are given by the elements of {x
g
k,j}, k ∈ {1, . . . ,Rg}, and
j ∈ {0, . . . , N − 1} (Fig. 3.3). From the NRg vertices in Gg, N are defined by the
experimental time points. We denote this set as Ve. The value associated with each
vertex in Ve is given by the optimization variables qˆg,j from problem (3.7), such that:
fg(x
g
1,j , x
g
2,j, . . . , x
g
Kg,j) ! qˆg,j, (3.14)
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where j ∈ {0, . . . , N − 1}. We denote the NKg − N remaining vertices of Gg as Vf .
The value assigned to each vertex in Vf is constrained such that fg must remain
continuous, non-negative, and monotonic. The non-uniqueness of this assignment
gives rise to a family of regulation functions that conform with Rg. Our goal is to
find a CNM function fg that satisfies the regulation hypothesisRg and that minimizes
ε2!(F,λ1, . . . ,λG). We propose two optimization procedures that aim at identifying
such a function.
The first method focuses on increasing the number of vertices by refining the
grid Gg. New vertices are identified while simulating expression time-series from the
gene model. The second method concentrates on the regulation values associated
with the vertices in Vf . Values are assigned by performing a stochastic gradient
descent method.
3.4.1 Domain Extension
The regulation values associated with the vertices in Gg are used to estimate
the value of the regulation function for the remaining points in RRg . A simple
improvement to the model consists in increasing the number of vertices to obtain a
finer grid. Refining Gg allows fg to be more sensitive to variations in the expression
of the regulatory genes, but comes at the expense of increasing the state space of the
gene model.
An initial gene model F is constructed from the list of vertices Ve defined by
each regulation hypothesis. Predicting expression time-series with this model will
give rise to simulated expression levels xˆg,j that do not exactly match experimental
values, since ‖εg‖F > 0 in practice. Better predictions can be obtained by identifying
the value of the regulation function that minimizes the distance between simulated
and experimental expressions at each iteration j of the prediction. This translates
to defining a new vertex Vr on the grid Gg, such that its coordinate is defined by
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Fig. 3.3: Schematic representations of the grid Gg. For simplicity, we show the
case where gene g has two regulatory genes (xg1 and x
g
2) and N + 1 = 5. The top
figure represents the grid Gg before any optimization procedure. Vertices in Ve and
Vf are shown with black and white circles, respectively. The bottom figure shows the
same grid after the Domain Extension procedure. New vertices Vr, shown in gray,
are identified by following Alg. 4. This procedure allows to refine the grid Gg and to
define a new CNM function fg that is more sensitive to the expression levels of x
g
1
and xg2.
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xˆg1,j , . . . , xˆ
g
Rg,j. The regulation value associated with this vertex is found by solving
the following problem:
min(xg,j+1 − xˆg,j+1)
2 subject to (3.15)
fg conforms with Rg,
xˆg,j+1 = xˆg,j − λgxˆg,j + fg(xˆ
g
1,j , . . . , xˆ
g
Rg ,j),
with fg(xˆ
g
1,j , . . . , xˆ
g
Rg,j) as the optimization variable. Note that by “fg conforms with
Rg” we mean that the choice of fg(xˆ
g
1,j , . . . , xˆ
g
Rg ,j) must not violate the properties of
regulatory functions (i.e. the CNM assumptions). This choice is thus constrained by
the previous vertices Vr and the ones in Ve.
Our refinement method is summarized in Alg. 4. Briefly, we start the model
predictions by initializing gene expression levels with the experimental values. For
each gene g, we solve problem (3.15) at each time step j. The solution defines a new
vertex Vr and a regulation value used to refine Gg. We then update gene expressions
and proceed to the next iteration. We assign at the end of the procedure values to
each vertices Vf and construct a new CNM function fg that satisfies the regulation
hypothesis Rg.
3.4.2 Gradient Descent
Our second optimization method focuses on the regulation values associated
with the vertices in Vf . Our goal is to assign regulation values that will minimize
the error of the model ε2!(F ,λ1, . . . ,λG). This is done by following a gradient descent
procedure.
Gradient descent methods are used to find the local minima of a function by
following the negative of its gradient. Since we cannot easily estimate the gradient of
F , we randomly explore the space of all piecewise multi-affine functions that satisfy
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Algorithm 4 Domain Extension
Input: Gene network with G genes,
regulation function F composed of individual functions fg, g ∈ {1, . . .G},
gene expression time series with N + 1 time points.
Output: Gene network with updated regulation function F
1: for j = 0 to N − 1 do
2: for all gene g ∈ {1, . . . G} do
3: if j = 0 then
4: xˆg,0 = xg,0
5: else
6: Solve problem (3.15) to find the best value for fg(xˆ
g
1,j , . . . , xˆ
g
Kg,j)
7: Refine grid Gg with the solution of problem (3.15)
8: xˆg,j+1 = xˆg,j − λgxˆg,j + fg(xˆ
g
1,j, . . . , xˆ
g
Rg ,j)
9: end if
10: end for
11: end for
12: for all gene i ∈ {1, . . .G} do
13: Assign new values to the vertices in Vf
14: Generate a new CNM function fg that satisfies the properties of Gg
15: end for
16: return F
the regulation hypotheses R1, . . . ,RG. Random steps are taken in this space if they
decrease ε2!(F ,λ1, . . . ,λG).
Our gradient descent method is described in Alg. 5. Briefly, each iteration of
the algorithm starts by creating a temporary regulation function F ′ from the original
function F . Each individual regulation function f ′g(·) of F
′ is modified by changing
the regulation value of a random number of vertices in Vf . The altered function F ′
is saved if these adjustments reduce ε2!(F ,λ1, . . . ,λG). Additionally, the number of
vertices whose value is changed decreases with each iteration. This allows for “big”
jumps in the space of regulatory functions at the beginning of the optimization and
more refined steps towards the end of the procedure. The algorithm terminates once
the error reaches a specified threshold or converges.
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Algorithm 5 Gradient Descent Optimization
Input: Gene network with regulation function F composed of individual functions
fg, g ∈ {1, . . .G}
desired error ε2,max! ,
gene expression time series with N + 1 time points.
Output: Gene network with optimized regulation function F
1: while ε2!(F ,λ1, . . . ,λG) > ε
2,max
! do
2: F ′ = F
3: for all f ′g in F
′, g ∈ {1, . . .G} do
4: Modify the value of random number of vertices in Vf . f ′ must conform with
Rg
5: end for
6: if ε2!(F ,λ1, . . . ,λG) > ε
2
!(F
′,λ1, . . . ,λG) then
7: F = F ′
8: end if
9: end while
10: return F
3.5 Model Validation
We used our model of the GRN to obtain simulated gene expression data for
the genes in the network. We initialized gene expressions with the initial values of
the data in [125]. We compared the simulated gene trajectories to the experimental
ones (Fig. 3.4 and Appendix F) and computed the )2 norm from Eq. (3.10). Many
of the genes have their simulated expressions close to the experimental ones.
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Fig. 3.4: Expression levels of marker genes for infection after an LPS
infection (gene model only). Each plot shows the gene experimental levels (black
curve) and gene simulated levels using the GRN developed in Chapter 3 (blue curve).
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Chapter 4
Development of a Modeling Framework
for the Response to Infection in
Macrophage
Improvements in modeling biochemical pathways arose by integrating networks
of different origins. Shlomi et al. integrated gene regulatory events in the form of
Boolean rules to produce a more comprehensive model of the metabolic pathways of
Escherichia coli (E. coli) [35]. Goelzer et al. used a similar approach to reconstruct
the genetic- and metabolic-regulatory networks of the central carbon metabolism
of Bacillus subtilis [36]. Covert et al. integrated an Ordinary Differential Equation
(ODE) model of signal transduction pathways to the stoichiometric model of the
E. coli central carbon metabolism [37]. Lee et al. used stoichiometrßic modeling to
account for signaling pathways in Saccharomyces cerevisiae and proposed a frame-
work for the dynamic modeling of metabolic, signaling, and regulatory networks
[38]. An other approach from Biggs and Papin consisted in integrating an agent-
based model and a stoichiometric model to analyze the formation of Pseudomonas
aeruginosa biofilms [39].
The framework detailed in this Chapter integrates the Toll-like Receptor (TLR)-
signaling and gene-regulatory networks from Chapters 2 and 3, respectively, to obtain
gene expression levels through time. Each iteration of the framework uses current
gene expressions to constrain the TLR stoichiometric model and obtain a flux dis-
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tribution for the signaling reactions, which in turn adjust gene expressions of the
regulatory network. One of the main challenges of the procedure concerns the gen-
eration of a flux distribution for the signaling network that is compatible with the
specified constraints. As mentioned in Sec. 2.1.2, the typical approach to obtain a
flux distribution from stoichiometric models is to use Flux Balance Analysis (FBA).
Typically, a “biomass function” is used as an objective to solve the FBA optimization
problem [55, 56, 31]. When dealing with more complex organisms, such as vertebrates
and plants, the usage of the biomass function is, in our opinion, no longer applicable.
In addition, the “objective” of the TLR pathways remains largely unknown. These
observations led us to use the TLR model in a non-classical way in order to avoid
introducing a bias using an inaccurate objective function in the FBA problem. We
decided to randomly sample the (convex) space of feasible solution defined by the
TLR model (see Eq. (2.5)) in order to obtain the flux distribution necessary for our
simulation. Many algorithms have been developed to sample convex regions, such
as the Hit-and Run and the Artificial Centering Hit-and-Run (ACHR) algorithms
[57, 58], and have been applied to stoichiometric models [59, 60, 61] (see Sec. 4.1.2).
However, past studies have focused on relatively small networks, and few attempts
at optimizing their usage to large-scale models, such as the ihsTLR v1.0 model, have
been published. In addition, our framework requires to sample the feasible space
of the signaling network at every iteration of the simulation. Developing methods
to optimize the sampling procedure was key in obtaining a framework that could
produce simulation runs in a timely manner.
Contributions
In this Chapter, we detail our procedure to integrate the TLR-signaling and
gene-regulatory networks to create a modeling framework for the macrophage re-
sponse to infection. We took into consideration the time scale difference between
65
these networks by updating the gene expressions from the regulatory network with
some delay. Our approach is based on dynamic Flux Balance Analysis (dFBA) (see
Sec. 4.1.1). We interfaced the two networks by modeling the effect of Transcrip-
tion Factors (TFs) on the regulatory network, and the effect of protein production
(estimated via gene expressions) on the TLR network. We used our integrated frame-
work to mimic a response to lipopolysaccharides (LPS) in macrophage. We obtained
expression levels for the genes in the regulatory network and compared them to
the simulated results from Chapter 3 (Sec. 3.5) and observations from experimental
results. In addition, we verified using formal verification techniques that our frame-
work produced traces satisfying several properties specific of an LPS infection (see
Sec. 4.6).
Early results from this Chapter were used for the publication of a first author
pier-reviewed full conference paper [49].
4.1 Background
4.1.1 Dynamic Flux Balance Analysis
The dynamical usage of FBA, or dFBA, is a method that captures the use of
a media by a population of cells [55, 77]. In brief, dFBA uses FBA over multiple
iterations to determine the consumption of external metabolites and the growth of
a cell population in time. Let E ⊂ M denote the set of all external metabolites
(M is the set of all metabolites in the system). We assume that there is exactly
one transport reaction for each external metabolite. Therefore, E also denotes the
set of transport reactions. Let B(t) denote the cell concentration, or biomass, at
time t. The equations governing the cell concentration and extracellular metabolite
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concentrations are given by:
B˙(t) = µB(n),
c˙e(t) = −veB(t), e ∈ E,
(4.1)
where µ is the growth rate, ce the concentration of metabolite e, and ve the flux for
reaction e.
The dFBA algorithm is summarized in Alg. 6. Briefly, the procedure starts by
initializing the biomass B and the concentration ce of each external metabolite e
(line 1). Assuming that there are T time steps of equal length ∆s in the simulation,
the algorithm then updates the upper bounds βe of each exchange reaction e. The
upper bounds correspond to amount of external metabolites, shared among all the
cells composing the biomass, that is available during the length of the time step
(line 3). FBA is then performed to maximize the growth rate µ of the population
(line 4). The solution gives specific values for all the fluxes, including those of the
transport reactions. The total biomass and external metabolite concentration are
then updated using the discrete time version of the equations in Eq. (4.1) (lines 5
and 6).
The time step ∆s is typically of several minutes [55, 38], which is in accordance
with the growth dynamics. Since metabolism is much faster, the quasi-steady state
assumption is justified.
4.1.2 Sampling Stoichiometric Models
An alternative to FBA when studying stoichiometric models is to sample their
space of feasible solution K, defined in Eq. (2.5). This method is particularly suitable
when an objective function cannot be easily formulated or when the entire feasible
space is analyzed.
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Algorithm 6 Dynamic Flux Balance Analysis
Input: Initial biomass B0,
exchange reactions E,
initial metabolite concentration c0e, ∀e ∈ E,
time step ∆s,
number of time steps T
Output: B, ce, ∀e ∈ E
1: B(0) = B0, ce(0) = c0e, ∀e ∈ E {initialization}
2: for n= 0 to T − 1 do
3: βe(n) =
ce(n)
B(n)∆s
, ∀e ∈ E {constrain bounds}
4: Solve the FBA problem by maximizing µ {flux values are obtained as a by-
product}
5: B(n + 1) = B(n)eµ∆s {update biomass}
6: ce(n + 1) = ce(n) +
veB(n)
µ
(1 − eµ∆s), ∀e ∈ E {update metabolite concentra-
tions}
7: end for
8: return B, ce, ∀e ∈ E
A simple method to obtain sample flux distributions is to select random coor-
dinates along each generator of K, as done by Price et al. [60]. An additional step is
performed to verify that the randomly generated point lies within K. This method
is however limited to rather small networks. Indeed, obtaining the comprehensive
set of generators is particularly difficult for large-scale networks.
The state-of-the-art for sampling large dimensional convex spaces (e.g. the space
of feasible solution) consists in using Hit-and-Run algorithms. These algorigthms al-
low to sample a convex region according to a target distribution, usually the uniform
distribution [57]. Hit-and-Run algorithms come down to performing a random walk,
by applying a random step in a random direction from an initial point. Samples ob-
tained from Hit-and-Run have been proven to converge asymptotically towards their
target distribution after a “sufficiently” large number of iterations [57, 129]. The
inability to precisely know when Hit-and-Run algorithms converge to their target
distribution has motivated the development of procedures accelerating the conver-
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gence rate. One of these methods, the ACHR algorithm, defines the best choice of
direction to cover the space as quickly as possible [58]. The direction is defined as the
line between the “center” of the sampled region and a random point from a previous
iteration. This center is recomputed after each iteration by averaging the coordinates
of each previous samples.
The ACHR algorithm for stoichiometric models has been implemented in the
COBRA toolbox for MATLAB R© (The MathWorks Inc., Natick, MA) [53] and is
summarized in Alg. 7. Briefly, the algorithm starts by generating W “warm-up”
points by solving the FBA problem with W random objective functions (line 2).
These warm-up points correspond to vertices of the feasible space K. The center of
mass x¯ is usually taken as the initial point x0 (line 5). A new point xi is obtained by
first randomly choosing one of theW warm-up points (line 7), which is used to define
u as the direction between the selected warm-up point and the center x¯ (line 8). The
new point xi will lie somewhere on the line segment within K that passes through
xi−1 with direction u. A random step λ is chosen along this segment (line 9) and
applied to xi−1 to produce xi (line 10). The center x¯ is then recomputed to take
into consideration the newly generated sample (line 11). This iterative process is
repeated until a desired number of points is obtained. The list of generated samples
are then returned as output.
4.1.3 Formal Verification
Formal verification groups methods historically used in Computer Sciences that
aim at verifying if a model can produce, or not, a trace satisfying a given specifi-
cation. This problem is usually solved by a Model Checker that exhaustively and
automatically searches the state space of the underlying model to verify the feasibility
of the specification [130, 131].
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Algorithm 7 Hit-and-Run algorithm for Stoichiometric Models
Input: Number of warm-up points W,
number of iterations s
Output: Trajectory of gene model
1: for i from 1 to W do
2: Generate a random vertex of K using FBA
3: end for
4: Compute center of mass x¯ of the W warm-up points
5: Current point x0 = x¯
6: for i from 1 to s do
7: Select a random warm-up point xW
8: Define the direction u =
xW − x¯
||xW − x¯||
9: Define the line segment within K passing through xi−1 with direction u. Select
a random step λ along this segment
10: xi = xi−1 + uλ
11: Update x¯ as the center of mass of theW warm-up points and all points xk, k ∈
{1, . . . , i}
12: end for
13: return sampled points xk, k ∈ {1, . . . , s}
Linear Temporal Logic (LTL) is a formalism allowing the description of such
specifications [132]. LTL combines propositional variables, usually denotes as pi1,
pi2, etc, with logic (Tab. 4.1) and temporal operators (Tab. 4.2). Propositional vari-
ables typically describe properties of a system (e.g. “concentration of protein A is
equal to 0”, “concentration of protein B is above 100 units”). The juxtaposition of
propositional variables with logic and temporal operators allows to express a wide
range of properties. An LTL formula can be satisfied, or not, by an infinite sequence
of events. These events typically correspond in biology to protein concentrations
or gene expression levels measured through time. Examples of LTL formulas are
presented in Tab. 4.3.
The bounded Linear Temporal Logic (bLTL) formalism expands LTL by adding
time bounds on the temporal operators [133]. A bLTL formula applies to a finite
sequence of events and can be verified using a Bayesian statistical model checker [134,
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Name Symbol
True true
False false
Conjunction (and) ∧
Disjunction (or) ∨
Negation (not) ¬
Implication →
Biconditional ↔
Table 4.1: Logic operators
Letter Symbol Description
G " Globally/Always
F ♦ Future/Eventually
U U Until
X © Next
Table 4.2: Temporal operators
LTL formula Description
pi1 [A] = 0 at the initial time
¬pi1 [A] 4= 0 at the initial time
F pi1 [A] = 0 at some point in time
pi2 [B] > 100 at the initial time
G (pi1 ∧ pi2) [B] > 100 and [A] = 0 at all points in time
pi1 U pi2 [A] = 0 at every point in time until [B] > 100
(F pi1) ∧ (G pi2) [A] = 0 at some point in time and [B] is always above 100
Table 4.3: Examples of LTL formulas. [X] = concentration of protein X. The
descriptions given for pi1 and pi2 are for illustration purposes only.
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bLTL formula Description
F5 pi1 [A] = 0 within the first 5 time units
G10(pi1 ∧ pi2) [B] > 100 and [A] = 0 at all time points under 10 time units
pi1 U20 pi2 There exist a time i < 20 for which [A] = 0 at every point
bellow i and [B] > 100 for all time points starting from i
(F5pi1) ∧ (G10pi2) [A] = 0 at some point within the first 5 time units and [B] is
always above 100 for the first 10 time units
Table 4.4: Examples of bLTL formulas. [X] = concentration of protein X. The
definitions of pi1 and pi2 are identical to the ones in Tab. 4.3.
133]. This method is particularly useful when a stochastic model is being evaluated.
During this procedure, traces, or simulations, of the model are successively generated
and checked against the specification. With enough traces, the Bayesian statistical
model checker answers the question of wether the model satisfies the specification
given a probability of satisfaction. Examples of bLTL formulas are shown in Tab. 4.4.
4.2 Modeling Time
The gene network evolves at a much slower rate than the signaling reactions
[52]. Let ∆s and ∆G be the time steps of the signaling reactions and gene network,
respectively. The time scale difference between the two networks is modeled by a
delay τ , such that:
∆G = τ∆s, τ ∈ N. (4.2)
The delay τ can essentialy be seen as the number of “fast” time steps the Gene
Regulatory Network (GRN) takes to update its expression.
We set ∆s = 6 minutes, which is consistent with time steps from previous
studies [55, 38]. The gene network time step comes directly from the reconstruction
procedure and corresponds to the time step between sample points (i.e. ∆G = 1 hour
= 60 minutes). This yielded τ = 10 (10∆s = ∆G).
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Let T be the number of time steps in our experiment. A simulation consists of
T steps of ∆s. Both the TLR-signaling and gene-regulatory networks are updated
at each time step n. However, we account for the gene slow dynamics by updating
the state of the gene network with some delay (i.e. τ). Formally,
xˆg(n) =


x0g ∀n = {0, . . . , τ − 1}
xˆg(n− τ) + fg(GRg (n− τ))− λgxˆg(n− τ) ∀n = {τ, . . . , T}
, (4.3)
for all genes g = {1, . . . , G} in the GRN, where x0g is the initial expression of g, xˆg(n)
the expression level of gene g at time n, fg the regulatory function of g, GRg the set
of regulatory genes of g, and λg the decay rate of the g.
4.3 Modeling Biological Interconnections
There are two interfaces between the TLR pathways and our gene regulatory
network: 1) TFs from the TLR pathways regulate the expression levels of some genes
in the regulatory network (“TLR pathways to gene network”), and 2) genes in the
regulatory networks code for proteins used in some reactions of the TLR pathways
(“gene network to TLR pathways”). These interfaces allow the regulatory network
to modulate the activity of the TLR pathways, and to integrate signals coming from
the TLRs.
4.3.1 Transcription Factors
The output TFs of the TLR pathways regulate genes in the regulatory network.
When a TFs is detected as being active, the corresponding targets will have their
respective expression levels slightly increased. These increases are not predefined,
but are instead randomly chosen when needed. Note that the output TFs affect the
73
gene expression of their targets only when activated. An inactive TF does not have
the opposite effect of an activated TF.
The “activity” of a TF is determined by a sampled flux value obtained by run-
ning an Artificial Centering Hit-and-Run algorithm [58, 61]. An offline step involved
sampling the “least constrained” feasible space K0 to determine a threshold for the
TFs activity (Fig. 4.1). The feasible cone K0 was obtained by enabling all reactions
of the TLR network (i.e. αj = 0 ≤ vj ≤ βj 4= 0, ∀j ∈ R). We obtained 10 millions
random sample flux distributions by sampling K0, and projected them to obtain
probability density functions for each of the output flux (Fig. 4.2). We considered
the median of these distributions as our thresholds for the TFs activity. Choosing
the median has the advantage of not introducing any bias. If the sampled flux values
of the output reactions lie above their respective median during the simulations, then
their corresponding TF is considered active. The TFs are inactive if the flux values
lie under their median value. Active TFs immediately change the expression of their
target genes. This change will however take some time (i.e. τ) to affect the rest of
the gene network. If an active TF regulates gene g, then:
xˆg(z) = xˆg(z) + %, ∀z ∈ {n, . . . , n+ τ − 1}, (4.4)
where % ≥ 0 is the change in expression due to the activated TF. The increase %
is chosen randomly between 0% and 10% of the range of expression of the gene
(i.e. xmaxg −x
min
g ). The effect of the TFs allows to provide small (i.e. %) and transient
(i.e. z ∈ {n, . . . , n + τ − 1}) adjustments to the expression levels of some genes in
the GRN.
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Fig. 4.1: Activity of output transcription factors.
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Fig. 4.2: Probability density function of the TLR outputs. Function were
obtained by projecting 10 million samples. Medians are shown in red.
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4.3.2 Protein Synthesis
Some genes of the regulatory network code from proteins used in reactions of
TLR pathways. When expressed, these genes will supply the components necessary
for these reactions to occur. Low gene expressions will however prevent the reactions
from functioning normally. The effect of gene expression can be modeled as a change
in the lower and upper bounds of the corresponding reactions.
The regulatory Flux Balance Analysis (rFBA) method typically uses a Boolean
approach to model the effect of gene g on reaction j (Fig. 4.3, left plot) [35, 36, 38].
In irreversible model, the upper bound of reaction j, βj , is either set to a minimum
or maximum value, βmin and βmax respectively. Note that βmin is usually set to 0 to
simulate a gene knockout. The value of βj depends on where xg, the expression level
of g, lies compared to an input threshold x′g. The reaction is virtually enabled only if
the expression of g lies above x′g. In our approach, we modeled the regulatory effect
of the gene network with a continuous value that is linearly interpolated between βmin
(i.e. 0) and βmax (Fig. 4.3, right plot). These limits are attained when the expression
level reaches its minimal (xming ) or maximal value (x
max
g ), respectively. Our method
has the advantage of not completely disabling reaction j if the expression level of
gene g is low. Biologically, only a true knockout of g would disable j.
Formally, if gene g codes for a protein used in reaction j, then:
αj ×
xg(n)− xming
xmaxg − xming
≤ vj(n) ≤ βj ×
xg(n)− xming
xmaxg − xming
, (4.5)
where vj(n) and xg(n) are the flux value of reaction j and the expression level of
gene g, respectively, at time n. Note that the TLR reactions adapt immediately to
any changes in expression levels since they evolve at a fast time scale.
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Fig. 4.3: Regulatory effect from gene network. The expression level xg of gene
g controls the value assigned to the upper bound of reaction j, βj. The upper bound
is usually set between βmin = 0 and βmax 4= 0. rFBA methods typically use the
Boolean approach to model the regulation. The reaction is enabled only if xg lies
above the threshold x′g. In the continuous approach we use, the upper bound is set
to a continuous value between βmin and βmax. The reaction is only knocked out when
g reaches its minimal expression xming .
4.4 Simulation Algorithm
4.4.1 Development and Implementation
Our procedure, described in Alg. 8, is essentially a modified version of dFBA.
Briefly, the simulation starts by initializing gene expression. At each time step, the
TLR network is constrained using the current state of the gene network. An infection
can also be modeled at this point by activated the desired set of TLRs. A random
flux distribution is then obtained by sampling the feasible space of the stoichiometric
model. TFs that are identified as being active modify the expression of their target
genes. Finally, the state of the gene network is updated according to the identified
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gene model F . The predicted expression of the gene network is returned at the end
of the simulation and can be compared to experimental values.
We first initialize gene expression levels for the first τ steps of the simulation
(line 1). Initializing only the first step is insufficient since the state of the gene
network at time n is obtained from the state at time n − τ . At each iteration n
of the algorithm, we constrain the TLR model using the current state of the gene
network (line 3). The expression levels are used in Eq. (4.5) to determine the bounds
of the signaling reactions. Simultaneously, we simulate an infection by enabling the
reactions triggering the desired TLRs, and deactivating the other ones (line 4). We
ensure the infection to be present by increasing the lower bounds of the activated
TLRs “reactions” (line 5). Next, we obtain a random flux distribution allowed by the
newly constrained system by using the ACHR algorithm detailed in Alg. 7 (line 6),
and then determine which output reactions are activated (line 7). If we identified an
output TF as active, then we modify the expression levels of the associated genes
according to Eq. (4.4) (line 9). Finally, we use Eq. (3.9) to update the state of the
gene network at time n+ τ according to the current state (i.e. at time n) (line 11).
Our simulation framework was implemented in MATLAB. Our implementation
make use of cluster computing by allowing multiple simulations to run simultaneously.
This allowed to obtained more results in less time. Each run returns the expression
levels of every gene from the GRN and the list of sample flux distributions obtained
at each iteration.
4.4.2 Numerical Simulations
We used our framework to simulate the macrophage response to a LPS infec-
tion. Similarly to the simulations in Sec. 3.5, we initialized gene expressions with the
expressions at time 0 of the dataset in [125] and let simulations run for 120 time steps
(i.e. corresponding to 12 hours of infections). The temporal expression values of 500
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Algorithm 8 Running the integrated framework
Input: TLR network,
model F of gene network,
initial expression X0,
set of reactions triggering the TLRs RTLR,
set of reactions modeling the infection RInf ⊂ RTLR,
set of reactions activating output TFs RTF.
Output: Matrix of gene expression Xˆ
1: Xˆ(n) = X0, n = {0, . . . , τ − 1} {initialization}
2: for time step n = 0 to last do
3: Use Xˆ(n) in Eq. (4.5) {constrain the TLR network}
4: Set αj = βj = 0, ∀j ∈ RTLR\RInf {disable the TLRs not involved with the
infection}
5: Set αj > 0, ∀j ∈ RInf {trigger the TLRs involved with the infection}
6: Obtain a flux distribution v using Alg. 7 {random sampling}
7: Determine which output TFs are active
8: for all genes g activated by the TFs do
9: Update expression of g according to (4.4)
10: end for
11: Use Xˆ(n) in Eq. (4.3) to obtain Xˆ(n+ τ) {update gene expressions}
12: end for
13: return Xˆ
traces for a subset of genes from the GRN (i.e. Ccl4, Ccr2, and Ncf4) are shown in
Fig. 4.4 (see Appendix F for the expression values of all the genes in the regulatory
network). On average, 67 genes from the network had their time behavior improved
upon integration of the TLR-signaling and gene-regulatory networks (smaller )2 norm
after network integration), and 38 genes had their time behavior worsen after inte-
gration (increase in the )2 norm of at least 50%). Globally, integrating the signaling
and regulatory network provided simulated results that were closer to experimental
observations, particularly on a qualitative level. Indeed, the trajectories (after inte-
gration) of every gene shown in Fig. 4.4 present similar patterns (i.e. increases and
decreases in expression levels) to the ones from the experimental observations. These
patterns are not observed before integration.
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Fig. 4.4: Expression levels of marker genes for infection after an LPS in-
fection. Each plot shows the gene experimental levels (black curve), gene simulated
levels using only the GRN developed in Chapter 3 (blue curve), and gene simulated
levels using the integrated framework described in Chapter 4 (red curve, average of
500 traces). The plot titles detail the error (i.e. the )2 norm) between each simulated
results and the experimental observations.
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4.5 Optimizations
The results from Sec. 4.4.2 were obtained after various optimizations. These
improvements were critical in order to obtain results in a timely manner. After several
procedures, we were able to obtain about 250 traces in roughly 2 days. Obtaining
the same number of traces without any optimization would have required months of
computations.
We performed optimizations at two levels: software and hardware optimizations.
Software optimizations consisted in code modifications that allowed our framework
to make better usage of available resources. Hardware optimizations consisted in
migrating our implementation of the framework to a cluster the HyNeSs lab acquired.
This allowed us to considerably reduce computation time by taking advantage of
parallel and cluster computing.
4.5.1 Software Optimizations
We proceeded to various optimization procedures to diminish the computation
time. Modifications were made in order to simplify existing algorithms or to optimize
their implementation. In addition, we made use of parallel computing to alleviate
bottlenecks rising from embarrassingly parallel problems.
An example of a simple optimization consisted in not saving temporary points
during the sampling procedure. The ACHR algorithm writes onto the hard drive
the coordinates of all the points generated during the random walk due to memory
limitations. Repeatedly writing the coordinates of thousands of points significantly
slowed this critical step of our simulations. In addition, saving the coordinates of
all generated points was unnecessary since we only required the coordinates of a
single random point. We were able to reduce the computation time of a trace by
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approximately 10 hours by disregarding previous iterates and by avoiding writing
files on the hard drive of our computers.
Other optimizations consisted in selecting different coding environments de-
pending on the type of computation. Most of our implementation was done in MAT-
LAB, but several steps were performed using Bash or Python scripts. Communication
between the different scripts had to be dealt appropriately to avoid further increases
in the computation time by unnecessarily writing and reading data files.
4.5.2 Hardware Optimizations
We were able to significantly reduce the computation time by adapting our
code to cluster computing, parallel to software optimizations. Adapting our imple-
mentation to cluster computing required us to change our optimization paradigm.
We no longer attempted to reduce the computation time spent for a single trace.
Instead, we tried to reduce the computation time to generate at large number of
traces simultaneously. Indeed, it rapidly became advantageous to run many “slow”
processes at once, rather than one “fast” process many times. This derived from
the fact that clusters are typically composed of many “slow” processors, compared
to desktop computers composed of a few “fast” ones. Additionally, many aspects of
our code, initially running on local computers, were not adapted to run efficiently on
a remote cluster. These hurdles mainly consisted in softwares or external toolboxes
licenses that could not be easily obtained or renewed on our cluster and were dealt
by prioritizing the usage of license-free softwares.
4.6 Validation using Statistical Model Checking
The traces we obtained during our simulations were tested to verify that they
satisfied properties observed in macrophages after being exposed to LPS. Specifi-
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cations were expressed in the form of bLTL formulas and tested using a statistical
model checker.:
• “Within 5 hours of infection with LPS, the expression of Irf7 increases by 10%
higher from its original value for a duration of 30 minutes”.
The modeling framework had a probability of satisfaction higher than 0.95 with an
error of 14%.
• “The expression of Il-6 increases by 2 folds within 3h of the LPS introduction and
stays high at least 2 hours.”
The modeling framework had a probability of satisfaction higher than 0.95 with an
error less than 1%.
These specifications, which are typically observed in macrophages exposed to
LPS [135], demonstrate that our framework is capable of producing traces that are
similar to experimental observations.
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Chapter 5
Application to a Porphyromonas
gingivalis infection
Porphyromonas gingivalis (P. gingivalis) is an anaerobe Gram-negative bacte-
ria that is found in the oral cavity and plays a major role in periodontal disease
[136]. P. gingivalis is known to engage the TLR1/TLR2, TLR2, and TLR4 dimers
[137, 138], as well as the NOD1 and NOD2 receptors [139]. Recent epidemiological
studies have linked obesity to periodontal disease, which is characterized by inflam-
mation and destruction of periodontal tissues. Research from the Amar lab showed
that feeding mice a high fat diet renders them defective in proinflammatory cytokine
response to P. gingivalis [126, 127]. Understanding the mechanisms by which P. gin-
givalis affects macrophages is critical to develop therapies aiming at improving their
response to infection. To do so, having a computational framework which is capa-
ble of simulating the response to infection and which can be used to test biological
hypotheses is invaluable for developing efficient treatments.
Contributions
We used our framework developed in Chapter 4 to simulate the macrophage re-
sponse to a P. gingivalis infection for a 24 hours period. We modeled a P. gingivalis
infection by activating in the TLR model the specific set of TLRs the bacterium trig-
gers and obtained 500 independent simulation runs. We compared results from our
framework, or traces, to a reference dataset from the Amar lab. This dataset con-
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sisted of a set of GeneChip R© Mouse Exon 1.0 ST Arrays from Affymetrix, Inc. that
followed the expression level of exons and genes in mouse macrophages after being
exposed to P. gingivalis for various lengths of time. We preprocessed the raw Exon
arrays dataset in order to obtain transcript levels and removed inaccurate probes
after performing several quality control procedures. In addition, we verified using
formal verification methods that the simulations obtained with our framework pro-
duce results characteristic to a P. gingivalis-response to infection in macrophage.
5.1 Reference Dataset
The dataset we used as a reference when comparing our simulation results is
a set of GeneChip R© Mouse Exon 1.0 ST Arrays from Affymetrix, Inc. The experi-
ments follows gene expression levels in macrophages from lean and obese mice. Each
condition was sampled in triplicates at four time points: 0, 1, 4, and 24 hours. We
chose the lean condition as our reference.
Probes on the Affymetrix Exon array come from various annotation sources,
each associated to a different degree of confidence. To distinguish between “high”
and “low” confidence probes, Affymetrix categorized the probes into three groups:
core, extended, and full, from highest to lowest confidence, respectively. Briefly, core
probes map to well annotated sequences (e.g. know exons of know genes), extended
probes map to sequences for which annotation is present, but not complete (e.g. exons
of genes with no known function, miRNA, pseudogenes), and finally, full probes
groups the remaining probes (e.g. predicted genes). We restricted our analysis of
this dataset to probes from the core annotation.
We processed the raw CEL files from the experiment using the R software [140]
and following the procedure detailed in [141]. The arrays were first processed using
the Affymetrix Power Tools (APT) software package [142]. APT groups several
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Fig. 5.1: Quality control plots for the Exon array normalization procedure.
normalizing algorithms (e.g. PLIER, RMA), as well as various analysis procedures
(e.g. detection above background, splicing index). We used RMA with APT to
normalize the raw CEL files in order to obtain exon intensity levels. Quality control
plots are shown in Fig. 5.1. Similarly, RMA can be used to summarize exon probes
into transcript level intensities. Since a transcript is very similar to the notion of gene,
we will now refer to transcript levels as gene levels. This first step yielded intensities
for 229,581 exons and 17,685 genes. Exons and genes were then filtered with R using
several quality control procedures, all described in [141]. These quality control steps
reduced the number of exons and genes to 153,364 and 14,831, respectively.
5.2 Modeling the P. gingivalis infection
We used the framework described in Chapter 4 to model the response to a
P. gingivalis-infection. We generated 500 independent simulation runs, or traces,
using our framework. The dynamics of the gene network reached a steady state
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when not integrated with the model of the TLR pathways. We used this steady state
as the initial state of the gene network. We left each trace run for 240 steps, which
corresponds to 24 hours of simulated time. At each step, we simulated a P. gingivalis-
infection in the TLR model by forcing a positive flux through the reactions triggering
the TLR1/TLR2, TLR2, TLR4, NOD1, and NOD2 receptors.
To validate the simulations, we compared the average time behavior of the genes
in the GRN to experimental data from the Amar lab. We analyzed the trajectories of
TFs involved with the TLR pathways, Fos and Irf7 (Fig. 5.2), inflammation markers,
Ccl4 and Ccr2 (Fig. 5.3), and Reactive Oxygen Species (ROS) production markers,
Ncf4 and Vav1 (Fig. 5.4). In each plot, we show the gene trajectories taken from our
reference dataset (left plot), the average of the simulated trajectories (center plot),
and the superimposition of the experimental and simulated trajectories (right plot).
We do not show the superimpositions of the scaled trajectories. Indeed, these plots
are informative of the qualitative similarities between the experimental and simulated
data. These results indicate that our modeling framework is capable of generating
gene dynamics that are consistent with experimental observations. In addition, we
want to emphasize that the reference dataset and the modeling framework are com-
pletely independent from one another. Indeed, the Exon dataset was never involved
with the creation of the modeling framework.
5.3 Formal Verification of Hypotheses using Statistical
Model Checking
We used the traces we obtained with our framework to verify several properties
characteristic of a P. gingivalis-response to infection in macrophage. We used ex-
perimental observations from our Exon dataset to derive specifications expressed as
bLTL formulas. Each property was tested using a Bayesian statical model checker to
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Fig. 5.2: Expression levels of transcription factors from the TLR network.
Experimental trajectory (left), average simulated trajectory (center), and superimpo-
sition of the experimental and simulated trajectories. The superimposition does not
preserve scaling, but rather shows the temporal similarities between the experimental
and simulated trajectories.
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Fig. 5.3: Expression levels of markers for inflammation. Experimental trajec-
tory (left), average simulated trajectory (center), and superimposition of the exper-
imental and simulated trajectories. The superimposition does not preserve scaling,
but rather shows the temporal similarities between the experimental and simulated
trajectories.
89
0 5 10 15 20 25
9.5
10
10.5
11
Time (h)
Ex
pr
es
sio
n
Experimental data
0 5 10 15 20 25
9.9
10
10.1
10.2
10.3
10.4
10.5
10.6
10.7
10.8
10.9
Time (h)
Ex
pr
es
sio
n
Simulated data (average of 270 traces) Superimposition
Ncf4
(a) Ncf4
0 5 10 15 20 25
9.4
9.6
9.8
10
10.2
10.4
10.6
10.8
11
Time (h)
Ex
pr
es
sio
n
Experimental data
0 5 10 15 20 25
6
6.5
7
7.5
Time (h)
Ex
pr
es
sio
n
Simulated data (average of 270 traces) Superimposition
Vav1
(b) Vav1
Fig. 5.4: Expression levels of markers for ROS production. Experimental
trajectory (left), average simulated trajectory (center), and superimposition of the
experimental and simulated trajectories. The superimposition does not preserve
scaling, but rather shows the temporal similarities between the experimental and
simulated trajectories.
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estimate how likely our modeling framework produces runs with such behavior. We
checked the following properties:
• “The expression of Fos decreases by 2 folds within the first two hours of infection,
and stays low for at least 12 hours.”
Our framework satisfied this property with a probability of at least 0.95 with an error
of 1%.
• “Within the first 20 hours of infection, all the subunits of the NADPH oxidase
complex have their expression increased during at least 1 hour.”
Our framework satisfied this property with a probability of at least 0.95 with an error
of 7%.
Here again, our framework was capable of producing runs that present properties
specific to the response to a P. gingivalis-infection in macrophages.
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Chapter 6
Conclusion
6.1 Summary
Excessive consumption of high energy food in conjunction with low physical
activity have resulted in overweight and obesity to reach epidemic proportions in
the recent years. The World Health Organization (WHO) estimated that 1.5 billion
adults were overweight in 2008 [1]. In addition, nearly 43 million children under the
age of five were overweight in 2010. In the United States, obesity is becoming a major
public health issue with approximately two thirds of the population being overweight
of whom half are obese [2]. The increased amount of body fat, or adipose tissue,
resulting from obesity has many detrimental effects on one’s health. Obesity increases
the risk factors of type II diabetes [3], atherosclrosis [4], asthma [5], cancer [6],
periodontal disease [7], and depression [8]. It also accentuates exciting neurological
[9], urologic [10], orthopedic [11], and pulmonary conditions [12]. Many studies
have described the effects of obesity on the immune system [20, 21, 18]. Developing
therapies that aim to improve the immune response is crucial in order to increase the
quality of life of obese subjects and to reduce their ever-increasing healthcare-related
costs. To this end, we focussed on the Toll-like Receptors (TLRs), which play an
essential role in the detection of pathogens and in the initiation of both innate and
acquired immune responses. Our goal was to use the TLR pathways to create a
framework capable of modeling the response to infection in macrophage.
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First, in Chapter 2, we studied the TLR pathways using a stoichiometric repre-
sentation of the reactions within these pathways. Using convex analysis, we identified
sets of reactions, or Minimal Cut Sets (MCSs), that control the activity of several
Transcription Factors (TFs) from the TLR pathways. We investigated epistatic rela-
tionships between modules of the TLR network (Fig. 2.1, 2.2, and 2.3). We mapped
proteins involved in the TLR pathways to human and mouse genes and extended the
concept of MCS to Essential Gene Set (EGS) (Appendix B). The EGS allowed us to
identify control genes within the TLR pathways that are essential for the transduc-
tion of the infection signal from the TLRs to the TFs (Appendix C).
In Chapter 3, we reconstructed a Gene Regulatory Network (GRN) involved in
the regulation the TLR pathways. We used a novel computational tool to identify
the topology of the network and to generate regulatory functions for genes in the
network. To reduce computation time we focused our reconstruction over sets of
genes related to the TLRs and to the immune response. The genes we identified
with the EGS provided the basis for the reconstruction of our GRN. In addition, we
included marker genes for infection to follow the state of the response to infection in
macrophage. The topology was identified using a tool developed by our collaborators
and described in [67, 68]. We defined methods using this tool to search for the best
set of regulators for each gene in the network (Alg. 1, 2, and 3). Our methodology
uses a parsimonious approach in order to avoid including spurious interconnections.
We constructed a GRN composed of 131 genes and generated regulatory functions
for every one of them (Fig. 3.2). We developed new methodologies to optimize the
creation of each regulatory function (Alg. 4 and 5).
In Chapter 4 we described the integration of our regulatory network with
the model of the TLR-signaling pathways to create a modeling framework for the
macrophage response to infection. We interfaced the two networks by modeling the
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effect of TFs on the regulatory network, and the effect of protein production (esti-
mated via gene expressions) on the TLR network. We performed several software and
hardware optimizations, such as parallel and cluster computing, in order to reduce
computation time and to obtain results in a timely manner. We compared simulated
results to experimental observations (Fig. 4.4 and Appendix F). Gene trajectories of
several markers for infection were closer to experimental observations when using the
integrated framework, compared to results using the gene network alone. In addition,
we verified using formal verification methods that our framework was able to produce
traces, or simulations, compatible with biological observations from a macrophage
lipopolysaccharides (LPS)-response to infection.
Finally, in Chapter 5 we applied our framework to model a Porphyromonas gin-
givalis (P. gingivalis)-response to infection in macrophage. The simulated expression
levels of many genes in the GRN qualitatively matched to the levels observed in an
independent experimental dataset (Fig. 5.2, 5.3, and 5.4). In addition, we verified us-
ing formal verification methods that our simulated results satisfied several properties
characteristic from a P. gingivalis-infection.
6.2 Future Directions
Computational challenges prevented us from integrating the mouse metabolic
network into our framework. Generating MCS and EGS for this network would allow
to identify reactions and genes controlling the metabolism, e.g. genes controlling the
production of ATP or other key metabolites. This could lead to the reconstruction
of a different GRN regulating both signaling and metabolic pathways.
Obesity induces many changes in metabolic pathways of the host. Including
a metabolic model in our framework would also have the advantage of addressing
the issue of rescuing the response to infection in obese subjects more accurately.
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Adapting our framework to obese macrophages is a step that remains to be achieved.
An option for implementing these changes would be to use a modified version of
the GRN we identified. The topology would remain unchanged, but new regulatory
functions could be learned using a dataset following gene expressions in obese immune
cells.
In general, our modeling framework is not specific to the response of P. gin-
givalis-infections. Specifying which set of TLRs to trigger would allow to virtually
simulate any type of infection. In addition, polymorphism data could also be applied
to produce models adapted to specific conditions or diseases. Changes in polymor-
phism may affect the activity of proteins involved either at the signaling or gene
level, which would affect the outcome of simulations.
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Appendix A
Modules of the ihsTLR v1.0 model
Bellow is the list of the different modules derived from the ihsTLR v1.0 . Each
module name is followed by a short description of its function. Only modules that
have been targeted by an Minimal Cut Set (MCS) are listed.
AP-1 : Binding of AP-1 complex to AP-1 site
Activating Protein 1 (AP-1) is a family of transcription factors. AP-1 consist of
heterodimers and homodimers of Jun, Fos, ATF, and JDP protein families [143, 72].
Homodimers are only formed by members of the Jun family. AP-1 complexes bind
to AP-1 sites contained in promoters of various genes. AP-1 can be activated by
cytokines [144], high glucose and angiotensin II [145], antioxidant conditions (stress
signals) [146], or infection [147, 148]. The activation process generally occurs through
the MAPKs pathways [149]. AP-1 has been shown to be associated with cell pro-
liferation, differentiation, and inflammation [72, 145]. AP-1 is commonly described
as a switch, deciding the fate of cells: survival or apoptosis [72, 150]. AP-1 can
either induce apoptosis or promote cell proliferation depending on the cell type, the
external stimuli, and the mixture of AP-1 dimers. Reactions in the modules include
the phosphorylation of the Jun and Fos proteins by the MAPK pathways, the AP-1
complex formation, and binding to the AP-1 site.
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Btk : Activation of Btk
Bruton’s tyrosine kinase (Btk) is a tyrosine kinase involved in LPS signaling. Btk
plays a role in the activation of NF-κBand AP-1, independently of MyD88, and is
important for growth and differentiation of immune cells [151]. This module groups
reactions necessary for the phosphorylation and ubiquitination of Btk
Calcium dependent cascade: Activation of calcium/calmodulin-dependent pro-
tein kinase
Calmodulins are calcium-binding proteins. The calcium/calmodulin complexes regu-
late calcium/calmodulin-dependent protein kinases, which are able to phosphorylate
CREB [152, 153]. Reactions in this module include the binding of calcium to calmod-
ulin and binding to calcium/calmodulin-dependent protein kinases.
Common metabolites : Transport of metabolites into the cytoplasm
Metabolites are necessary to model accurately the transduction of a signal [30]. This
module allows the transport of metabolites across the cell membrane. Transport is
achieve via channels or active transport.
CREB : Binding of CREB to CRE site
The cAMP response element binding protein (CREB) is a transcription factor which
binds as a dimer to a specific response element called the cAMP response element
(CRE). The best-known stimuli of CREB is cAMP which activate the catalytic sub-
unit of the cAMP-dependent protein kinase (PKA). Once activated, PKA phospho-
rylates CREB in the nucleus which activates transcription of genes containing a
CRE site [154]. Other stimuli can activate different kinases which all phosphorylate
CREB. Among these stimuli are calcium, various growth factors, and survival and
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stress signals [73]. Although CREB is best known for its role in memory and com-
plex behavior, it has been shown that CREB is involved in cell survival, proliferation,
and cancer [73, 155, 156, 157]. Reactions in this module include dimerization and
phosphorylation of CREB, and the binding of CREB and CBP to the CRE site.
Cytoplasm-Nucleus transport : Transport of various species into the nucleus
This module corresponds to the transport reactions allowing species from the net-
work (metabolites and proteins) to cross the nuclear envelope. Transport is achieved
via the nuclear pores.
Early endosome: Degradation and recycling of receptors
Endosomes are cellular compartment in eukaryotic cells where compounds are stored
before degradation. They act as “sorting stations” where ligands are separated from
their receptors. Receptors stay there until they are recycled or degraded [158].
GSK3β: Activation of GSK3β
Glycogen synthase kinase 3β (GSK3β) has been shown to play an important role
for the phosphorylation of NF-κB[159]. Reactions in this module correspond to the
phosphorylation (activation) of GSK3β and its transport between the cytoplasm and
the nucleus.
IFN genes: Binding of IFN with the ISRE site
Interferons (IFN) are proteins expressed by lymphocytes and are involved in antivi-
ral defense, cell growth, and immune activation. IFN are cytokines that enable cells
to communicate with their neighbors and are described as the primary host defense
mechanism in innate immunity [160]. IFN expression is controlled by a class of tran-
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scription factor known as the interferon regulatory factors (IRF). Nine IRF proteins
have currently been identified, each having a specific role [74]. Reactions in this
module include transport of the active form of IRF3 and IRF7 from the cytoplasm
to the nucleus and their binding with their respective ISRE.
KSR1 : Activation of the MAPK pathway
Kinase suppressor of Ras (KSR) is a conserved element involved in the Ras signal-
ing pathway. It is use as a scaffold to facilitate activation of the MAPK pathway
[161, 162]. Ras is a family of proteins sensible to growth factor stimuli and is in-
volved in cell proliferation [163]. This module groups reactions of the Ras signaling
pathway, including activation of the MAPK pathway.
Ligands: Import of ligands in the system
The ligands represent all the species that interact with the TLR. Ligands can be
self-proteins and bacterial or viral particles. Reactions in this module include the
import of ligands in the system.
Lipids: Lipids phosphorylation
Many proteins involved in signal transduction pathway can interact with lipids
[151, 164, 165, 166]. This module groups reaction involved in the metabolism of
lipids (mostly phosphorylation).
MAPK : Transmission of stimuli
Mitogen-Activated Protein Kinases (MAPKs) is family composed of three distinct
subfamilies, each involved at a specific level. The MAPK pathways consist in cascades
of phosphorylation events involving all three subfamilies. The MAPK kinase kinases
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(MKKKs) are first activated by specific stimuli and then phosphorylate MAPK ki-
nases (MKKs). Once activated, MKKs phosphorylate MAKPs, which in turn activate
various other proteins, including kinases, phospholipases, and transcription factors.
Cells can respond to a variety of different stimuli by activating specific MAPK path-
ways [167]. Reactions in this module correspond to the various MAPK pathways and
the phosphorylation cascade.
MAP3K7 : Transmission of stimuli
MAP3K7 (also known as TAK1) is an ubiquitin-dependent kinase that can form a
complex with TRAF6, TAB1 (also known as MAP3K7IP1), and TAB2 (also known
as MAP3K7IP2). Once ubiquitinated, MAP3K7 can activate the IKK and JNK
pathways [168]. This complex is thus linked to the activation of NF-κBand AP-1.
This module contains reactions forming the MAP3K7/TRAF6/TAB1/TAB2 com-
plex and its ubiquitination.
MyD88 : Transmission of stimuli from the TLRs
MyD88 is a TIR domain-containing adaptor protein that is being recruited by the
TLRs to transmit signals to specific kinases. MyD88 is involved in a wide range
of signaling pathways, such as IL-1 [169], and is shown to be essential to induce a
response to LPS in mice [170]. MyD88 also interacts directly with IRF7 to activate it
[171]. This module groups all the reactions that are dependent from the recruitment
of MyD88 by the TLRs.
NF-κB: Dissociation of NF-κB from IκB
The nuclear factor κB is a family of transcription factors involved in the immune and
inflammatory responses. They consist in dimers formed by members of the NF-κB
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family: RELA, NF-κB1, NF-κB2, c-REL, and RELB. NF-κBis in an inactive form
when bound to one of the IκB proteins. These inhibitory proteins (IκBα, IκBβ,
IκBε) retain the NF-κBcomplex in the cytoplasm [172]. NF-κBis activated in re-
sponse to various stimuli (pathogens, stress signals, pro-inflammatory cytokines). A
special family of kinases (IKK) is activated by these stimuli and phosphorylate IκB.
IκB is ubiquitinated and then degraded as a result, leaving NF-κB free for phospho-
rylation (activation) and translocation to the nucleus. GSK3β, TBK1, IKK1, PKCζ
proteins seems to play an important role in NF-κBphosphorylation [159]. NF-κBhas
a decisive role in the response of bacterial infections by regulating the expression of
many pro-inflammatory genes, such as cytokines, chemokines, or iNOS, and is im-
portant in the regulation of lymphocytes maturation [159]. NF-κBhas both pro- and
anti-apoptotic effects and has been linked with cancer [108]. This module includes
all the reactions related to NF-κBwith the exception of the ones necessary for the
phosphorylation of the complex, and the recruitment of IKK.
NF-κB phosphorylation: Activation of NF-κB
Once dissociated with its inhibitory protein IκB, NF-κBis free for phosphorylation
and activation. This module groups the reactions necessary for the phosphorylation
of NF-κBand its translocation to the nucleus.
PDK1 : Activation of PDK1
Phosphoinositide-dependent protein kinase (PDK-1) is a serine/threonine kinase and
a regulator of cell migration. It is linked to Reactive Oxygen Species (ROS) [173]
and has been shown to be activated by phospholipids [165]. Reactions in this module
correspond to the activation by phospholipids and phosphorylation of PDK1.
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PKCζ: Activation of PKCζ
Protein kinase C (PKC) is a family of enzymes which have an important role in
several signal transduction pathways such as the Ras one [174]. The ζ isoform of this
family (PKCζ) can be activated by various phospholipids and can influence gene ex-
pression in T-cells [166]. PKCζ is involved in the regulation of the MAPK pathway,
and the NF-κBand AP-1 transcription factors. PKCζ has also been related to ROS
production [175]. Reactions in this module include the activation (phosphorylation)
of PKCζ by phospholipids and its transport between the cytoplasm and the nucleus.
Rho GTPases: Activation of GTPases
GTPases are a class of proteins which are in an active form when bound to GTP and
in an inactive form when bound to GDP. Five family of GTPases exist in mammals:
Ras, Rho, Rab, Arf, and Ran. This “switch”-like behavior allows them to regulate
many signal transduction pathways. They have been linked with the production of
ROS and with the regulation of NF-κBand AP-1, thus regulating proliferation and
cell survival pathways [176, 177]. Reactions in this module correspond to the cycles
between active (GTP) and inactive (GDP) form of the Rho GTPases.
ROS production: Formation of the NADPH oxidase complex
ROS are a class of highly reactive chemicals which contain oxygen. Most of them
consist in superoxide anion, hydrogen peroxide, and hydroxyl radicals. ROS are a
by-product of the mitochondrion activity. At high dose, ROS provoke oxidative dam-
age which is harmful for the cells. At low dose they can regulate intracellular signal
transduction pathways and act as second messenger molecules [178, 76]. Their pro-
duction is induced in immune cells by various stimuli leading to a “respiratory burst”.
This activity is used to kill pathogens, but provokes “collateral damage”. ROS have
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also been described for their role in wound healing and platelets [164, 178]. ROS
are synthesized by the NADPH oxidase complex (or phox complex) composed of
p22phox, gp91phox, p47phox, p67phox, and Rac2. The p47phox subunit is the site
of many phosphorylation events which are necessary for NADPH oxidase activation
[179, 180, 181]. This module groups reactions necessary for the formation of the phox
complex. Most of the reactions correspond to the phosphorylation of p47phox.
Thioredoxin: Oxidation and reduction of thioredoxin
Thioredoxins are proteins with oxidoreductase activity and has been highly linked
with ROS. They can have a growth factor-like effect and can stimulate the recruit-
ment and proliferation of lymphocytes. Thioredoxins regulate AP-1, NF-κB, and the
expression of some cytokines [182]. This module includes the necessary reactions for
oxidation and reduction of thioredoxin.
TICAM : Transmission of stimuli from the TLRs and activation of IRF3
The TIR-containing adapter molecule (TICAM) is an adaptor molecule that trans-
mits the signal from the TLRs to specific kinases. This pathway is independent from
the MyD88 one. More specifically, TICAM-1 has been shown to transmit signals
from TLR3 to IKKε and TBK1, both kinases responsible for the induction of IRF3
and NF-κB[183]. Reactions in this module comprise the transmission of the signal
from TLR3 and TLR4 to IKKε and TBK1, as the phosphorylation of IRF3.
TLR: Binding of ligands with the TLRs
Reactions in this module correspond to the binding of the TLRs with their corre-
sponding ligands.
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Appendix B
Proteins to Genes Mapping
The following table maps species from the ihsTLR v1.0 model to genes in human
and mouse. Indexes and species names are taken from the original ihsTLR v1.0
model. Human and mouse genes are listed using their Entrez ID. Species can derive
from a single or multiple genes. Isoenzymes are separated with “|” and complex
subunits with “&”. The “|” character has priority over “&” in the formulas. As an
example, “Gene1&Gene2|Gene3” corresponds to a complex coded by Gene1 AND
(Gene2 OR Gene3).
Index Name Human genes (Entrez ID) Mouse genes (Entrez ID)
1 14-3-3(c) 7531 |7532 |7533 |10971 |7534 |7529 |2810 22627 |22628 |22629 |22630 |22631 |54401
|55948
2 14-3-3 KSR1(c) 7531 |7532 |7533 |10971 |7534 |7529 |2810&
8844&5604
22627 |22628 |22629 |22630 |22631 |54401
|55948&16706&26395
3 14-3-3 RAF1(c) 7531 |7532 |7533 |10971 |7534 |7529 |2810&
5894
22627 |22628 |22629 |22630 |22631 |54401
|55948&110157
12 A20(c) 7128 21929
24 ABIN(c) 10318 57783
25 ABIN A20(c) 10318&7128 57783&21929
26 AJUBA(c) 84962 16475
27 AJUBA CPX-2P3U(c) 84962&3654&7189&92610&7334&7335&
5590
16475&16179&22034&211550&93765&
66589&18762
28 AJUBA CPX-3P3U(c) 84962&3654&7189&92610&7334&7335&
5590
16475&16179&22034&211550&93765&
66589&18762
29 AKT(c) 207 |208 |10000 11651 |11652 |23797
30 AKT-2P(c) 207 |208 |10000 11651 |11652 |23797
31 AKT pail345p hs(c) 207 |208 |10000 11651 |11652 |23797
32 AKT pail345p hs-2P(c) 207 |208 |10000 11651 |11652 |23797
33 AKT pail345p hs-P(c) 207 |208 |10000 11651 |11652 |23797
34 BCL3(c) 602 12051
35 BTK(c) 695 12229
36 BTK-2PU(c) 695 12229
37 BTK CBL(c) 695&867 12229&12402
38 BTK IBTK(c) 695&25998 12229&108837
39 BTK SH3BP5(c) 695&9467 12229&24056
40 BTK pail345p hs(c) 695 12229
41 BTK pail345p hs-2P(c) 695 12229
42 BTK pail345p hs-P(c) 695 12229
43 BTRCP2(c) 23291 103583
44 CALPN(c) 823 |824 |825 |726 |827 |23473 |11132
|147968 |10753 |388743 |11131 |92291
|440854 |826 |84290
12333 |12334 |12335 |12337 |12338 |12339
|23830 |60594 |73647 |170725 |268958
|381122 |12336 |69543
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45 CALPN 3ca2(c) 823 |824 |825 |726 |827 |23473 |11132
|147968 |10753 |388743 |11131 |92291
|440854 |826 |84290
12333 |12334 |12335 |12337 |12338 |12339
|23830 |60594 |73647 |170725 |268958
|381122 |12336 |69543
46 CAM(c) 801 12313
47 CAMK2(c) 815 |816 |818 |817 12322 |12323 |12325 |108058
48 CAM 3ca2(c) 801 12313
49 CAM CAMK2(c) 801&815 |816 |818 |817 12313&12322 |12323 |12325 |108058
50 CAM CAMK2-P(c) 801&815 |816 |818 |817 12313&12322 |12323 |12325 |108058
51 CASP1(c) 834 12362
52 CASP3(c) 836 12367
53 CASP8(c) 841 12370
54 CASP9(c) 842 12371
55 CBL(c) 867 12402
56 CBL-P(c) 867 12402
57 CD14(c) 929 12475
58 CDC42 GDP(c) 998 12540
59 CDC42 GTP(c) 998 12540
60 CDC42 VAV1(c) 998&7409 12540&22324
61 CK2(c) 1457&1459&1460 12995&13000&13001
62 CK2-P(c) 1457&1459&1460 12995&13000&13001
63 CTAK1(c) 4140 17169
64 CTAK1-P(c) 4140 17169
65 CYLD(c) 1540 74256
66 DAGK(c) 1606 |8526 |8525 |1608 |1609 |1607 |8526
|9162 |139189 |160851
13139 |56077 |104418 |110197 |110524
|217480 |227333 |320127 |331374 |380921
67 DAGK-P(c) 1606 |8526 |8525 |1608 |1609 |1607 |8526
|9162 |139189 |160851
13139 |56077 |104418 |110197 |110524
|217480 |227333 |320127 |331374 |380921
69 ECSIT(c) 51295 26940
70 EEA1(c) 8411 216238
71 EEA1-D(c) 8411 216238
72 EIF2A(c) 83939 229317
73 EIF2A-P(c) 83939 229317
74 EIF4E(c) 1977 13684
75 EIF4E-P(c) 1977 13684
76 FADD(c) 8772 14082
77 FADD PCASP8(c) 8772&841 14082&12370
78 FMAP3K1(c) 4214 26401
85 GP91PHOX(c) 1536 13058
86 GSK3B(c) 2932 56637
87 GSK3B-2P(c) 2932 56637
88 GSK3B-P(c) 2932 56637
89 HSP27(c) 3315 |3316 15507 |69253
90 HSP27-3P(c) 3315 |3316 15507 |69253
91 IBTK(c) 25998 108837
92 IKBA(c) 4792 18035
93 IKBA-2P2U(c) 4792 18035
94 IKBB(c) 4793 18036
95 IKBB-2P(c) 4793 18036
96 IKBB-2P2U(c) 4793 18036
97 IKBB-2PU(c) 4793 18036
98 IKK(c) 1147&3551&8517 12675&16150&16151
99 IKK-2P(c) 1147&3551&8517 12675&16150&16151
100 IKK-3P(c) 1147&3551&8517 12675&16150&16151
101 IKK-P(c) 1147&3551&8517 12675&16150&16151
102 IKKE(c) 9641 56489
103 IKKE-P(c) 9641 56489
104 IKK PKR(c) 1147&3551&8517&5610 12675&16150&16151&19106
105 IKK PKR TRAF6(c) 1147&3551&8517&5610&7189 12675&16150&16151&19106&22034
106 IKK RIP1 TICAM1P(c) 1147&3551&8517&8737&148022 12675&16150&16151&19766&106759
107 IKK RIP2 NOD1P(c) 1147&3551&8517&8767&10392 12675&16150&16151&192656&107607
108 IKK RIP2 NOD2P(c) 1147&3551&8517&8767&64127 12675&16150&16151&192656&257632
109 IKK RIP2 TRIP6
TRAF2(c)
1147&3551&8517&8767&7205&7186 12675&16150&16151&192656&22051&
22030
110 IKK SRC(c) 1147&3551&8517&6714 12675&16150&16151&20779
111 IL1A(c) 3552 16175
112 IL1B(c) 3553 16176
113 IL1R1(c) 3554 16177
114 IL1R1/L(c) 3554 16177
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115 IL1R1/L/AP(c) 3554 16177
116 IL1R1/L/AP-P(c) 3554 16177
118 IL1R2(c) 7850 16178
119 IL1R2/AP(c) 7850 16178
120 IL1RAP(c) 3556 16180
121 IMPA3(c) 3839 16648
122 IRAK1(c) 3654 16179
123 IRAK1-2PU(c) 3654 16179
124 IRAK1C(c) 3654 16179
125 IRAK1C TOLLIP(c) 3654&54472 16179&54473
126 IRAK1 ECSIT(c) 3654&92610&7189&7334&7335&51295 16179&211550&22034&93765&66589&
26940
127 IRAK1 ECSIT
FMAP3K1(c)
3654&92610&7189&7334&7335&51295&
4214&836
16179&211550&22034&93765&66589&
26940&26401&12367
128 IRAK1 MAP3K3-2P3U(c) 3654&92610&7189&7334&7335&4215 16179&211550&22034&93765&66589&
26406
129 IRAK1 MAP3K3-3P3U(c) 3654&92610&7189&7334&7335&4215 16179&211550&22034&93765&66589&
26406
130 IRAK1 MAP3K3-4P3U(c) 3654&92610&7189&7334&7335&4215 16179&211550&22034&93765&66589&
26406
131 IRAK1 MAP3K5(c) 3654&92610&7189&7334&7335&4217 16179&211550&22034&93765&66589&
26408
132 IRAK1 MAP3K7-2P3U(c) 3654&92610&7189&7334&7335&6885&
10454&257397&23118
16179&211550&22034&93765&66589&
26409&66513&66724&68652
133 IRAK1 MAP3K7-4P3U(c) 3654&92610&7189&7334&7335&6885&
10454&257397&23118
16179&211550&22034&93765&66589&
26409&66513&66724&68652
134 IRAK1 PLNO3(c) 3654&246330 16179&240518
135 IRAK1 TIFA-2P(c) 3654&92610&7189&7334&7335 16179&211550&22034&93765&66589
136 IRAK1 TIFA-2P3U(c) 3654&92610&7189&7334&7335 16179&211550&22034&93765&66589
137 IRAK1 TIFA A20(c) 3654&92610&7189&7334&7335&7128 16179&211550&22034&93765&66589&
21929
138 IRAK1 TIFA CYLD(c) 3654&92610&7189&7334&7335&1540 16179&211550&22034&93765&66589&
74256
139 IRAK1 TOLLIP(c) 3654&54472 16179&54473
140 IRAK2(c) 3656 108960
141 IRAK4(c) 51135 266632
142 IRAK MYD TIR(c) 3654&51135&4615 16179&266632&17874
143 IRAK MYD TIR-2P(c) 3654&51135&4615 16179&266632&17874
144 IRAK MYD TIR-P(c) 3654&51135&4615 16179&266632&17874
145 IRAK MYD TIRAP-2P(c) 3654&51135&4615&114609 16179&266632&17874&117149
146 IRAK TOLLIP TIR(c) 3654&51135&4615&114609&54472&7189 16179&266632&17874&117149&54473&
22034
147 IRAK TRAF6(c) 3654&51135&4615&7189&7334&7335&
92610
16179&266632&17874&22034&93765&
66589&211550
148 IRAK TRAF6 TIRAP(c) 3654&51135&4615&7189&7334&7335&
92610
16179&266632&17874&22034&93765&
66589&211550
149 IRF3(c) 3661 54131
150 IRF3-2P(c) 3661 54131
151 IRF3-2PD(c) 3661 54131
152 IRF7(c) 3665 54123
153 IRF7-2P(c) 3665 54123
154 KSR1(c) 8844 16706
155 KSR1-P(c) 8844 16706
156 KSR1 MAP2K1(c) 8844&5604 16706&26395
157 KSR1 RAF1-7P(c) 8844&5604&5894 16706&26395&110157
158 KSR1 RAF1 MAPK3/1-
4P(c)
8844&5604&5894&5594&5595 16706&26395&110157&26413&26417
159 KSR1 RAF1 MAPK3/1-
5P(c)
8844&5604&5894&5594&5595 16706&26395&110157&26413&26417
160 KSR1 RAF1 MAPK3/1-
7P(c)
8844&5604&5894&5594&5595 16706&26395&110157&26413&26417
161 KSR1 RAF1 MAPK3/1-
9P(c)
8844&5604&5894&5594&5595 16706&26395&110157&26413&26417
162 KSR2(c) 283455 333050
163 LBP(c) 3929 16803
164 MAP2K1(c) 5604 26395
165 MAP2K1-2P(c) 5604 26395
166 MAP2K3(c) 5606 26397
167 MAP2K3-2P(c) 5606 26397
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168 MAP2K4(c) 6416 26398
169 MAP2K4-2P(c) 6416 26398
170 MAP2K6(c) 5608 26399
171 MAP2K6-P(c) 5608 26399
172 MAP2K7(c) 5609 26400
173 MAP2K7-2P(c) 5609 26400
174 MAP3K1(c) 4214 26401
175 MAP3K1-P(c) 4214 26401
176 MAP3K1-PU(c) 4214 26401
177 MAP3K14(c) 9020 53859
178 MAP3K14-P(c) 9020 53859
179 MAP3K3(c) 4215 26406
180 MAP3K5(c) 4217 26408
181 MAP3K5-2P(c) 4217 26408
182 MAP3K5-P(c) 4217 26408
183 MAP3K5 TRXRED(c) 4217&7295 26408&22166
184 MAP3K7(c) 6885 26409
185 MAP3K7/IP123(c) 6885&10454&257397&23118 26409&66513&66724&68652
186 MAP3K7IP1(c) 10454 66513
187 MAP3K7IP2/3(c) 257397&23118 66724&68652
188 MAP3K7IP TRAF6-
2P2U(c)
6885&10454&257397&23118&7189&7334&
7335
26409&66513&66724&68652&22034&
93765&66589
189 MAP3K7IP TRAF6-
2P3U(c)
6885&10454&257397&23118&7189&7334&
7335
26409&66513&66724&68652&22034&
93765&66589
190 MAP3K7IP TRAF6-
3P3U(c)
6885&10454&257397&23118&7189&7334&
7335
26409&66513&66724&68652&22034&
93765&66589
191 MAP3K7IP TRAF6-
5P3U(c)
6885&10454&257397&23118&7189&7334&
7335
26409&66513&66724&68652&22034&
93765&66589
192 MAP3K7IP TRAF6-
6P3U(c)
6885&10454&257397&23118&7189&7334&
7335
26409&66513&66724&68652&22034&
93765&66589
193 MAP3K8(p52)(c) 1326 26410
194 MAP3K8(p52) NFKB(c) 1326&4790 26410&18033
195 MAP3K8(p58)(c) 1326 26410
196 MAP3K8(p58)-P(c) 1326 26410
197 MAP3K8(p58) KSR2(c) 1326&283455 26410&333050
198 MAP3K8 NFKB(c) 1326&4790 26410&18033
199 MAP3K8 NFKB-P(c) 1326&4790 26410&18033
200 MAPK11(c) 5600 19094
201 MAPK11-2P(c) 5600 19094
202 MAPK14(c) 1432 26416
203 MAPK14-2P(c) 1432 26416
204 MAPK3/1(c) 5594&5595 26413&26417
205 MAPK3/1-2P(c) 5594&5595 26413&26417
206 MAPK3/1-2PD(c) 5594&5595 26413&26417
207 MAPK8(c) 5599 26419
208 MAPK8-2P(c) 5599 26419
209 MAPK8-P(c) 5599 26419
210 MAPKAPK2(c) 9261 17164
211 MAPKAPK2-2P(c) 9261 17164
212 MBP(c) 4155 17196
213 MBP-P(c) 4155 17196
214 MD2(c) 23643 17087
215 MD2-D(c) 23643 17087
216 MKNK1(c) 8569 17346
217 MKNK1-P(c) 8569 17346
218 MKNK2(c) 2872 17347
219 MKNK2-P(c) 2872 17347
221 MSK1(c) 9252 73086
222 MSK1-5P(c) 9252 73086
223 MYD88(c) 4615 17874
224 MYD88-D(c) 4615 17874
225 MYD88S(c) 4615 17874
226 MYD88 IRAK TOLLIP(c) 4615&54472&3654&51135 17874&54473&16179&266632
227 MYD88 IRAK TOLLIP-
2P(c)
4615&54472&3654&51135 17874&54473&16179&266632
228 MYD88 IRAK TOLLIP-
P(c)
4615&54472&3654&51135 17874&54473&16179&266632
229 MYD88 IRF7(c) 4615&7189&3665 17874&22034&54123
107
230 MYD88 MyD88S(c) 4615 17874
231 NFKB(p105)(c) 4790 18033
232 NFKB(p105)-2P(c) 4790 18033
233 NFKB(p105)-2PU(c) 4790 18033
234 NFKB(p105) BTRCP2(c) 4790&23291 18033&103583
235 NFKB(p105) UBCH5A(c) 4790&7321 18033&216080
236 NFKB(p50)(c) 4790 18033
237 NFKB(p50)-PD(c) 4790 18033
238 NFKB(p50) BCL3(c) 4790&602 18033&12051
239 NFKB(p50) IMPA3(c) 4790&3839 18033&16648
240 NFKB(p50/p105)(c) 4790 18033
241 NFKB(p50/p65)(c) 4790&5970 18033&19697
242 NFKB(p50/p65)-5P(c) 4790&5970 18033&19697
243 NFKB(p50/p65)-P(c) 4790&5970 18033&19697
244 NFKB(p50/p65)-P2(c) 4790&5970 18033&19697
245 NFKB(p50/p65)-P3(c) 4790&5970 18033&19697
246 NFKB(p50/p65)-P4(c) 4790&5970 18033&19697
247 NFKB(p50/p65)-P5(c) 4790&5970 18033&19697
248 NFKB(p65)(c) 5970 19697
249 NFKB(p65) SOCS1(c) 5970&8651 19697&12703
250 NFKB FRAG(c) 4790 18033
251 NFKB FRAG2(c) 4790 18033
252 NFKB IKBA(c) 4790&5970&4792 18033&19697&18035
253 NFKB IKBA-2P(c) 4790&5970&4792 18033&19697&18035
254 NFKB IKBA-2P2U(c) 4790&5970&4792 18033&19697&18035
255 NFKB IKBA-5P(c) 4790&5970&4792 18033&19697&18035
256 NFKB IKBA-5P2A(c) 4790&5970&4792 18033&19697&18035
257 NFKB IKBA-5P5A(c) 4790&5970&4792 18033&19697&18035
258 NFKB IKBA BTRCP2(c) 4790&5970&4792&23291 18033&19697&18035&103583
259 NFKB IKBA UBCH5(c) 4790&5970&4792&7322 |7323 18033&19697&18035&56550 |66105
260 NFKB IKBB(c) 4790&5970&4793 18033&19697&18036
261 NFKB IKBB-2P(c) 4790&5970&4793 18033&19697&18036
262 NFKB IKBB-2PU(c) 4790&5970&4793 18033&19697&18036
263 NFKB IKBB-7P(c) 4790&5970&4793 18033&19697&18036
264 NFKB IKBB BTRCP2(c) 4790&5970&4793&23291 18033&19697&18036&103583
275 NFKB PKAC(c) 4790&5970&5566&5567 18033&19697&18747&18749
276 NFKB PKAC IKBA(c) 4790&5970&5566&5567&4792 18033&19697&18747&18749&18035
277 NFKB PKAC IKBB(c) 4790&5970&5566&5567&4793 18033&19697&18747&18749&18036
278 NOD1(c) 10392 107607
279 NOD1P(c) 10392 107607
280 NOD2(c) 64127 257632
281 NOD2P(c) 64127 257632
282 NSF(c) 4905 18195
283 NSF STXN13(c) 4905&23673 18195&100226
284 P22PHOX(c) 1535 13057
285 P40PHOX(c) 4689 17972
286 P47PHOX(c) 653361 17969
287 P47PHOX-3P(c) 653361 17969
288 P47PHOX-8P(c) 653361 17969
289 P67PHOX(c) 4688 17970
290 PAK1(c) 5058 18479
291 PAK1P(c) 5058 18479
292 PAK1P-P(c) 5058 18479
293 PCASP8(c) 841 12370
294 PCASP9(c) 842 12371
295 PCASP9 NOD1P(c) 842&10392 12371&107607
296 PCASP9 NOD2P(c) 842&64127 12371&257632
297 PDK1(c) 5170 18607
298 PDK1 pail345p hs(c) 5170 18607
299 PDK1 pail345p hs-P(c) 5170 18607
300 PI34P5K(c) 80243 |57580 109294 |277360
301 PI34P5K-P(c) 80243 |57580 109294 |277360
302 PI3K(p150)(c) 30849 75669
303 PI3K(vps34)(c) 5289 225326
304 PI3K1A(c) 5290&5293&5294&5291 18706&18707&30955&74769
305 PI3K1A-P(c) 5290&5293&5294&5291 18706&18707&30955&74769
306 PI3K3(c) 5295 18708
307 PI3K3 RAB5(c) 5295&5869 |5878 |5868 18708&19344 |19345 |271457
108
308 PI3K3 RAB5 pail hs(c) 5295&5869 |5878 |5868 18708&19344 |19345 |271457
309 PI3P4K(c) 55300&55361&5298&5297 67073&84095&107650&224020
310 PI3P4K-P(c) 55300&55361&5298&5297 67073&84095&107650&224020
311 PI4P5K(c) 23396&8395&8394 18717&18719&18720
312 PI4P5K-P(c) 23396&8395&8394 18717&18719&18720
313 PKA(c) (5573&5575) |(5576&5577) (19084&19085) |(19087&19088)
314 PKA-2P(c) (5573&5575) |(5576&5577) (19084&19085) |(19087&19088)
315 PKAC(c) 5566&5567 18747&18749
316 PKAC-P(c) 5566&5567 18747&18749
317 PKCA(c) 5578 18750
318 PKCA-3P(c) 5578 18750
319 PKCA-P(c) 5578 18750
320 PKCA ca2(c) 5578 18750
321 PKCA dag ps hs(c) 5578 18750
322 PKCB2(c) 5579 18751
323 PKCB2-3P(c) 5579 18751
324 PKCB2-P(c) 5579 18751
325 PKCB2 ca2(c) 5579 18751
326 PKCB2 dag ps hs(c) 5579 18751
327 PKCD(c) 5580 18753
328 PKCD-2P(c) 5580 18753
329 PKCD-P(c) 5580 18753
330 PKCD dag ps hs-2P(c) 5580 18753
331 PKCZ(c) 5590 18762
332 PKCZ-P(c) 5590 18762
333 PKCZ pa hs(c) 5590 18762
334 PKCZ ps hs(c) 5590 18762
335 PKR(c) 5610 19106
336 PKR-2PD(c) 5610 19106
337 PKR-D(c) 5610 19106
338 PKR TRAF6-2PD(c) 5610&7189 19106&22034
339 PLCB2(c) 5330 18796
340 PLCB2P(c) 5330 18796
341 PLCG(c) 5335 |5336 18803 |234779
342 PLCG-P(c) 5335 |5336 18803 |234779
343 PLD(c) 5337 18805
344 PLDP(c) 5337 18805
345 PLNO1(c) 57162 67245
346 PLNO1 IRAK4(c) 57162&4615&51135 67245&17874&266632
347 PLNO1 IRAK4 TIRAP(c) 57162&4615&51135&114609 67245&17874&266632&117149
348 PLNO3(c) 246330 240518
349 PP2A ABC(c) 5518&5519&5515&5516&5520&5521&
5522&55844 |5518&5519&5515&5516&
5523&28227&55012 |5518&5519&5515&
5516&5524 |5518&5519&5515&5516&
5525&5526&5527&5528&5529
51792&73699&19052&19053&71978&
72930&269643&52432 |51792&73699&
19052&19053&235542&59032&19054
|51792&73699&19052&19053&110849
|51792&73699&19052&19053&226849&
225849&26931&21770&26932
350 PP2A ABC-P(c) 5518&5519&5515&5516&5520&5521&
5522&55844 |5518&5519&5515&5516&
5523&28227&55012 |5518&5519&5515&
5516&5524 |5518&5519&5515&5516&
5525&5526&5527&5528&5529
51792&73699&19052&19053&71978&
72930&269643&52432 |51792&73699&
19052&19053&235542&59032&19054
|51792&73699&19052&19053&110849
|51792&73699&19052&19053&226849&
225849&26931&21770&26932
351 PP2C B1(c) 5495 19043
352 PP2C B1-P(c) 5495 19043
353 PP2C E(c) 151742 242083
354 PP2C E-P(c) 151742 242083
355 PPAP(c) 8611 |8612 |8613 |84513 |403313 |84814
|196051
19012 |50784 |67916 |71910 |74411 |227721
|381925
356 PPAP-P(c) 8611 |8612 |8613 |84513 |403313 |84814
|196051
19012 |50784 |67916 |71910 |74411 |227721
|381925
357 PRE IL1A(c) 3552 16175
358 PRE IL1A CALPN
3ca2(c)
3552&823 |824 |825 |726 |827 |23473 |11132
|147968 |10753 |388743 |11131 |92291
|440854 |826 |84290
16175&12333 |12334 |12335 |12337 |12338
|12339 |23830 |60594 |73647 |170725
|268958 |381122 |12336 |69543
359 PRE IL1B(c) 3553 16176
360 PRE IL1B CASP1(c) 3553&834 16176&12362
361 RAB5 GDP(c) 5869 |5878 |5868 19344 |19345 |271457
109
362 RAB5 GTP(c) 5869 |5878 |5868 19344 |19345 |271457
363 RAB5 RBPTIN5 RBX5(c) 5869 |5878 |5868&9135&27342 19344 |19345 |271457&54189&56715
364 RAC1 GDP(c) 5879 19353
365 RAC1 GTP(c) 5879 19353
366 RAC1 VAV1(c) 5879&7409 19353&22324
367 RAF1(c) 5894 110157
368 RAF1-2P(c) 5894 110157
369 RAF1-4P(c) 5894 110157
370 RAF1-P(c) 5894 110157
371 RAS GDP(c) 2669 |3265 |3845 |22808 |4893 |51655
|28954 |6237 |5898 |6236 |5899 |22800
|54769 |9077 |387496 |65997 |28512 |51285
|28511 |57826 |5912 |23551 |10633 |5908
|5911 |5906 |161253 |148252 |85004 |91608
|3266 |79785
14579 |15461 |16653 |17532 |18176 |19416
|19700 |20130 |56044 |56437 |64143 |66922
|68203 |68895 |68939 |69721 |70784 |71966
|72065 |74012 |75141 |75668 |76108 |215449
|109905 |140743 |208666 |232441 |276952
|353283 |632971
372 RAS GTP(c) 2669 |3265 |3845 |22808 |4893 |51655
|28954 |6237 |5898 |6236 |5899 |22800
|54769 |9077 |387496 |65997 |28512 |51285
|28511 |57826 |5912 |23551 |10633 |5908
|5911 |5906 |161253 |148252 |85004 |91608
|3266 |79785
14579 |15461 |16653 |17532 |18176 |19416
|19700 |20130 |56044 |56437 |64143 |66922
|68203 |68895 |68939 |69721 |70784 |71966
|72065 |74012 |75141 |75668 |76108 |215449
|109905 |140743 |208666 |232441 |276952
|353283 |632971
373 RAS GTP RAF1(c) 5894&2669 |3265 |3845 |22808 |4893 |51655
|28954 |6237 |5898 |6236 |5899 |22800
|54769 |9077 |387496 |65997 |28512 |51285
|28511 |57826 |5912 |23551 |10633 |5908
|5911 |5906 |161253 |148252 |85004 |91608
|3266 |79785
110157&14579 |15461 |16653 |17532 |18176
|19416 |19700 |20130 |56044 |56437 |64143
|66922 |68203 |68895 |68939 |69721 |70784
|71966 |72065 |74012 |75141 |75668 |76108
|215449 |109905 |140743 |208666 |232441
|276952 |353283 |632971
374 RAS GTP RIN1(c) 9610&2669 |3265 |3845 |22808 |4893 |51655
|28954 |6237 |5898 |6236 |5899 |22800
|54769 |9077 |387496 |65997 |28512 |51285
|28511 |57826 |5912 |23551 |10633 |5908
|5911 |5906 |161253 |148252 |85004 |91608
|3266 |79785
225870&14579 |15461 |16653 |17532 |18176
|19416 |19700 |20130 |56044 |56437 |64143
|66922 |68203 |68895 |68939 |69721 |70784
|71966 |72065 |74012 |75141 |75668 |76108
|215449 |109905 |140743 |208666 |232441
|276952 |353283 |632971
375 RBPTIN5(c) 9135 54189
376 RBPTIN5 RBX5(c) 9135&27342 54189&56715
377 RBX5(c) 27342 56715
378 RHOA GDP(c) 387 11848
379 RHOA GTP(c) 387 11848
380 RIN1(c) 9610 225870
381 RIP1(c) 8737 19766
382 RIP1 TICAM1P(c) 8737&7189&148022 19766&22034&106759
383 RIP2(c) 8767 192656
384 RIP2 NOD1P(c) 8767&10392 192656&107607
385 RIP2 NOD2P(c) 8767&64127 192656&257632
386 RIP2 TRIP6 NOD1P(c) 8767&10392&7205 192656&107607&22051
387 RIP2 TRIP6 TRAF2(c) 8767&64127&7205 192656&22030&22051
388 RKIP(c) 5037 23980
389 RKIP MAP3K14(c) 5037&9020 23980&53859
390 RKIP MAP3K7IP
TRAF6(c)
5037&10454&257397&23118&7189&7334&
7335
23980&66513&66724&68652&22034&
93765&66589
391 SCD14(c) 929 12475
392 SGK(c) 6446 |10110 |23678 20393 |27219 |170755
393 SGK-P(c) 6446 |10110 |23678 20393 |27219 |170755
394 SH3BP5(c) 9467 24056
395 SIGIRR(c) 59307 24058
396 SIGIRR-D(c) 59307 24058
397 SOCS1(c) 8651 12703
398 SQSTM1(c) 8878 18412
399 SQSTM1 PKCZ(c) 8878&5590 18412&18762
400 SRCK(c) 6714 20779
401 SRCK-P(c) 6714 20779
402 SRTK(c) 7006 |7294 20963 |21682 |22165
403 SRTK-P(c) 7006 |7294 20963 |21682 |22165
404 ST2L(c) 9173 |11018 17082 |17083
405 ST2L TIRAP(c) 9173 |11018&114609&4615 17082 |17083&117149&17874
406 STLR2(c) 7097 24088
407 STLR2/L SCD14(c) 7097&929 24088&12475
408 STLR2 CD14(c) 7097&929 24088&12475
409 STLR4(c) 7099 21898
110
410 STLR4/L MD2(c) 7099&23643 21898&17087
411 STLR4 MD2(c) 7099&23643 21898&17087
412 STXN13(c) 23673 100226
413 TBK1(c) 29110 56480
414 TBK1-P(c) 29110 56480
415 TICAM1(c) 148022 106759
416 TICAM1P(c) 148022 106759
417 TICAM1P IKKE(c) 148022&9641 106759&56489
418 TICAM1P TBK1(c) 148022&29110 106759&56480
419 TICAM2(c) 353376 225471
420 TICAM2 TLR4/L MD2(c) 353376&7099&23643 225471&21898&17087
421 TIFA(c) 92610 211550
423 TIRAP(c) 114609 117149
424 TIR MYD(c) 4615 17874
425 TIR MYD FADD(c) 4615&8772 17874&14082
426 TIR MYD IRAK4(c) 4615&51135 17874&266632
427 TIR MYD TOLLIP(c) 114609&4615&3654&51135&54472 117149&17874&16179&266632&54473
428 TIR TIRAP(c) 114609 117149
429 TIR TIRAP IRAK2(c) 114609&4615&51135&3656 117149&17874&266632&108960
430 TIR TIRAP IRAK4(c) 114609&4615&51135 117149&17874&266632
431 TIR TIRAP MYD(c) 114609&4615 117149&17874
432 TIR TIRAP MYD
FADD(c)
114609&4615&8772 117149&17874&14082
433 TIR TIRAP TOLLIP(c) 114609&4615&3654&51135&54472 117149&17874&16179&266632&54473
434 TIR TIRAP TOLLIP-
2P(c)
114609&4615&3654&51135&54472 117149&17874&16179&266632&54473
435 TIR TIRAP TOLLIP-P(c) 114609&4615&3654&51135&54472 117149&17874&16179&266632&54473
436 TLR1(c) 7096 21897
437 TLR1/10/L(c) 7096&81793
438 TLR1/2/L(c) 7096&7097 21897&24088
439 TLR10(c) 81793
440 TLR10/L-D(c) 81793
441 TLR11(c) 442887 239081
442 TLR11/L-D(c) 442887 239081
443 TLR2(c) 7097 24088
444 TLR2/10/L(c) 7097&81793
445 TLR2/6/L(c) 7097&10333 24088&21899
446 TLR2/L-2PD(c) 7097 24088
447 TLR2/L-D(c) 7097 24088
448 TLR4(c) 7099 21898
449 TLR4/L MD2-D(c) 7099&23643 21898&17087
450 TLR4/L MD2 TRD3A(c) 7099&23643&54476 21898&17087&108086
451 TLR4 MD2(c) 7099&23643 21898&17087
452 TLR4 SIGIRR(c) 7099&59307 21898&24058
453 TLR4 SIGIRR TRAF6(c) 7099&59307&7189 21898&24058&22034
454 TLR5(c) 7100 53791
455 TLR5/L-D(c) 7100 53791
456 TLR5 SIGIRR(c) 7100&59307 53791&24058
457 TLR5 SIGIRR TRAF6(c) 7100&59307&7189 53791&24058&22034
458 TLR6(c) 10333 21899
459 TLR9/L TRD3A(c) 54106&54476 81897&108086
460 TLR9 SIGIRR(c) 54106&59307 81897&24058
461 TLR9 SIGIRR TRAF6(c) 54106&59307&7189 81897&24058&22034
476 TOLLIP(c) 54472 54473
477 TOLLIP-P(c) 54472 54473
478 TOLLIP-PU(c) 54472 54473
479 TOLLIP pail345p hs(c) 54472 54473
480 TOLLIP pail3p hs(c) 54472 54473
481 TRAF2(c) 7186 22030
482 TRAF6(c) 7189 22034
483 TRAF6-D(c) 7189 22034
484 TRAF6-UD(c) 7189 22034
485 TRAF6 SIGIRR(c) 7189&59307 22034&24058
486 TRD3A(c) 54476 108086
487 TRIP6(c) 7205 22051
488 TRXOX(c) 7295 22166
489 TRXRD(c) 10587 |7296 |114112 26462 |50493 |232223
490 TRXRED(c) 7295 22166
111
491 TRX NADPH(c) 10587 |7296 |114112 26462 |50493 |232223
492 UBC13(c) 7334 93765
493 UBCH5(c) 7322 |7323 56550 |66105
494 UBCH5A(c) 7321 216080
496 UEV1A(c) 7335 66589
497 VAV1(c) 7409 22324
498 VAV1-P(c) 7409 22324
531 BDFN2(e) 1673 13215
550 HSP60(e) 3329 15510
551 HSP70(e) 3303 15511
552 IL1A(e) 3552 16175
553 IL1B(e) 3553 16176
579 PRE IL1A(e) 3552 16175
640 TLR3(l) 7098 142980
641 TLR3/L-2PD(l) 7098 142980
642 TLR3/L-D(l) 7098 142980
649 AKT-2P(n) 207 |208 |10000 11651 |11652 |23797
650 AP1 FOS JUN(n) 2353&3725 14281&16476
652 AP1 JUN(n) 3725 16476
653 ATF2(n) 1386 11909
654 ATF2-P(n) 1386 11909
655 BCL3(n) 602 12051
656 BTRCP1(n) 8945 12234
657 CAM CAMK2(n) 801&815 |816 |818 |817 12313&12322 |12323 |12325 |108058
658 CAM CAMK2-P(n) 801&815 |816 |818 |817 12313&12322 |12323 |12325 |108058
659 CBP(n) 1387 12914
660 CREB(n) 468 |1385 |10488 |9586 11911 |12912 |12913 |231991
661 CREB-2PD(n) 468 |1385 |10488 |9586 11911 |12912 |12913 |231991
662 CREB-D(n) 468 |1385 |10488 |9586 11911 |12912 |12913 |231991
663 CREB CBP(n) 468 |1385 |10488 |9586&1387 11911 |12912 |12913 |231991&12914
664 CREB CRE(n) 468 |1385 |10488 |9586 11911 |12912 |12913 |231991
665 CREB CRE-2P(n) 468 |1385 |10488 |9586 11911 |12912 |12913 |231991
666 CREB CRE-P(n) 468 |1385 |10488 |9586 11911 |12912 |12913 |231991
668 ELK1(n) 2002 13712
669 ELK1-2P(n) 2002 13712
670 ELK1 SRE(n) 2002 13712
671 FOS(n) 2353 14281
672 FOS-6P(n) 2353 14281
673 FOS JUN(n) 2353&3725 14281&16476
674 GSK3B(n) 2932 56637
675 GSK3B-P(n) 2932 56637
676 HDAC1(n) 3065 433759
677 HDAC3(n) 8841 15183
678 HDAC3-A(n) 8841 15183
679 HH3(n) 15077 |3020 |3021 |97114 |8355 |8968 |8352
|8351 |8358 |8353 |8357 |8354 |8356 |333932
|333931 |126961 |653604 |8350 |440093
15077 |15078 |15081 |97114 |97908 |260423
|319148 |319149 |319150 |319151 |319152
|319153 |319154 |360198 |625328
680 HH3-P(n) 15077 |3020 |3021 |97114 |8355 |8968 |8352
|8351 |8358 |8353 |8357 |8354 |8356 |333932
|333931 |126961 |653604 |8350 |440093
15077 |15078 |15081 |97114 |97908 |260423
|319148 |319149 |319150 |319151 |319152
|319153 |319154 |360198 |625328
681 HMG14(n) 3150 15312
682 HMG14-P(n) 3150 15312
683 HNRNPA1(n) 3178 15382
684 HNRNPA1-3P(n) 3178 15382
685 IKBA(n) 4792 18035
686 IKBB-2P(n) 4793 18036
687 IKBZ(n) 64332 80859
688 IMPA3(n) 3839 16648
689 IRF3-2PD(n) 3661 54131
690 IRF7-2P(n) 3665 54123
692 ISRE IRF3(n) 3661 54131
693 ISRE IRF7(n) 3665 54123
694 JUN(n) 3725 16476
695 JUN-2P(n) 3725 16476
696 JUN-2PD(n) 3725 16476
698 MAP2K3(n) 5606 26397
699 MAP2K3-2P(n) 5606 26397
700 MAP2K6(n) 5608 26399
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701 MAP2K6-P(n) 5608 26399
702 MAPK11(n) 5600 19094
703 MAPK11-2P(n) 5600 19094
704 MAPK11 MAPKAPK2(n) 5600&9261 19094&17164
705 MAPK14(n) 1432 26416
706 MAPK14-2P(n) 1432 26416
707 MAPK14 MAPKAPK2(n) 1432&9261 26416&17164
708 MAPK3/1-2PD(n) 5594&5595 26413&26417
709 MAPK3/1-D(n) 5594&5595 26413&26417
710 MAPK8(n) 5599 26419
711 MAPK8-2P(n) 5599 26419
712 MAPKAPK2(n) 9261 17164
713 MAPKAPK2-2P(n) 9261 17164
714 MAPKAPK2-P(n) 9261 17164
715 MKP(n) 1844 |1850 |1843 |51207 |11072 |11221
|78986 |285193 |1848 |142679 |54935 |80824
|8446 |1845 |63904 |150290 |1852 |11266
|56940 |1849 |1847 |92235 |128853 |1846
13537 |18218 |19252 |27389 |56405 |63953
|66959 |67446 |67603 |68082 |68440 |70686
|72102 |72349 |73547 |75219 |75590 |80915
|105352 |235584 |240672 |240892 |252864
|319520
716 MKP-P(n) 1844 |1850 |1843 |51207 |11072 |11221
|78986 |285193 |1848 |142679 |54935 |80824
|8446 |1845 |63904 |150290 |1852 |11266
|56940 |1849 |1847 |92235 |128853 |1846
13537 |18218 |19252 |27389 |56405 |63953
|66959 |67446 |67603 |68082 |68440 |70686
|72102 |72349 |73547 |75219 |75590 |80915
|105352 |235584 |240672 |240892 |252864
|319520
717 MSK1(n) 9252 73086
718 MSK1-2P(n) 9252 73086
719 MSK1-5P(n) 9252 73086
720 MYC(n) 4609 17869
721 MYC-2P(n) 4609 17869
722 NFKB(p50)(n) 4790 18033
723 NFKB(p50)-PD(n) 4790 18033
724 NFKB(p50) BCL3(n) 4790&602 18033&12051
725 NFKB(p50) IKBZ(n) 4790&64332 18033&80859
726 NFKB(p50) IMPA3(n) 4790&3839 18033&16648
727 NFKB(p50) KB SITE(n) 4790 18033
728 NFKB(p50/p65)-5P(n) 4790&5970 18033&19697
729 NFKB(p50/p65)-5P2A(n) 4790&5970 18033&19697
730 NFKB(p50/p65)-5P3A(n) 4790&5970 18033&19697
731 NFKB(p50/p65)-5P5A(n) 4790&5970 18033&19697
732 NFKB(p50/p65) CBP-
5P(n)
4790&5970&1387 18033&19697&12914
733 NFKB(p50/p65) CBP-
5P3A(n)
4790&5970&1387 18033&19697&12914
734 NFKB(p65)-5P3A(n) 5970 19697
735 NFKB(p65)-5P3AU(n) 5970 19697
736 NFKB CBP KB(n) 4790&5970&1387 18033&19697&12914
737 NFKB IKBA-2P(n) 4790&5970&4792 18033&19697&18035
738 NFKB IKBA-2P2U(n) 4790&5970&4792 18033&19697&18035
739 NFKB IKBA-5P(n) 4790&5970&4792 18033&19697&18035
740 NFKB IKBA-5P2A(n) 4790&5970&4792 18033&19697&18035
741 NFKB IKBA-5P5A(n) 4790&5970&4792 18033&19697&18035
742 NFKB IKBA BTRCP1(n) 4790&5970&4792&23291 18033&19697&18035&103583
743 NFKB IKBA UBCH5(n) 4790&5970&4792&7323 18033&19697&18035&66105
744 NFKB IKBB-7P(n) 4790&5970&4793 18033&19697&18036
745 PKA(n) (5573&5575) |(5576&5577) (19084&19085) |(19087&19088)
746 PKA-2P(n) (5573&5575) |(5576&5577) (19084&19085) |(19087&19088)
747 PKCZ(n) 5590 18762
748 PKCZ-P(n) 5590 18762
749 PP2A ABC(n) 5518&5519&5515&5516&5520&5521&
5522&55844 |5518&5519&5515&5516&
5523&28227&55012 |5518&5519&5515&
5516&5524 |5518&5519&5515&5516&
5525&5526&5527&5528&5529
51792&73699&19052&19053&71978&
72930&269643&52432 |51792&73699&
19052&19053&235542&59032&19054
|51792&73699&19052&19053&110849
|51792&73699&19052&19053&226849&
225849&26931&21770&26932
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750 PP2A ABC-P(n) 5518&5519&5515&5516&5520&5521&
5522&55844 |5518&5519&5515&5516&
5523&28227&55012 |5518&5519&5515&
5516&5524 |5518&5519&5515&5516&
5525&5526&5527&5528&5529
51792&73699&19052&19053&71978&
72930&269643&52432 |51792&73699&
19052&19053&235542&59032&19054
|51792&73699&19052&19053&110849
|51792&73699&19052&19053&226849&
225849&26931&21770&26932
751 PP2B(n) 5530&5532&5533&5534&5535 19055&19056&19057&19058&19059
752 PP2B-P(n) 5530&5532&5533&5534&5535 19055&19056&19057&19058&19059
754 UBCH5(n) 7323 66105
764 IP3R(r) 3710 16440
765 IP3R mi145p(r) 3710 16440
766 SERCA(r) 487 |488 |489 11937 |11938 |53313
767 SERCA-P(r) 487 |488 |489 11937 |11938 |53313
768 TLR9(r) 54106 81897
770 EEA1 pail3p hs(v) 8411 216238
771 GP91 P22(v) 1536&1535 13058&13057
772 NSF EEA1 RAB5(v) 4905&23673&8411&27342 18195&100226&216238&56715
773 PHOX GTP-3P(v) 1536&1535&4689&653361&4688&5879 13058&13057&17972&17969&17970&
19353
774 PHOX GTP-8P(v) 1536&1535&4689&653361&4688&5879 13058&13057&17972&17969&17970&
19353
775 TLR7(v) 51284 170743
776 TLR7/L-D(v) 51284 170743
777 TLR8(v) 51311 170744
778 TLR8/L-D(v) 51311 170744
779 TLR9(v) 54106 81897
780 TLR9/L-D(v) 54106 81897
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Appendix C
Essential Gene Sets
List of the initial Essential Gene Set (EGS) obtained from our computation.
Experimental validations of the predictions are found it the cited publications. Ci-
tations followed by a start (*) were also used for the reconstruction of the ihsTLR
v1.0 model [30].
Format: genes in EGS (targeted outputs): comments and validation.
1. Fos (AP1): gene is part of the targeted output;
2. Jun (AP1, AP1(2)): gene is part of the targeted output;
3. Mapk8 (AP1, AP1(2)): Mapk8 directly binds to Jun and activates it [184];
4. Map2k4 (AP1, AP1(2)): Map2k4 directly activates Mapk8 (which activates
Jun) [185];
5. Map2k7 (AP1, AP1(2)): Map2k7 directly activates Mapk8 (which activates
Jun) [186];
6. Irak1, Tifa, Traf6, Map3k7, Tab1, Ube2v1, Tab3, Tab2, Ube2n (AP1, AP1(2),
IRF7): no validation found;
7. Casp3, Traf6, Map3k3, Map3k7, Tab1, Ube2v1, Tab3, Tab2, Ube2n (AP1,
AP1(2), IRF7): no validation found;
8. Irak1, Traf6, Map3k3, Map3k7, Tab1, Ube2v1, Tab3, Tab2, Ube2n (AP1,
AP1(2), IRF7): no validation found;
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9. Traf6, Map3k1, Map3k3, Map3k7, Tab1, Ube2v1, Tab3, Tab2, Ube2n (AP1,
AP1(2), IRF7): no validation found;
10. Traf6, Map3k3, Map3k7, Ecsit, Tab1, Ube2v1, Tab3, Tab2, Ube2n (AP1,
AP1(2), IRF7): no validation found;
11. Atf4 (CREB): gene is part of the targeted output;
12. Creb1 (CREB): gene is part of the targeted output;
13. Creb3 (CREB): gene is part of the targeted output;
14. Creb5 (CREB): gene is part of the targeted output;
15. Irf3 (IRF3): gene is part of the targeted output;
16. Tbk1, Ikke (IRF3, IRF7): RNAi experiment, simultaneous knockout of TBK1
and IKKe. Phosphorylation of IRF3 was inhibited and activity of IRF7 was
decreased [187]*;
17. Ticam1 (IRF3, IRF7): (partial validation) siRNA experiment, knockout of
TICAM-1 decreases level of IFN-β (IFN-β promoters can be activated by IRF3)
[26];
18. Tlr7, Tlr8, Tlr9 (IRF7): no validation found;
19. Irf7 (IRF7): gene is part of the targeted output;
20. Traf6 (IRF7): mutant experiment. Inactive mutants of Traf6 inhibit activation
of Irf7. Morever, Traf6 directly interact with Irf7 [171]*;
21. Myd88 (IRF7): transfection experiment. Irf7 was activated only when trans-
fected with Myd88. Moreover, Myd88 directly interact with Irf7. [171]*;
22. Ikba (NF-κB): no validation found;
23. β-TrCP (NF-κB(2)): mutant experiment. Deletion mutants of β-TrCP inhibits
the activation of NF-κB[188].
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24. Ikbb (NF-κB(2)): no validation found;
25. β-TrCP, Btrc, Ube2d3 (NF-κB, NF-κB(2)): (partial validation) Deletion mu-
tants of β-TrCP inhibits the activation of NF- kB [188]. Reduced degradation
of IkB (IkBa and IkBb) in BTRC(β-TrCP1)- knockout mice [189];
26. Rela (NF-κB, NF-κB(2)): gene is part of the targeted output;
27. Nfkb1 (NF-κB, NF-κB(2)): gene is part of the targeted output;
28. Ikka, Ikkb, Ikkg (NF-κB, NF-κB(2)): no validation found;
29. Pkcz (ROS): inhibition of Pkcz reduced induced respiratory burst [190]*;
30. Pkca, Pkcb, Pkcd (ROS(2)): no validation found;
31. Pdk1 (ROS(2)): phosphorylation of mTOR is decreased in Pdk1-knockout mice
[191]. Inhibition of mTOR reduces levels of ROS [192].
32. Ncf2 (ROS, ROS(2)): gene is part of the targeted output;
33. Ncf4 (ROS, ROS(2)): gene is part of the targeted output;
34. Cyba (ROS, ROS(2)): gene is part of the targeted output;
35. Cybb (ROS, ROS(2)): gene is part of the targeted output;
36. Rac1 (ROS, ROS(2)): gene is part of the targeted output;
37. Vav1 (ROS, ROS(2)): knockout experiment. Production of ROS is decreased
in Vav1-knockout mice [193];
38. Ncf1 (ROS, ROS(2)): gene is part of the targeted output;
39. Btk, Sykb (ROS, ROS(2)): no validation found. EGS found in mouse only;
40. Btk, Tec (ROS, ROS(2)): no validation found;
41. Btk, Txk (ROS, ROS(2)): no validation found;
42. Src, Sykb (ROS, ROS(2)): no validation found. EGS found in mouse only;
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43. Src, Tec (ROS, ROS(2)): no validation found;
44. Src, Txk (ROS, ROS(2)): no validation found;
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Appendix D
Impact of Essential Gene Sets
The following table shows the combinations of genes whose knockout disable
the power set of outputs of the ihsTLR v1.0 model with minimum side effect. The
impact of the gene deletions were estimated with the “species impact” (SI), “reaction
impact” (RI), and “module impact” (MI). These estimates correspond to the number
of species, reactions, and modules each gene set disables when knocked out. Results
are shown for human (H) and mouse (M).
Genes H
SI
H
RI
H
MI
M
SI
M
RI
M
MI
Outputs Disabled
Pkcz 31 75 7 31 75 7 ROS
Pkca, Pkcb, Pkcd 16 20 1 16 20 1 ROS2
Irf3 5 13 2 5 13 2 IRF3
Irf7 6 17 2 6 17 2 IRF7
Atf4 9 24 2 9 24 2 CRE
Creb1 9 24 2 9 24 2 CRE
Creb3 9 24 2 9 24 2 CRE
Creb5 9 24 2 9 24 2 CRE
Fos 5 15 1 5 15 1 AP1
Nfkbia 20 46 1 20 46 1 NFκB
Fbxw11 7 12 1 7 12 1 NFκB2
Ncf2 3 9 1 3 9 1 ROS ROS2
Ncf4 3 9 1 3 9 1 ROS ROS2
Pkcz, Irf3 36 88 9 36 88 9 ROS IRF3
Pkcz, Irf7 37 92 9 37 92 9 ROS IRF7
Atf4, Pkcz 40 99 9 40 99 9 ROS CRE
Creb1, Pkcz 40 99 9 40 99 9 ROS CRE
Creb3, Pkcz 40 99 9 40 99 9 ROS CRE
Pkcz, Creb5 40 99 9 40 99 9 ROS CRE
Fos, Pkcz 36 90 8 36 90 8 ROS AP1
Nfkbia, Pkcz 44 105 7 44 105 7 ROS NFκB
Fbxw11, Pkcz 38 87 7 38 87 7 ROS NFκB2
Pkca, Pkcb, Pkcd, Irf3 21 33 3 21 33 3 ROS2 IRF3
Pkca, Pkcb, Pkcd, Irf7 22 37 3 22 37 3 ROS2 IRF7
Atf4, Pkca, Pkcb, Pkcd 25 44 3 25 44 3 ROS2 CRE
Creb1, Pkca, Pkcb, Pkcd 25 44 3 25 44 3 ROS2 CRE
Creb3, Pkca, Pkcb, Pkcd 25 44 3 25 44 3 ROS2 CRE
Pkca, Pkcb, Pkcd, Creb5 25 44 3 25 44 3 ROS2 CRE
Fos, Pkca, Pkcb, Pkcd 21 35 2 21 35 2 ROS2 AP1
Nfkbia, Pkca, Pkcb, Pkcd 36 66 2 36 66 2 ROS2 NFκB
Fbxw11, Pkca, Pkcb, Pkcd 23 32 2 23 32 2 ROS2 NFκB2
Irf7, Irf3 11 30 3 11 30 3 IRF3 IRF7
Atf4, Irf3 14 37 4 14 37 4 IRF3 CRE
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Creb1, Irf3 14 37 4 14 37 4 IRF3 CRE
Creb3, Irf3 14 37 4 14 37 4 IRF3 CRE
Creb5, Irf3 14 37 4 14 37 4 IRF3 CRE
Fos, Irf3 10 28 3 10 28 3 IRF3 AP1
Nfkbia, Irf3 25 59 3 25 59 3 IRF3 NFκB
Fbxw11, Irf3 12 25 3 12 25 3 IRF3 NFκB2
Atf4, Irf7 15 41 4 15 41 4 IRF7 CRE
Creb1, Irf7 15 41 4 15 41 4 IRF7 CRE
Creb3, Irf7 15 41 4 15 41 4 IRF7 CRE
Creb5, Irf7 15 41 4 15 41 4 IRF7 CRE
Fos, Irf7 11 32 3 11 32 3 IRF7 AP1
Nfkbia, Irf7 26 63 3 26 63 3 IRF7 NFκB
Fbxw11, Irf7 13 29 3 13 29 3 IRF7 NFκB2
Atf4, Fos 14 39 3 14 39 3 CRE AP1
Creb1, Fos 14 39 3 14 39 3 CRE AP1
Creb3, Fos 14 39 3 14 39 3 CRE AP1
Fos, Creb5 14 39 3 14 39 3 CRE AP1
Atf4, Nfkbia 29 70 3 29 70 3 CRE NFκB
Creb1, Nfkbia 29 70 3 29 70 3 CRE NFκB
Creb3, Nfkbia 29 70 3 29 70 3 CRE NFκB
Nfkbia, Creb5 29 70 3 29 70 3 CRE NFκB
Fbxw11, Atf4 16 36 3 16 36 3 CRE NFκB2
Fbxw11, Creb1 16 36 3 16 36 3 CRE NFκB2
Fbxw11, Creb3 16 36 3 16 36 3 CRE NFκB2
Fbxw11, Creb5 16 36 3 16 36 3 CRE NFκB2
Jun 7 18 1 7 18 1 AP1 AP12
Fos, Nfkbia 25 61 2 25 61 2 AP1NFκB
Fbxw11, Fos 12 27 2 12 27 2 AP1 NFκB2
Fbxw11, Btrc, Ube2d3 18 44 2 18 44 2 NFκB NFκB2
Ncf2, Irf3 8 22 3 8 22 3 ROS ROS2 IRF3
Ncf4, Irf3 8 22 3 8 22 3 ROS ROS2 IRF3
Ncf2, Irf7 9 26 3 9 26 3 ROS ROS2 IRF7
Ncf4, Irf7 9 26 3 9 26 3 ROS ROS2 IRF7
Atf4, Ncf2 12 33 3 12 33 3 ROS ROS2 CRE
Creb1, Ncf2 12 33 3 12 33 3 ROS ROS2 CRE
Creb3, Ncf2 12 33 3 12 33 3 ROS ROS2 CRE
Ncf2, Creb5 12 33 3 12 33 3 ROS ROS2 CRE
Atf4, Ncf4 12 33 3 12 33 3 ROS ROS2 CRE
Creb1, Ncf4 12 33 3 12 33 3 ROS ROS2 CRE
Creb3, Ncf4 12 33 3 12 33 3 ROS ROS2 CRE
Ncf4, Creb5 12 33 3 12 33 3 ROS ROS2 CRE
Fos, Ncf2 8 24 2 8 24 2 ROS ROS2 AP1
Fos, Ncf4 8 24 2 8 24 2 ROS ROS2 AP1
Ncf2, Nfkbia 23 55 2 23 55 2 ROS ROS2 NFκB
Ncf4, Nfkbia 23 55 2 23 55 2 ROS ROS2 NFκB
Fbxw11, Ncf2 10 21 2 10 21 2 ROS ROS2 NFκB2
Fbxw11, Ncf4 10 21 2 10 21 2 ROS ROS2 NFκB2
Pkcz, Irf7, Irf3 42 105 10 42 105 10 ROS IRF3 IRF7
Atf4, Pkcz, Irf3 45 112 11 45 112 11 ROS IRF3 CRE
Creb1, Pkcz, Irf3 45 112 11 45 112 11 ROS IRF3 CRE
Creb3, Pkcz, Irf3 45 112 11 45 112 11 ROS IRF3 CRE
Pkcz, Creb5, Irf3 45 112 11 45 112 11 ROS IRF3 CRE
Fos, Pkcz, Irf3 41 103 10 41 103 10 ROS IRF3 AP1
Nfkbia, Pkcz, Irf3 49 118 9 49 118 9 ROS IRF3 NFκB
Fbxw11, Pkcz, Irf3 43 100 9 43 100 9 ROS IRF3 NFκB2
Atf4, Pkcz, Irf7 46 116 11 46 116 11 ROS IRF7 CRE
Creb1, Pkcz, Irf7 46 116 11 46 116 11 ROS IRF7 CRE
Creb3, Pkcz, Irf7 46 116 11 46 116 11 ROS IRF7 CRE
Pkcz, Creb5, Irf7 46 116 11 46 116 11 ROS IRF7 CRE
Fos, Pkcz, Irf7 42 107 10 42 107 10 ROS IRF7 AP1
Nfkbia, Pkcz, Irf7 50 122 9 50 122 9 ROS IRF7 NFκB
Fbxw11, Pkcz, Irf7 44 104 9 44 104 9 ROS IRF7 NFκB2
Atf4, Fos, Pkcz 45 114 10 45 114 10 ROS CRE AP1
Creb1, Fos, Pkcz 45 114 10 45 114 10 ROS CRE AP1
Creb3, Fos, Pkcz 45 114 10 45 114 10 ROS CRE AP1
Fos, Pkcz, Creb5 45 114 10 45 114 10 ROS CRE AP1
Atf4, Nfkbia, Pkcz 53 129 9 53 129 9 ROS CRE NFκB
Creb1, Nfkbia, Pkcz 53 129 9 53 129 9 ROS CRE NFκB
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Creb3, Nfkbia, Pkcz 53 129 9 53 129 9 ROS CRE NFκB
Nfkbia, Pkcz, Creb5 53 129 9 53 129 9 ROS CRE NFκB
Fbxw11, Atf4, Pkcz 47 111 9 47 111 9 ROS CRE NFκB2
Fbxw11, Creb1, Pkcz 47 111 9 47 111 9 ROS CRE NFκB2
Fbxw11, Creb3, Pkcz 47 111 9 47 111 9 ROS CRE NFκB2
Fbxw11, Pkcz, Creb5 47 111 9 47 111 9 ROS CRE NFκB2
Fos, Nfkbia, Pkcz 49 120 8 49 120 8 ROS AP1NFκB
Fbxw11, Fos, Pkcz 43 102 8 43 102 8 ROS AP1 NFκB2
Fbxw11, Nfkbia, Pkcz 54 129 7 54 129 7 ROS NFκB NFκB2
Pkca, Pkcb, Pkcd, Irf7, Irf3 27 50 4 27 50 4 ROS2 IRF3 IRF7
Atf4, Pkca, Pkcb, Pkcd, Irf3 30 57 5 30 57 5 ROS2 IRF3 CRE
Creb1, Pkca, Pkcb, Pkcd, Irf3 30 57 5 30 57 5 ROS2 IRF3 CRE
Creb3, Pkca, Pkcb, Pkcd, Irf3 30 57 5 30 57 5 ROS2 IRF3 CRE
Pkca, Pkcb, Pkcd, Creb5, Irf3 30 57 5 30 57 5 ROS2 IRF3 CRE
Fos, Pkca, Pkcb, Pkcd, Irf3 26 48 4 26 48 4 ROS2 IRF3 AP1
Nfkbia, Pkca, Pkcb, Pkcd, Irf3 41 79 4 41 79 4 ROS2 IRF3 NFκB
Fbxw11, Pkca, Pkcb, Pkcd, Irf3 28 45 4 28 45 4 ROS2 IRF3 NFκB2
Atf4, Pkca, Pkcb, Pkcd, Irf7 31 61 5 31 61 5 ROS2 IRF7 CRE
Creb1, Pkca, Pkcb, Pkcd, Irf7 31 61 5 31 61 5 ROS2 IRF7 CRE
Creb3, Pkca, Pkcb, Pkcd, Irf7 31 61 5 31 61 5 ROS2 IRF7 CRE
Pkca, Pkcb, Pkcd, Creb5, Irf7 31 61 5 31 61 5 ROS2 IRF7 CRE
Fos, Pkca, Pkcb, Pkcd, Irf7 27 52 4 27 52 4 ROS2 IRF7 AP1
Nfkbia, Pkca, Pkcb, Pkcd, Irf7 42 83 4 42 83 4 ROS2 IRF7 NFκB
Fbxw11, Pkca, Pkcb, Pkcd, Irf7 29 49 4 29 49 4 ROS2 IRF7 NFκB2
Atf4, Fos, Pkca, Pkcb, Pkcd 30 59 4 30 59 4 ROS2 CRE AP1
Creb1, Fos, Pkca, Pkcb, Pkcd 30 59 4 30 59 4 ROS2 CRE AP1
Creb3, Fos, Pkca, Pkcb, Pkcd 30 59 4 30 59 4 ROS2 CRE AP1
Fos, Pkca, Pkcb, Pkcd, Creb5 30 59 4 30 59 4 ROS2 CRE AP1
Atf4, Nfkbia, Pkca, Pkcb, Pkcd 45 90 4 45 90 4 ROS2 CRE NFκB
Creb1, Nfkbia, Pkca, Pkcb, Pkcd 45 90 4 45 90 4 ROS2 CRE NFκB
Creb3, Nfkbia, Pkca, Pkcb, Pkcd 45 90 4 45 90 4 ROS2 CRE NFκB
Nfkbia, Pkca, Pkcb, Pkcd, Creb5 45 90 4 45 90 4 ROS2 CRE NFκB
Fbxw11, Atf4, Pkca, Pkcb, Pkcd 32 56 4 32 56 4 ROS2 CRE NFκB2
Fbxw11, Creb1, Pkca, Pkcb, Pkcd 32 56 4 32 56 4 ROS2 CRE NFκB2
Fbxw11, Creb3, Pkca, Pkcb, Pkcd 32 56 4 32 56 4 ROS2 CRE NFκB2
Fbxw11, Pkca, Pkcb, Pkcd, Creb5 32 56 4 32 56 4 ROS2 CRE NFκB2
Fos, Nfkbia, Pkca, Pkcb, Pkcd 41 81 3 41 81 3 ROS2 AP1NFκB
Fbxw11, Fos, Pkca, Pkcb, Pkcd 28 47 3 28 47 3 ROS2 AP1 NFκB2
Fbxw11, Nfkbia, Pkca, Pkcb, Pkcd 47 98 3 47 98 3 ROS2 NFκB NFκB2
Atf4, Irf7, Irf3 20 54 5 20 54 5 IRF3 IRF7 CRE
Creb1, Irf7, Irf3 20 54 5 20 54 5 IRF3 IRF7 CRE
Creb3, Irf7, Irf3 20 54 5 20 54 5 IRF3 IRF7 CRE
Creb5, Irf7, Irf3 20 54 5 20 54 5 IRF3 IRF7 CRE
Fos, Irf7, Irf3 16 45 4 16 45 4 IRF3 IRF7 AP1
Nfkbia, Irf7, Irf3 31 76 4 31 76 4 IRF3 IRF7 NFκB
Fbxw11, Irf7, Irf3 18 42 4 18 42 4 IRF3 IRF7 NFκB2
Atf4, Fos, Irf3 19 52 5 19 52 5 IRF3 CRE AP1
Creb1, Fos, Irf3 19 52 5 19 52 5 IRF3 CRE AP1
Creb3, Fos, Irf3 19 52 5 19 52 5 IRF3 CRE AP1
Fos, Creb5, Irf3 19 52 5 19 52 5 IRF3 CRE AP1
Atf4, Nfkbia, Irf3 34 83 5 34 83 5 IRF3 CRE NFκB
Creb1, Nfkbia, Irf3 34 83 5 34 83 5 IRF3 CRE NFκB
Creb3, Nfkbia, Irf3 34 83 5 34 83 5 IRF3 CRE NFκB
Nfkbia, Creb5, Irf3 34 83 5 34 83 5 IRF3 CRE NFκB
Fbxw11, Atf4, Irf3 21 49 5 21 49 5 IRF3 CRE NFκB2
Fbxw11, Creb1, Irf3 21 49 5 21 49 5 IRF3 CRE NFκB2
Fbxw11, Creb3, Irf3 21 49 5 21 49 5 IRF3 CRE NFκB2
Fbxw11, Creb5, Irf3 21 49 5 21 49 5 IRF3 CRE NFκB2
Fos, Nfkbia, Irf3 30 74 4 30 74 4 IRF3 AP1NFκB
Fbxw11, Fos, Irf3 17 40 4 17 40 4 IRF3 AP1 NFκB2
Fbxw11, Nfkbia, Irf3 36 91 4 36 91 4 IRF3 NFκB NFκB2
Atf4, Fos, Irf7 20 56 5 20 56 5 IRF7 CRE AP1
Creb1, Fos, Irf7 20 56 5 20 56 5 IRF7 CRE AP1
Creb3, Fos, Irf7 20 56 5 20 56 5 IRF7 CRE AP1
Fos, Creb5, Irf7 20 56 5 20 56 5 IRF7 CRE AP1
Atf4, Nfkbia, Irf7 35 87 5 35 87 5 IRF7 CRE NFκB
Creb1, Nfkbia, Irf7 35 87 5 35 87 5 IRF7 CRE NFκB
Creb3, Nfkbia, Irf7 35 87 5 35 87 5 IRF7 CRE NFκB
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Nfkbia, Creb5, Irf7 35 87 5 35 87 5 IRF7 CRE NFκB
Fbxw11, Atf4, Irf7 22 53 5 22 53 5 IRF7 CRE NFκB2
Fbxw11, Creb1, Irf7 22 53 5 22 53 5 IRF7 CRE NFκB2
Fbxw11, Creb3, Irf7 22 53 5 22 53 5 IRF7 CRE NFκB2
Fbxw11, Creb5, Irf7 22 53 5 22 53 5 IRF7 CRE NFκB2
Casp3, Traf6, Map3k3, Map3k7, Tab1, Ube2v1, Tab3,
Tab2, Ube2n
86 161 9 86 161 9 IRF7 AP1 AP12
Traf6, Map3k3, Map3k7, Ecsit, Tab1, Ube2v1, Tab3,
Tab2, Ube2n
86 161 9 86 161 9 IRF7 AP1 AP12
Fos, Nfkbia, Irf7 31 78 4 31 78 4 IRF7 AP1NFκB
Fbxw11, Fos, Irf7 18 44 4 18 44 4 IRF7 AP1 NFκB2
Fbxw11, Nfkbia, Irf7 37 95 4 37 95 4 IRF7 NFκB NFκB2
Atf4, Fos, Nfkbia 34 85 4 34 85 4 CRE AP1NFκB
Creb1, Fos, Nfkbia 34 85 4 34 85 4 CRE AP1NFκB
Creb3, Fos, Nfkbia 34 85 4 34 85 4 CRE AP1NFκB
Fos, Nfkbia, Creb5 34 85 4 34 85 4 CRE AP1NFκB
Fbxw11, Atf4, Fos 21 51 4 21 51 4 CRE AP1 NFκB2
Fbxw11, Creb1, Fos 21 51 4 21 51 4 CRE AP1 NFκB2
Fbxw11, Creb3, Fos 21 51 4 21 51 4 CRE AP1 NFκB2
Fbxw11, Fos, Creb5 21 51 4 21 51 4 CRE AP1 NFκB2
Fbxw11, Atf4, Nfkbia 40 102 4 40 102 4 CRE NFκB NFκB2
Fbxw11, Creb1, Nfkbia 40 102 4 40 102 4 CRE NFκB NFκB2
Fbxw11, Creb3, Nfkbia 40 102 4 40 102 4 CRE NFκB NFκB2
Fbxw11, Nfkbia, Creb5 40 102 4 40 102 4 CRE NFκB NFκB2
Jun, Nfkbia 27 64 2 27 64 2 AP1 AP12NFκB
Fbxw11, Jun 14 30 2 14 30 2 AP1 AP12 NFκB2
Fbxw11, Fos, Nfkbia 36 93 3 36 93 3 AP1 NFκB NFκB2
Ncf2, Irf7, Irf3 14 39 4 14 39 4 ROS ROS2 IRF3 IRF7
Ncf4, Irf7, Irf3 14 39 4 14 39 4 ROS ROS2 IRF3 IRF7
Atf4, Ncf2, Irf3 17 46 5 17 46 5 ROS ROS2 IRF3 CRE
Creb1, Ncf2, Irf3 17 46 5 17 46 5 ROS ROS2 IRF3 CRE
Creb3, Ncf2, Irf3 17 46 5 17 46 5 ROS ROS2 IRF3 CRE
Ncf2, Creb5, Irf3 17 46 5 17 46 5 ROS ROS2 IRF3 CRE
Atf4, Ncf4, Irf3 17 46 5 17 46 5 ROS ROS2 IRF3 CRE
Creb1, Ncf4, Irf3 17 46 5 17 46 5 ROS ROS2 IRF3 CRE
Creb3, Ncf4, Irf3 17 46 5 17 46 5 ROS ROS2 IRF3 CRE
Ncf4, Creb5, Irf3 17 46 5 17 46 5 ROS ROS2 IRF3 CRE
Fos, Ncf2, Irf3 13 37 4 13 37 4 ROS ROS2 IRF3 AP1
Fos, Ncf4, Irf3 13 37 4 13 37 4 ROS ROS2 IRF3 AP1
Ncf2, Nfkbia, Irf3 28 68 4 28 68 4 ROS ROS2 IRF3 NFκB
Ncf4, Nfkbia, Irf3 28 68 4 28 68 4 ROS ROS2 IRF3 NFκB
Fbxw11, Ncf2, Irf3 15 34 4 15 34 4 ROS ROS2 IRF3 NFκB2
Fbxw11, Ncf4, Irf3 15 34 4 15 34 4 ROS ROS2 IRF3 NFκB2
Atf4, Ncf2, Irf7 18 50 5 18 50 5 ROS ROS2 IRF7 CRE
Creb1, Ncf2, Irf7 18 50 5 18 50 5 ROS ROS2 IRF7 CRE
Creb3, Ncf2, Irf7 18 50 5 18 50 5 ROS ROS2 IRF7 CRE
Ncf2, Creb5, Irf7 18 50 5 18 50 5 ROS ROS2 IRF7 CRE
Atf4, Ncf4, Irf7 18 50 5 18 50 5 ROS ROS2 IRF7 CRE
Creb1, Ncf4, Irf7 18 50 5 18 50 5 ROS ROS2 IRF7 CRE
Creb3, Ncf4, Irf7 18 50 5 18 50 5 ROS ROS2 IRF7 CRE
Ncf4, Creb5, Irf7 18 50 5 18 50 5 ROS ROS2 IRF7 CRE
Fos, Ncf2, Irf7 14 41 4 14 41 4 ROS ROS2 IRF7 AP1
Fos, Ncf4, Irf7 14 41 4 14 41 4 ROS ROS2 IRF7 AP1
Ncf2, Nfkbia, Irf7 29 72 4 29 72 4 ROS ROS2 IRF7 NFκB
Ncf4, Nfkbia, Irf7 29 72 4 29 72 4 ROS ROS2 IRF7 NFκB
Fbxw11, Ncf2, Irf7 16 38 4 16 38 4 ROS ROS2 IRF7 NFκB2
Fbxw11, Ncf4, Irf7 16 38 4 16 38 4 ROS ROS2 IRF7 NFκB2
Atf4, Fos, Ncf2 17 48 4 17 48 4 ROS ROS2 CRE AP1
Creb1, Fos, Ncf2 17 48 4 17 48 4 ROS ROS2 CRE AP1
Creb3, Fos, Ncf2 17 48 4 17 48 4 ROS ROS2 CRE AP1
Fos, Ncf2, Creb5 17 48 4 17 48 4 ROS ROS2 CRE AP1
Atf4, Fos, Ncf4 17 48 4 17 48 4 ROS ROS2 CRE AP1
Creb1, Fos, Ncf4 17 48 4 17 48 4 ROS ROS2 CRE AP1
Creb3, Fos, Ncf4 17 48 4 17 48 4 ROS ROS2 CRE AP1
Fos, Ncf4, Creb5 17 48 4 17 48 4 ROS ROS2 CRE AP1
Atf4, Ncf2, Nfkbia 32 79 4 32 79 4 ROS ROS2 CRE NFκB
Creb1, Ncf2, Nfkbia 32 79 4 32 79 4 ROS ROS2 CRE NFκB
Creb3, Ncf2, Nfkbia 32 79 4 32 79 4 ROS ROS2 CRE NFκB
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Ncf2, Nfkbia, Creb5 32 79 4 32 79 4 ROS ROS2 CRE NFκB
Atf4, Ncf4, Nfkbia 32 79 4 32 79 4 ROS ROS2 CRE NFκB
Creb1, Ncf4, Nfkbia 32 79 4 32 79 4 ROS ROS2 CRE NFκB
Creb3, Ncf4, Nfkbia 32 79 4 32 79 4 ROS ROS2 CRE NFκB
Ncf4, Nfkbia, Creb5 32 79 4 32 79 4 ROS ROS2 CRE NFκB
Fbxw11, Atf4, Ncf2 19 45 4 19 45 4 ROS ROS2 CRE NFκB2
Fbxw11, Creb1, Ncf2 19 45 4 19 45 4 ROS ROS2 CRE NFκB2
Fbxw11, Creb3, Ncf2 19 45 4 19 45 4 ROS ROS2 CRE NFκB2
Fbxw11, Ncf2, Creb5 19 45 4 19 45 4 ROS ROS2 CRE NFκB2
Fbxw11, Atf4, Ncf4 19 45 4 19 45 4 ROS ROS2 CRE NFκB2
Fbxw11, Creb1, Ncf4 19 45 4 19 45 4 ROS ROS2 CRE NFκB2
Fbxw11, Creb3, Ncf4 19 45 4 19 45 4 ROS ROS2 CRE NFκB2
Fbxw11, Ncf4, Creb5 19 45 4 19 45 4 ROS ROS2 CRE NFκB2
Fos, Ncf2, Nfkbia 28 70 3 28 70 3 ROS ROS2 AP1NFκB
Fos, Ncf4, Nfkbia 28 70 3 28 70 3 ROS ROS2 AP1NFκB
Fbxw11, Fos, Ncf2 15 36 3 15 36 3 ROS ROS2 AP1 NFκB2
Fbxw11, Fos, Ncf4 15 36 3 15 36 3 ROS ROS2 AP1 NFκB2
Fbxw11, Ncf2, Nfkbia 34 87 3 34 87 3 ROS ROS2 NFκB NFκB2
Fbxw11, Ncf4, Nfkbia 34 87 3 34 87 3 ROS ROS2 NFκB NFκB2
Atf4, Pkcz, Irf7, Irf3 51 129 12 51 129 12 ROS IRF3 IRF7 CRE
Creb1, Pkcz, Irf7, Irf3 51 129 12 51 129 12 ROS IRF3 IRF7 CRE
Creb3, Pkcz, Irf7, Irf3 51 129 12 51 129 12 ROS IRF3 IRF7 CRE
Pkcz, Creb5, Irf7, Irf3 51 129 12 51 129 12 ROS IRF3 IRF7 CRE
Fos, Pkcz, Irf7, Irf3 47 120 11 47 120 11 ROS IRF3 IRF7 AP1
Nfkbia, Pkcz, Irf7, Irf3 55 135 10 55 135 10 ROS IRF3 IRF7 NFκB
Fbxw11, Pkcz, Irf7, Irf3 49 117 10 49 117 10 ROS IRF3 IRF7 NFκB2
Atf4, Fos, Pkcz, Irf3 50 127 12 50 127 12 ROS IRF3 CRE AP1
Creb1, Fos, Pkcz, Irf3 50 127 12 50 127 12 ROS IRF3 CRE AP1
Creb3, Fos, Pkcz, Irf3 50 127 12 50 127 12 ROS IRF3 CRE AP1
Fos, Pkcz, Creb5, Irf3 50 127 12 50 127 12 ROS IRF3 CRE AP1
Atf4, Nfkbia, Pkcz, Irf3 58 142 11 58 142 11 ROS IRF3 CRE NFκB
Creb1, Nfkbia, Pkcz, Irf3 58 142 11 58 142 11 ROS IRF3 CRE NFκB
Creb3, Nfkbia, Pkcz, Irf3 58 142 11 58 142 11 ROS IRF3 CRE NFκB
Nfkbia, Pkcz, Creb5, Irf3 58 142 11 58 142 11 ROS IRF3 CRE NFκB
Fbxw11, Atf4, Pkcz, Irf3 52 124 11 52 124 11 ROS IRF3 CRE NFκB2
Fbxw11, Creb1, Pkcz, Irf3 52 124 11 52 124 11 ROS IRF3 CRE NFκB2
Fbxw11, Creb3, Pkcz, Irf3 52 124 11 52 124 11 ROS IRF3 CRE NFκB2
Fbxw11, Pkcz, Creb5, Irf3 52 124 11 52 124 11 ROS IRF3 CRE NFκB2
Fos, Nfkbia, Pkcz, Irf3 54 133 10 54 133 10 ROS IRF3 AP1NFκB
Fbxw11, Fos, Pkcz, Irf3 48 115 10 48 115 10 ROS IRF3 AP1 NFκB2
Fbxw11, Nfkbia, Pkcz, Irf3 59 142 9 59 142 9 ROS IRF3 NFκB NFκB2
Atf4, Fos, Pkcz, Irf7 51 131 12 51 131 12 ROS IRF7 CRE AP1
Creb1, Fos, Pkcz, Irf7 51 131 12 51 131 12 ROS IRF7 CRE AP1
Creb3, Fos, Pkcz, Irf7 51 131 12 51 131 12 ROS IRF7 CRE AP1
Fos, Pkcz, Creb5, Irf7 51 131 12 51 131 12 ROS IRF7 CRE AP1
Atf4, Nfkbia, Pkcz, Irf7 59 146 11 59 146 11 ROS IRF7 CRE NFκB
Creb1, Nfkbia, Pkcz, Irf7 59 146 11 59 146 11 ROS IRF7 CRE NFκB
Creb3, Nfkbia, Pkcz, Irf7 59 146 11 59 146 11 ROS IRF7 CRE NFκB
Nfkbia, Pkcz, Creb5, Irf7 59 146 11 59 146 11 ROS IRF7 CRE NFκB
Fbxw11, Atf4, Pkcz, Irf7 53 128 11 53 128 11 ROS IRF7 CRE NFκB2
Fbxw11, Creb1, Pkcz, Irf7 53 128 11 53 128 11 ROS IRF7 CRE NFκB2
Fbxw11, Creb3, Pkcz, Irf7 53 128 11 53 128 11 ROS IRF7 CRE NFκB2
Fbxw11, Pkcz, Creb5, Irf7 53 128 11 53 128 11 ROS IRF7 CRE NFκB2
Fos, Nfkbia, Pkcz, Irf7 55 137 10 55 137 10 ROS IRF7 AP1NFκB
Fbxw11, Fos, Pkcz, Irf7 49 119 10 49 119 10 ROS IRF7 AP1 NFκB2
Fbxw11, Nfkbia, Pkcz, Irf7 60 146 9 60 146 9 ROS IRF7 NFκB NFκB2
Atf4, Fos, Nfkbia, Pkcz 58 144 10 58 144 10 ROS CRE AP1NFκB
Creb1, Fos, Nfkbia, Pkcz 58 144 10 58 144 10 ROS CRE AP1NFκB
Creb3, Fos, Nfkbia, Pkcz 58 144 10 58 144 10 ROS CRE AP1NFκB
Fos, Nfkbia, Pkcz, Creb5 58 144 10 58 144 10 ROS CRE AP1NFκB
Fbxw11, Atf4, Fos, Pkcz 52 126 10 52 126 10 ROS CRE AP1 NFκB2
Fbxw11, Creb1, Fos, Pkcz 52 126 10 52 126 10 ROS CRE AP1 NFκB2
Fbxw11, Creb3, Fos, Pkcz 52 126 10 52 126 10 ROS CRE AP1 NFκB2
Fbxw11, Fos, Pkcz, Creb5 52 126 10 52 126 10 ROS CRE AP1 NFκB2
Fbxw11, Atf4, Nfkbia, Pkcz 63 153 9 63 153 9 ROS CRE NFκB NFκB2
Fbxw11, Creb1, Nfkbia, Pkcz 63 153 9 63 153 9 ROS CRE NFκB NFκB2
Fbxw11, Creb3, Nfkbia, Pkcz 63 153 9 63 153 9 ROS CRE NFκB NFκB2
Fbxw11, Nfkbia, Pkcz, Creb5 63 153 9 63 153 9 ROS CRE NFκB NFκB2
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Fbxw11, Fos, Nfkbia, Pkcz 59 144 8 59 144 8 ROS AP1 NFκB NFκB2
Atf4, Pkca, Pkcb, Pkcd, Irf7, Irf3 36 74 6 36 74 6 ROS2 IRF3 IRF7 CRE
Creb1, Pkca, Pkcb, Pkcd, Irf7, Irf3 36 74 6 36 74 6 ROS2 IRF3 IRF7 CRE
Creb3, Pkca, Pkcb, Pkcd, Irf7, Irf3 36 74 6 36 74 6 ROS2 IRF3 IRF7 CRE
Pkca, Pkcb, Pkcd, Creb5, Irf7, Irf3 36 74 6 36 74 6 ROS2 IRF3 IRF7 CRE
Fos, Pkca, Pkcb, Pkcd, Irf7, Irf3 32 65 5 32 65 5 ROS2 IRF3 IRF7 AP1
Nfkbia, Pkca, Pkcb, Pkcd, Irf7, Irf3 47 96 5 47 96 5 ROS2 IRF3 IRF7 NFκB
Fbxw11, Pkca, Pkcb, Pkcd, Irf7, Irf3 34 62 5 34 62 5 ROS2 IRF3 IRF7 NFκB2
Atf4, Fos, Pkca, Pkcb, Pkcd, Irf3 35 72 6 35 72 6 ROS2 IRF3 CRE AP1
Creb1, Fos, Pkca, Pkcb, Pkcd, Irf3 35 72 6 35 72 6 ROS2 IRF3 CRE AP1
Creb3, Fos, Pkca, Pkcb, Pkcd, Irf3 35 72 6 35 72 6 ROS2 IRF3 CRE AP1
Fos, Pkca, Pkcb, Pkcd, Creb5, Irf3 35 72 6 35 72 6 ROS2 IRF3 CRE AP1
Atf4, Nfkbia, Pkca, Pkcb, Pkcd, Irf3 50 103 6 50 103 6 ROS2 IRF3 CRE NFκB
Creb1, Nfkbia, Pkca, Pkcb, Pkcd, Irf3 50 103 6 50 103 6 ROS2 IRF3 CRE NFκB
Creb3, Nfkbia, Pkca, Pkcb, Pkcd, Irf3 50 103 6 50 103 6 ROS2 IRF3 CRE NFκB
Nfkbia, Pkca, Pkcb, Pkcd, Creb5, Irf3 50 103 6 50 103 6 ROS2 IRF3 CRE NFκB
Fbxw11, Atf4, Pkca, Pkcb, Pkcd, Irf3 37 69 6 37 69 6 ROS2 IRF3 CRE NFκB2
Fbxw11, Creb1, Pkca, Pkcb, Pkcd, Irf3 37 69 6 37 69 6 ROS2 IRF3 CRE NFκB2
Fbxw11, Creb3, Pkca, Pkcb, Pkcd, Irf3 37 69 6 37 69 6 ROS2 IRF3 CRE NFκB2
Fbxw11, Pkca, Pkcb, Pkcd, Creb5, Irf3 37 69 6 37 69 6 ROS2 IRF3 CRE NFκB2
Fos, Nfkbia, Pkca, Pkcb, Pkcd, Irf3 46 94 5 46 94 5 ROS2 IRF3 AP1NFκB
Fbxw11, Fos, Pkca, Pkcb, Pkcd, Irf3 33 60 5 33 60 5 ROS2 IRF3 AP1 NFκB2
Fbxw11, Nfkbia, Pkca, Pkcb, Pkcd, Irf3 52 111 5 52 111 5 ROS2 IRF3 NFκB NFκB2
Atf4, Fos, Pkca, Pkcb, Pkcd, Irf7 36 76 6 36 76 6 ROS2 IRF7 CRE AP1
Creb1, Fos, Pkca, Pkcb, Pkcd, Irf7 36 76 6 36 76 6 ROS2 IRF7 CRE AP1
Creb3, Fos, Pkca, Pkcb, Pkcd, Irf7 36 76 6 36 76 6 ROS2 IRF7 CRE AP1
Fos, Pkca, Pkcb, Pkcd, Creb5, Irf7 36 76 6 36 76 6 ROS2 IRF7 CRE AP1
Atf4, Nfkbia, Pkca, Pkcb, Pkcd, Irf7 51 107 6 51 107 6 ROS2 IRF7 CRE NFκB
Creb1, Nfkbia, Pkca, Pkcb, Pkcd, Irf7 51 107 6 51 107 6 ROS2 IRF7 CRE NFκB
Creb3, Nfkbia, Pkca, Pkcb, Pkcd, Irf7 51 107 6 51 107 6 ROS2 IRF7 CRE NFκB
Nfkbia, Pkca, Pkcb, Pkcd, Creb5, Irf7 51 107 6 51 107 6 ROS2 IRF7 CRE NFκB
Fbxw11, Atf4, Pkca, Pkcb, Pkcd, Irf7 38 73 6 38 73 6 ROS2 IRF7 CRE NFκB2
Fbxw11, Creb1, Pkca, Pkcb, Pkcd, Irf7 38 73 6 38 73 6 ROS2 IRF7 CRE NFκB2
Fbxw11, Creb3, Pkca, Pkcb, Pkcd, Irf7 38 73 6 38 73 6 ROS2 IRF7 CRE NFκB2
Fbxw11, Pkca, Pkcb, Pkcd, Creb5, Irf7 38 73 6 38 73 6 ROS2 IRF7 CRE NFκB2
Fos, Nfkbia, Pkca, Pkcb, Pkcd, Irf7 47 98 5 47 98 5 ROS2 IRF7 AP1NFκB
Fbxw11, Fos, Pkca, Pkcb, Pkcd, Irf7 34 64 5 34 64 5 ROS2 IRF7 AP1 NFκB2
Fbxw11, Nfkbia, Pkca, Pkcb, Pkcd, Irf7 53 115 5 53 115 5 ROS2 IRF7 NFκB NFκB2
Atf4, Fos, Nfkbia, Pkca, Pkcb, Pkcd 50 105 5 50 105 5 ROS2 CRE AP1NFκB
Creb1, Fos, Nfkbia, Pkca, Pkcb, Pkcd 50 105 5 50 105 5 ROS2 CRE AP1NFκB
Creb3, Fos, Nfkbia, Pkca, Pkcb, Pkcd 50 105 5 50 105 5 ROS2 CRE AP1NFκB
Fos, Nfkbia, Pkca, Pkcb, Pkcd, Creb5 50 105 5 50 105 5 ROS2 CRE AP1NFκB
Fbxw11, Atf4, Fos, Pkca, Pkcb, Pkcd 37 71 5 37 71 5 ROS2 CRE AP1 NFκB2
Fbxw11, Creb1, Fos, Pkca, Pkcb, Pkcd 37 71 5 37 71 5 ROS2 CRE AP1 NFκB2
Fbxw11, Creb3, Fos, Pkca, Pkcb, Pkcd 37 71 5 37 71 5 ROS2 CRE AP1 NFκB2
Fbxw11, Fos, Pkca, Pkcb, Pkcd, Creb5 37 71 5 37 71 5 ROS2 CRE AP1 NFκB2
Fbxw11, Atf4, Nfkbia, Pkca, Pkcb, Pkcd 56 122 5 56 122 5 ROS2 CRE NFκB NFκB2
Fbxw11, Creb1, Nfkbia, Pkca, Pkcb, Pkcd 56 122 5 56 122 5 ROS2 CRE NFκB NFκB2
Fbxw11, Creb3, Nfkbia, Pkca, Pkcb, Pkcd 56 122 5 56 122 5 ROS2 CRE NFκB NFκB2
Fbxw11, Nfkbia, Pkca, Pkcb, Pkcd, Creb5 56 122 5 56 122 5 ROS2 CRE NFκB NFκB2
Fbxw11, Fos, Nfkbia, Pkca, Pkcb, Pkcd 52 113 4 52 113 4 ROS2 AP1 NFκB NFκB2
Atf4, Fos, Irf7, Irf3 25 69 6 25 69 6 IRF3 IRF7 CRE AP1
Creb1, Fos, Irf7, Irf3 25 69 6 25 69 6 IRF3 IRF7 CRE AP1
Creb3, Fos, Irf7, Irf3 25 69 6 25 69 6 IRF3 IRF7 CRE AP1
Fos, Creb5, Irf7, Irf3 25 69 6 25 69 6 IRF3 IRF7 CRE AP1
Atf4, Nfkbia, Irf7, Irf3 40 100 6 40 100 6 IRF3 IRF7 CRE NFκB
Creb1, Nfkbia, Irf7, Irf3 40 100 6 40 100 6 IRF3 IRF7 CRE NFκB
Creb3, Nfkbia, Irf7, Irf3 40 100 6 40 100 6 IRF3 IRF7 CRE NFκB
Nfkbia, Creb5, Irf7, Irf3 40 100 6 40 100 6 IRF3 IRF7 CRE NFκB
Fbxw11, Atf4, Irf7, Irf3 27 66 6 27 66 6 IRF3 IRF7 CRE NFκB2
Fbxw11, Creb1, Irf7, Irf3 27 66 6 27 66 6 IRF3 IRF7 CRE NFκB2
Fbxw11, Creb3, Irf7, Irf3 27 66 6 27 66 6 IRF3 IRF7 CRE NFκB2
Fbxw11, Creb5, Irf7, Irf3 27 66 6 27 66 6 IRF3 IRF7 CRE NFκB2
Fos, Nfkbia, Irf7, Irf3 36 91 5 36 91 5 IRF3 IRF7 AP1NFκB
Fbxw11, Fos, Irf7, Irf3 23 57 5 23 57 5 IRF3 IRF7 AP1 NFκB2
Atf4, Fos, Nfkbia, Irf3 39 98 6 39 98 6 IRF3 CRE AP1NFκB
Creb1, Fos, Nfkbia, Irf3 39 98 6 39 98 6 IRF3 CRE AP1NFκB
Creb3, Fos, Nfkbia, Irf3 39 98 6 39 98 6 IRF3 CRE AP1NFκB
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Fos, Nfkbia, Creb5, Irf3 39 98 6 39 98 6 IRF3 CRE AP1NFκB
Fbxw11, Atf4, Fos, Irf3 26 64 6 26 64 6 IRF3 CRE AP1 NFκB2
Fbxw11, Creb1, Fos, Irf3 26 64 6 26 64 6 IRF3 CRE AP1 NFκB2
Fbxw11, Creb3, Fos, Irf3 26 64 6 26 64 6 IRF3 CRE AP1 NFκB2
Fbxw11, Fos, Creb5, Irf3 26 64 6 26 64 6 IRF3 CRE AP1 NFκB2
Fbxw11, Atf4, Nfkbia, Irf3 45 115 6 45 115 6 IRF3 CRE NFκB NFκB2
Fbxw11, Creb1, Nfkbia, Irf3 45 115 6 45 115 6 IRF3 CRE NFκB NFκB2
Fbxw11, Creb3, Nfkbia, Irf3 45 115 6 45 115 6 IRF3 CRE NFκB NFκB2
Fbxw11, Nfkbia, Creb5, Irf3 45 115 6 45 115 6 IRF3 CRE NFκB NFκB2
Fbxw11, Fos, Nfkbia, Irf3 41 106 5 41 106 5 IRF3 AP1 NFκB NFκB2
Atf4, Fos, Nfkbia, Irf7 40 102 6 40 102 6 IRF7 CRE AP1NFκB
Creb1, Fos, Nfkbia, Irf7 40 102 6 40 102 6 IRF7 CRE AP1NFκB
Creb3, Fos, Nfkbia, Irf7 40 102 6 40 102 6 IRF7 CRE AP1NFκB
Fos, Nfkbia, Creb5, Irf7 40 102 6 40 102 6 IRF7 CRE AP1NFκB
Fbxw11, Atf4, Fos, Irf7 27 68 6 27 68 6 IRF7 CRE AP1 NFκB2
Fbxw11, Creb1, Fos, Irf7 27 68 6 27 68 6 IRF7 CRE AP1 NFκB2
Fbxw11, Creb3, Fos, Irf7 27 68 6 27 68 6 IRF7 CRE AP1 NFκB2
Fbxw11, Fos, Creb5, Irf7 27 68 6 27 68 6 IRF7 CRE AP1 NFκB2
Fbxw11, Atf4, Nfkbia, Irf7 46 119 6 46 119 6 IRF7 CRE NFκB NFκB2
Fbxw11, Creb1, Nfkbia, Irf7 46 119 6 46 119 6 IRF7 CRE NFκB NFκB2
Fbxw11, Creb3, Nfkbia, Irf7 46 119 6 46 119 6 IRF7 CRE NFκB NFκB2
Fbxw11, Nfkbia, Creb5, Irf7 46 119 6 46 119 6 IRF7 CRE NFκB NFκB2
Casp3, Nfkbia, Traf6, Map3k3, Map3k7, Tab1,
Ube2v1, Tab3, Tab2, Ube2n
106 207 10 106 207 10 IRF7 AP1 AP12NFκB
Nfkbia, Traf6, Map3k3, Map3k7, Ecsit, Tab1,
Ube2v1, Tab3, Tab2, Ube2n
106 207 10 106 207 10 IRF7 AP1 AP12NFκB
Fbxw11, Casp3, Traf6, Map3k3, Map3k7, Tab1,
Ube2v1, Tab3, Tab2, Ube2n
93 173 10 93 173 10 IRF7 AP1 AP12 NFκB2
Fbxw11, Traf6, Map3k3, Map3k7, Ecsit, Tab1,
Ube2v1, Tab3, Tab2, Ube2n
93 173 10 93 173 10 IRF7 AP1 AP12 NFκB2
Fbxw11, Fos, Nfkbia, Irf7 42 110 5 42 110 5 IRF7 AP1 NFκB NFκB2
Fbxw11, Atf4, Fos, Nfkbia 45 117 5 45 117 5 CRE AP1 NFκB NFκB2
Fbxw11, Creb1, Fos, Nfkbia 45 117 5 45 117 5 CRE AP1 NFκB NFκB2
Fbxw11, Creb3, Fos, Nfkbia 45 117 5 45 117 5 CRE AP1 NFκB NFκB2
Fbxw11, Fos, Nfkbia, Creb5 45 117 5 45 117 5 CRE AP1 NFκB NFκB2
Fbxw11, Jun, Nfkbia 38 96 3 38 96 3 AP1 AP12 NFκB NFκB2
Atf4, Ncf2, Irf7, Irf3 23 63 6 23 63 6 ROS ROS2 IRF3 IRF7 CRE
Creb1, Ncf2, Irf7, Irf3 23 63 6 23 63 6 ROS ROS2 IRF3 IRF7 CRE
Creb3, Ncf2, Irf7, Irf3 23 63 6 23 63 6 ROS ROS2 IRF3 IRF7 CRE
Ncf2, Creb5, Irf7, Irf3 23 63 6 23 63 6 ROS ROS2 IRF3 IRF7 CRE
Atf4, Ncf4, Irf7, Irf3 23 63 6 23 63 6 ROS ROS2 IRF3 IRF7 CRE
Creb1, Ncf4, Irf7, Irf3 23 63 6 23 63 6 ROS ROS2 IRF3 IRF7 CRE
Creb3, Ncf4, Irf7, Irf3 23 63 6 23 63 6 ROS ROS2 IRF3 IRF7 CRE
Ncf4, Creb5, Irf7, Irf3 23 63 6 23 63 6 ROS ROS2 IRF3 IRF7 CRE
Fos, Ncf2, Irf7, Irf3 19 54 5 19 54 5 ROS ROS2 IRF3 IRF7 AP1
Fos, Ncf4, Irf7, Irf3 19 54 5 19 54 5 ROS ROS2 IRF3 IRF7 AP1
Ncf2, Nfkbia, Irf7, Irf3 34 85 5 34 85 5 ROS ROS2 IRF3 IRF7 NFκB
Ncf4, Nfkbia, Irf7, Irf3 34 85 5 34 85 5 ROS ROS2 IRF3 IRF7 NFκB
Fbxw11, Ncf2, Irf7, Irf3 21 51 5 21 51 5 ROS ROS2 IRF3 IRF7 NFκB2
Fbxw11, Ncf4, Irf7, Irf3 21 51 5 21 51 5 ROS ROS2 IRF3 IRF7 NFκB2
Atf4, Fos, Ncf2, Irf3 22 61 6 22 61 6 ROS ROS2 IRF3 CRE AP1
Creb1, Fos, Ncf2, Irf3 22 61 6 22 61 6 ROS ROS2 IRF3 CRE AP1
Creb3, Fos, Ncf2, Irf3 22 61 6 22 61 6 ROS ROS2 IRF3 CRE AP1
Fos, Ncf2, Creb5, Irf3 22 61 6 22 61 6 ROS ROS2 IRF3 CRE AP1
Atf4, Fos, Ncf4, Irf3 22 61 6 22 61 6 ROS ROS2 IRF3 CRE AP1
Creb1, Fos, Ncf4, Irf3 22 61 6 22 61 6 ROS ROS2 IRF3 CRE AP1
Creb3, Fos, Ncf4, Irf3 22 61 6 22 61 6 ROS ROS2 IRF3 CRE AP1
Fos, Ncf4, Creb5, Irf3 22 61 6 22 61 6 ROS ROS2 IRF3 CRE AP1
Atf4, Ncf2, Nfkbia, Irf3 37 92 6 37 92 6 ROS ROS2 IRF3 CRE NFκB
Creb1, Ncf2, Nfkbia, Irf3 37 92 6 37 92 6 ROS ROS2 IRF3 CRE NFκB
Creb3, Ncf2, Nfkbia, Irf3 37 92 6 37 92 6 ROS ROS2 IRF3 CRE NFκB
Ncf2, Nfkbia, Creb5, Irf3 37 92 6 37 92 6 ROS ROS2 IRF3 CRE NFκB
Atf4, Ncf4, Nfkbia, Irf3 37 92 6 37 92 6 ROS ROS2 IRF3 CRE NFκB
Creb1, Ncf4, Nfkbia, Irf3 37 92 6 37 92 6 ROS ROS2 IRF3 CRE NFκB
Creb3, Ncf4, Nfkbia, Irf3 37 92 6 37 92 6 ROS ROS2 IRF3 CRE NFκB
Ncf4, Nfkbia, Creb5, Irf3 37 92 6 37 92 6 ROS ROS2 IRF3 CRE NFκB
Fbxw11, Atf4, Ncf2, Irf3 24 58 6 24 58 6 ROS ROS2 IRF3 CRE NFκB2
Fbxw11, Creb1, Ncf2, Irf3 24 58 6 24 58 6 ROS ROS2 IRF3 CRE NFκB2
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Fbxw11, Creb3, Ncf2, Irf3 24 58 6 24 58 6 ROS ROS2 IRF3 CRE NFκB2
Fbxw11, Ncf2, Creb5, Irf3 24 58 6 24 58 6 ROS ROS2 IRF3 CRE NFκB2
Fbxw11, Atf4, Ncf4, Irf3 24 58 6 24 58 6 ROS ROS2 IRF3 CRE NFκB2
Fbxw11, Creb1, Ncf4, Irf3 24 58 6 24 58 6 ROS ROS2 IRF3 CRE NFκB2
Fbxw11, Creb3, Ncf4, Irf3 24 58 6 24 58 6 ROS ROS2 IRF3 CRE NFκB2
Fbxw11, Ncf4, Creb5, Irf3 24 58 6 24 58 6 ROS ROS2 IRF3 CRE NFκB2
Fos, Ncf2, Nfkbia, Irf3 33 83 5 33 83 5 ROS ROS2 IRF3 AP1NFκB
Fos, Ncf4, Nfkbia, Irf3 33 83 5 33 83 5 ROS ROS2 IRF3 AP1NFκB
Fbxw11, Fos, Ncf2, Irf3 20 49 5 20 49 5 ROS ROS2 IRF3 AP1 NFκB2
Fbxw11, Fos, Ncf4, Irf3 20 49 5 20 49 5 ROS ROS2 IRF3 AP1 NFκB2
Fbxw11, Ncf2, Nfkbia, Irf3 39 100 5 39 100 5 ROS ROS2 IRF3 NFκB NFκB2
Fbxw11, Ncf4, Nfkbia, Irf3 39 100 5 39 100 5 ROS ROS2 IRF3 NFκB NFκB2
Atf4, Fos, Ncf2, Irf7 23 65 6 23 65 6 ROS ROS2 IRF7 CRE AP1
Creb1, Fos, Ncf2, Irf7 23 65 6 23 65 6 ROS ROS2 IRF7 CRE AP1
Creb3, Fos, Ncf2, Irf7 23 65 6 23 65 6 ROS ROS2 IRF7 CRE AP1
Fos, Ncf2, Creb5, Irf7 23 65 6 23 65 6 ROS ROS2 IRF7 CRE AP1
Atf4, Fos, Ncf4, Irf7 23 65 6 23 65 6 ROS ROS2 IRF7 CRE AP1
Creb1, Fos, Ncf4, Irf7 23 65 6 23 65 6 ROS ROS2 IRF7 CRE AP1
Creb3, Fos, Ncf4, Irf7 23 65 6 23 65 6 ROS ROS2 IRF7 CRE AP1
Fos, Ncf4, Creb5, Irf7 23 65 6 23 65 6 ROS ROS2 IRF7 CRE AP1
Atf4, Ncf2, Nfkbia, Irf7 38 96 6 38 96 6 ROS ROS2 IRF7 CRE NFκB
Creb1, Ncf2, Nfkbia, Irf7 38 96 6 38 96 6 ROS ROS2 IRF7 CRE NFκB
Creb3, Ncf2, Nfkbia, Irf7 38 96 6 38 96 6 ROS ROS2 IRF7 CRE NFκB
Ncf2, Nfkbia, Creb5, Irf7 38 96 6 38 96 6 ROS ROS2 IRF7 CRE NFκB
Atf4, Ncf4, Nfkbia, Irf7 38 96 6 38 96 6 ROS ROS2 IRF7 CRE NFκB
Creb1, Ncf4, Nfkbia, Irf7 38 96 6 38 96 6 ROS ROS2 IRF7 CRE NFκB
Creb3, Ncf4, Nfkbia, Irf7 38 96 6 38 96 6 ROS ROS2 IRF7 CRE NFκB
Ncf4, Nfkbia, Creb5, Irf7 38 96 6 38 96 6 ROS ROS2 IRF7 CRE NFκB
Fbxw11, Atf4, Ncf2, Irf7 25 62 6 25 62 6 ROS ROS2 IRF7 CRE NFκB2
Fbxw11, Creb1, Ncf2, Irf7 25 62 6 25 62 6 ROS ROS2 IRF7 CRE NFκB2
Fbxw11, Creb3, Ncf2, Irf7 25 62 6 25 62 6 ROS ROS2 IRF7 CRE NFκB2
Fbxw11, Ncf2, Creb5, Irf7 25 62 6 25 62 6 ROS ROS2 IRF7 CRE NFκB2
Fbxw11, Atf4, Ncf4, Irf7 25 62 6 25 62 6 ROS ROS2 IRF7 CRE NFκB2
Fbxw11, Creb1, Ncf4, Irf7 25 62 6 25 62 6 ROS ROS2 IRF7 CRE NFκB2
Fbxw11, Creb3, Ncf4, Irf7 25 62 6 25 62 6 ROS ROS2 IRF7 CRE NFκB2
Fbxw11, Ncf4, Creb5, Irf7 25 62 6 25 62 6 ROS ROS2 IRF7 CRE NFκB2
Fos, Ncf2, Nfkbia, Irf7 34 87 5 34 87 5 ROS ROS2 IRF7 AP1NFκB
Fos, Ncf4, Nfkbia, Irf7 34 87 5 34 87 5 ROS ROS2 IRF7 AP1NFκB
Fbxw11, Fos, Ncf2, Irf7 21 53 5 21 53 5 ROS ROS2 IRF7 AP1 NFκB2
Fbxw11, Fos, Ncf4, Irf7 21 53 5 21 53 5 ROS ROS2 IRF7 AP1 NFκB2
Fbxw11, Ncf2, Nfkbia, Irf7 40 104 5 40 104 5 ROS ROS2 IRF7 NFκB NFκB2
Fbxw11, Ncf4, Nfkbia, Irf7 40 104 5 40 104 5 ROS ROS2 IRF7 NFκB NFκB2
Atf4, Fos, Ncf2, Nfkbia 37 94 5 37 94 5 ROS ROS2 CRE AP1NFκB
Creb1, Fos, Ncf2, Nfkbia 37 94 5 37 94 5 ROS ROS2 CRE AP1NFκB
Creb3, Fos, Ncf2, Nfkbia 37 94 5 37 94 5 ROS ROS2 CRE AP1NFκB
Fos, Ncf2, Nfkbia, Creb5 37 94 5 37 94 5 ROS ROS2 CRE AP1NFκB
Atf4, Fos, Ncf4, Nfkbia 37 94 5 37 94 5 ROS ROS2 CRE AP1NFκB
Creb1, Fos, Ncf4, Nfkbia 37 94 5 37 94 5 ROS ROS2 CRE AP1NFκB
Creb3, Fos, Ncf4, Nfkbia 37 94 5 37 94 5 ROS ROS2 CRE AP1NFκB
Fos, Ncf4, Nfkbia, Creb5 37 94 5 37 94 5 ROS ROS2 CRE AP1NFκB
Fbxw11, Atf4, Fos, Ncf2 24 60 5 24 60 5 ROS ROS2 CRE AP1 NFκB2
Fbxw11, Creb1, Fos, Ncf2 24 60 5 24 60 5 ROS ROS2 CRE AP1 NFκB2
Fbxw11, Creb3, Fos, Ncf2 24 60 5 24 60 5 ROS ROS2 CRE AP1 NFκB2
Fbxw11, Fos, Ncf2, Creb5 24 60 5 24 60 5 ROS ROS2 CRE AP1 NFκB2
Fbxw11, Atf4, Fos, Ncf4 24 60 5 24 60 5 ROS ROS2 CRE AP1 NFκB2
Fbxw11, Creb1, Fos, Ncf4 24 60 5 24 60 5 ROS ROS2 CRE AP1 NFκB2
Fbxw11, Creb3, Fos, Ncf4 24 60 5 24 60 5 ROS ROS2 CRE AP1 NFκB2
Fbxw11, Fos, Ncf4, Creb5 24 60 5 24 60 5 ROS ROS2 CRE AP1 NFκB2
Fbxw11, Atf4, Ncf2, Nfkbia 43 111 5 43 111 5 ROS ROS2 CRE NFκB NFκB2
Fbxw11, Creb1, Ncf2, Nfkbia 43 111 5 43 111 5 ROS ROS2 CRE NFκB NFκB2
Fbxw11, Creb3, Ncf2, Nfkbia 43 111 5 43 111 5 ROS ROS2 CRE NFκB NFκB2
Fbxw11, Ncf2, Nfkbia, Creb5 43 111 5 43 111 5 ROS ROS2 CRE NFκB NFκB2
Fbxw11, Atf4, Ncf4, Nfkbia 43 111 5 43 111 5 ROS ROS2 CRE NFκB NFκB2
Fbxw11, Creb1, Ncf4, Nfkbia 43 111 5 43 111 5 ROS ROS2 CRE NFκB NFκB2
Fbxw11, Creb3, Ncf4, Nfkbia 43 111 5 43 111 5 ROS ROS2 CRE NFκB NFκB2
Fbxw11, Ncf4, Nfkbia, Creb5 43 111 5 43 111 5 ROS ROS2 CRE NFκB NFκB2
Fbxw11, Fos, Ncf2, Nfkbia 39 102 4 39 102 4 ROS ROS2 AP1 NFκB NFκB2
Fbxw11, Fos, Ncf4, Nfkbia 39 102 4 39 102 4 ROS ROS2 AP1 NFκB NFκB2
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Atf4, Fos, Pkcz, Irf7, Irf3 56 144 13 56 144 13 ROS IRF3 IRF7 CRE AP1
Creb1, Fos, Pkcz, Irf7, Irf3 56 144 13 56 144 13 ROS IRF3 IRF7 CRE AP1
Creb3, Fos, Pkcz, Irf7, Irf3 56 144 13 56 144 13 ROS IRF3 IRF7 CRE AP1
Fos, Pkcz, Creb5, Irf7, Irf3 56 144 13 56 144 13 ROS IRF3 IRF7 CRE AP1
Atf4, Nfkbia, Pkcz, Irf7, Irf3 64 159 12 64 159 12 ROS IRF3 IRF7 CRE NFκB
Creb1, Nfkbia, Pkcz, Irf7, Irf3 64 159 12 64 159 12 ROS IRF3 IRF7 CRE NFκB
Creb3, Nfkbia, Pkcz, Irf7, Irf3 64 159 12 64 159 12 ROS IRF3 IRF7 CRE NFκB
Nfkbia, Pkcz, Creb5, Irf7, Irf3 64 159 12 64 159 12 ROS IRF3 IRF7 CRE NFκB
Fbxw11, Atf4, Pkcz, Irf7, Irf3 58 141 12 58 141 12 ROS IRF3 IRF7 CRE NFκB2
Fbxw11, Creb1, Pkcz, Irf7, Irf3 58 141 12 58 141 12 ROS IRF3 IRF7 CRE NFκB2
Fbxw11, Creb3, Pkcz, Irf7, Irf3 58 141 12 58 141 12 ROS IRF3 IRF7 CRE NFκB2
Fbxw11, Pkcz, Creb5, Irf7, Irf3 58 141 12 58 141 12 ROS IRF3 IRF7 CRE NFκB2
Fos, Nfkbia, Pkcz, Irf7, Irf3 60 150 11 60 150 11 ROS IRF3 IRF7 AP1NFκB
Fbxw11, Fos, Pkcz, Irf7, Irf3 54 132 11 54 132 11 ROS IRF3 IRF7 AP1 NFκB2
Fbxw11, Nfkbia, Pkcz, Irf7, Irf3 65 163 10 65 163 10 ROS IRF3 IRF7 NFκB NFκB2
Atf4, Fos, Nfkbia, Pkcz, Irf3 63 157 12 63 157 12 ROS IRF3 CRE AP1NFκB
Creb1, Fos, Nfkbia, Pkcz, Irf3 63 157 12 63 157 12 ROS IRF3 CRE AP1NFκB
Creb3, Fos, Nfkbia, Pkcz, Irf3 63 157 12 63 157 12 ROS IRF3 CRE AP1NFκB
Fos, Nfkbia, Pkcz, Creb5, Irf3 63 157 12 63 157 12 ROS IRF3 CRE AP1NFκB
Fbxw11, Atf4, Fos, Pkcz, Irf3 57 139 12 57 139 12 ROS IRF3 CRE AP1 NFκB2
Fbxw11, Creb1, Fos, Pkcz, Irf3 57 139 12 57 139 12 ROS IRF3 CRE AP1 NFκB2
Fbxw11, Creb3, Fos, Pkcz, Irf3 57 139 12 57 139 12 ROS IRF3 CRE AP1 NFκB2
Fbxw11, Fos, Pkcz, Creb5, Irf3 57 139 12 57 139 12 ROS IRF3 CRE AP1 NFκB2
Fbxw11, Atf4, Nfkbia, Pkcz, Irf3 68 166 11 68 166 11 ROS IRF3 CRE NFκB NFκB2
Fbxw11, Creb1, Nfkbia, Pkcz, Irf3 68 166 11 68 166 11 ROS IRF3 CRE NFκB NFκB2
Fbxw11, Creb3, Nfkbia, Pkcz, Irf3 68 166 11 68 166 11 ROS IRF3 CRE NFκB NFκB2
Fbxw11, Nfkbia, Pkcz, Creb5, Irf3 68 166 11 68 166 11 ROS IRF3 CRE NFκB NFκB2
Fbxw11, Fos, Nfkbia, Pkcz, Irf3 64 157 10 64 157 10 ROS IRF3 AP1 NFκB NFκB2
Atf4, Fos, Nfkbia, Pkcz, Irf7 64 161 12 64 161 12 ROS IRF7 CRE AP1NFκB
Creb1, Fos, Nfkbia, Pkcz, Irf7 64 161 12 64 161 12 ROS IRF7 CRE AP1NFκB
Creb3, Fos, Nfkbia, Pkcz, Irf7 64 161 12 64 161 12 ROS IRF7 CRE AP1NFκB
Fos, Nfkbia, Pkcz, Creb5, Irf7 64 161 12 64 161 12 ROS IRF7 CRE AP1NFκB
Fbxw11, Atf4, Fos, Pkcz, Irf7 58 143 12 58 143 12 ROS IRF7 CRE AP1 NFκB2
Fbxw11, Creb1, Fos, Pkcz, Irf7 58 143 12 58 143 12 ROS IRF7 CRE AP1 NFκB2
Fbxw11, Creb3, Fos, Pkcz, Irf7 58 143 12 58 143 12 ROS IRF7 CRE AP1 NFκB2
Fbxw11, Fos, Pkcz, Creb5, Irf7 58 143 12 58 143 12 ROS IRF7 CRE AP1 NFκB2
Fbxw11, Atf4, Nfkbia, Pkcz, Irf7 69 170 11 69 170 11 ROS IRF7 CRE NFκB NFκB2
Fbxw11, Creb1, Nfkbia, Pkcz, Irf7 69 170 11 69 170 11 ROS IRF7 CRE NFκB NFκB2
Fbxw11, Creb3, Nfkbia, Pkcz, Irf7 69 170 11 69 170 11 ROS IRF7 CRE NFκB NFκB2
Fbxw11, Nfkbia, Pkcz, Creb5, Irf7 69 170 11 69 170 11 ROS IRF7 CRE NFκB NFκB2
Fbxw11, Fos, Nfkbia, Pkcz, Irf7 65 161 10 65 161 10 ROS IRF7 AP1 NFκB NFκB2
Fbxw11, Atf4, Fos, Nfkbia, Pkcz 68 168 10 68 168 10 ROS CRE AP1 NFκB NFκB2
Fbxw11, Creb1, Fos, Nfkbia, Pkcz 68 168 10 68 168 10 ROS CRE AP1 NFκB NFκB2
Fbxw11, Creb3, Fos, Nfkbia, Pkcz 68 168 10 68 168 10 ROS CRE AP1 NFκB NFκB2
Fbxw11, Fos, Nfkbia, Pkcz, Creb5 68 168 10 68 168 10 ROS CRE AP1 NFκB NFκB2
Atf4, Fos, Pkca, Pkcb, Pkcd, Irf7, Irf3 41 89 7 41 89 7 ROS2 IRF3 IRF7 CRE AP1
Creb1, Fos, Pkca, Pkcb, Pkcd, Irf7, Irf3 41 89 7 41 89 7 ROS2 IRF3 IRF7 CRE AP1
Creb3, Fos, Pkca, Pkcb, Pkcd, Irf7, Irf3 41 89 7 41 89 7 ROS2 IRF3 IRF7 CRE AP1
Fos, Pkca, Pkcb, Pkcd, Creb5, Irf7, Irf3 41 89 7 41 89 7 ROS2 IRF3 IRF7 CRE AP1
Atf4, Nfkbia, Pkca, Pkcb, Pkcd, Irf7, Irf3 56 120 7 56 120 7 ROS2 IRF3 IRF7 CRE NFκB
Creb1, Nfkbia, Pkca, Pkcb, Pkcd, Irf7, Irf3 56 120 7 56 120 7 ROS2 IRF3 IRF7 CRE NFκB
Creb3, Nfkbia, Pkca, Pkcb, Pkcd, Irf7, Irf3 56 120 7 56 120 7 ROS2 IRF3 IRF7 CRE NFκB
Nfkbia, Pkca, Pkcb, Pkcd, Creb5, Irf7, Irf3 56 120 7 56 120 7 ROS2 IRF3 IRF7 CRE NFκB
Fbxw11, Atf4, Pkca, Pkcb, Pkcd, Irf7, Irf3 43 86 7 43 86 7 ROS2 IRF3 IRF7 CRE NFκB2
Fbxw11, Creb1, Pkca, Pkcb, Pkcd, Irf7, Irf3 43 86 7 43 86 7 ROS2 IRF3 IRF7 CRE NFκB2
Fbxw11, Creb3, Pkca, Pkcb, Pkcd, Irf7, Irf3 43 86 7 43 86 7 ROS2 IRF3 IRF7 CRE NFκB2
Fbxw11, Pkca, Pkcb, Pkcd, Creb5, Irf7, Irf3 43 86 7 43 86 7 ROS2 IRF3 IRF7 CRE NFκB2
Fos, Nfkbia, Pkca, Pkcb, Pkcd, Irf7, Irf3 52 111 6 52 111 6 ROS2 IRF3 IRF7 AP1NFκB
Fbxw11, Fos, Pkca, Pkcb, Pkcd, Irf7, Irf3 39 77 6 39 77 6 ROS2 IRF3 IRF7 AP1 NFκB2
Fbxw11, Nfkbia, Pkca, Pkcb, Pkcd, Irf7, Irf3 58 128 6 58 128 6 ROS2 IRF3 IRF7 NFκB NFκB2
Atf4, Fos, Nfkbia, Pkca, Pkcb, Pkcd, Irf3 55 118 7 55 118 7 ROS2 IRF3 CRE AP1NFκB
Creb1, Fos, Nfkbia, Pkca, Pkcb, Pkcd, Irf3 55 118 7 55 118 7 ROS2 IRF3 CRE AP1NFκB
Creb3, Fos, Nfkbia, Pkca, Pkcb, Pkcd, Irf3 55 118 7 55 118 7 ROS2 IRF3 CRE AP1NFκB
Fos, Nfkbia, Pkca, Pkcb, Pkcd, Creb5, Irf3 55 118 7 55 118 7 ROS2 IRF3 CRE AP1NFκB
Fbxw11, Atf4, Fos, Pkca, Pkcb, Pkcd, Irf3 42 84 7 42 84 7 ROS2 IRF3 CRE AP1 NFκB2
Fbxw11, Creb1, Fos, Pkca, Pkcb, Pkcd, Irf3 42 84 7 42 84 7 ROS2 IRF3 CRE AP1 NFκB2
Fbxw11, Creb3, Fos, Pkca, Pkcb, Pkcd, Irf3 42 84 7 42 84 7 ROS2 IRF3 CRE AP1 NFκB2
Fbxw11, Fos, Pkca, Pkcb, Pkcd, Creb5, Irf3 42 84 7 42 84 7 ROS2 IRF3 CRE AP1 NFκB2
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Fbxw11, Atf4, Nfkbia, Pkca, Pkcb, Pkcd, Irf3 61 135 7 61 135 7 ROS2 IRF3 CRE NFκB NFκB2
Fbxw11, Creb1, Nfkbia, Pkca, Pkcb, Pkcd, Irf3 61 135 7 61 135 7 ROS2 IRF3 CRE NFκB NFκB2
Fbxw11, Creb3, Nfkbia, Pkca, Pkcb, Pkcd, Irf3 61 135 7 61 135 7 ROS2 IRF3 CRE NFκB NFκB2
Fbxw11, Nfkbia, Pkca, Pkcb, Pkcd, Creb5, Irf3 61 135 7 61 135 7 ROS2 IRF3 CRE NFκB NFκB2
Fbxw11, Fos, Nfkbia, Pkca, Pkcb, Pkcd, Irf3 57 126 6 57 126 6 ROS2 IRF3 AP1 NFκB NFκB2
Atf4, Fos, Nfkbia, Pkca, Pkcb, Pkcd, Irf7 56 122 7 56 122 7 ROS2 IRF7 CRE AP1NFκB
Creb1, Fos, Nfkbia, Pkca, Pkcb, Pkcd, Irf7 56 122 7 56 122 7 ROS2 IRF7 CRE AP1NFκB
Creb3, Fos, Nfkbia, Pkca, Pkcb, Pkcd, Irf7 56 122 7 56 122 7 ROS2 IRF7 CRE AP1NFκB
Fos, Nfkbia, Pkca, Pkcb, Pkcd, Creb5, Irf7 56 122 7 56 122 7 ROS2 IRF7 CRE AP1NFκB
Fbxw11, Atf4, Fos, Pkca, Pkcb, Pkcd, Irf7 43 88 7 43 88 7 ROS2 IRF7 CRE AP1 NFκB2
Fbxw11, Creb1, Fos, Pkca, Pkcb, Pkcd, Irf7 43 88 7 43 88 7 ROS2 IRF7 CRE AP1 NFκB2
Fbxw11, Creb3, Fos, Pkca, Pkcb, Pkcd, Irf7 43 88 7 43 88 7 ROS2 IRF7 CRE AP1 NFκB2
Fbxw11, Fos, Pkca, Pkcb, Pkcd, Creb5, Irf7 43 88 7 43 88 7 ROS2 IRF7 CRE AP1 NFκB2
Fbxw11, Atf4, Nfkbia, Pkca, Pkcb, Pkcd, Irf7 62 139 7 62 139 7 ROS2 IRF7 CRE NFκB NFκB2
Fbxw11, Creb1, Nfkbia, Pkca, Pkcb, Pkcd, Irf7 62 139 7 62 139 7 ROS2 IRF7 CRE NFκB NFκB2
Fbxw11, Creb3, Nfkbia, Pkca, Pkcb, Pkcd, Irf7 62 139 7 62 139 7 ROS2 IRF7 CRE NFκB NFκB2
Fbxw11, Nfkbia, Pkca, Pkcb, Pkcd, Creb5, Irf7 62 139 7 62 139 7 ROS2 IRF7 CRE NFκB NFκB2
Fbxw11, Fos, Nfkbia, Pkca, Pkcb, Pkcd, Irf7 58 130 6 58 130 6 ROS2 IRF7 AP1 NFκB NFκB2
Fbxw11, Atf4, Fos, Nfkbia, Pkca, Pkcb, Pkcd 61 137 6 61 137 6 ROS2 CRE AP1 NFκB NFκB2
Fbxw11, Creb1, Fos, Nfkbia, Pkca, Pkcb, Pkcd 61 137 6 61 137 6 ROS2 CRE AP1 NFκB NFκB2
Fbxw11, Creb3, Fos, Nfkbia, Pkca, Pkcb, Pkcd 61 137 6 61 137 6 ROS2 CRE AP1 NFκB NFκB2
Fbxw11, Fos, Nfkbia, Pkca, Pkcb, Pkcd, Creb5 61 137 6 61 137 6 ROS2 CRE AP1 NFκB NFκB2
Atf4, Fos, Nfkbia, Irf7, Irf3 45 115 7 45 115 7 IRF3 IRF7 CRE AP1NFκB
Creb1, Fos, Nfkbia, Irf7, Irf3 45 115 7 45 115 7 IRF3 IRF7 CRE AP1NFκB
Creb3, Fos, Nfkbia, Irf7, Irf3 45 115 7 45 115 7 IRF3 IRF7 CRE AP1NFκB
Fos, Nfkbia, Creb5, Irf7, Irf3 45 115 7 45 115 7 IRF3 IRF7 CRE AP1NFκB
Fbxw11, Atf4, Fos, Irf7, Irf3 32 81 7 32 81 7 IRF3 IRF7 CRE AP1 NFκB2
Fbxw11, Creb1, Fos, Irf7, Irf3 32 81 7 32 81 7 IRF3 IRF7 CRE AP1 NFκB2
Fbxw11, Creb3, Fos, Irf7, Irf3 32 81 7 32 81 7 IRF3 IRF7 CRE AP1 NFκB2
Fbxw11, Fos, Creb5, Irf7, Irf3 32 81 7 32 81 7 IRF3 IRF7 CRE AP1 NFκB2
Fbxw11, Atf4, Fos, Nfkbia, Irf3 50 130 7 50 130 7 IRF3 CRE AP1 NFκB NFκB2
Fbxw11, Creb1, Fos, Nfkbia, Irf3 50 130 7 50 130 7 IRF3 CRE AP1 NFκB NFκB2
Fbxw11, Creb3, Fos, Nfkbia, Irf3 50 130 7 50 130 7 IRF3 CRE AP1 NFκB NFκB2
Fbxw11, Fos, Nfkbia, Creb5, Irf3 50 130 7 50 130 7 IRF3 CRE AP1 NFκB NFκB2
Fbxw11, Atf4, Fos, Nfkbia, Irf7 51 134 7 51 134 7 IRF7 CRE AP1 NFκB NFκB2
Fbxw11, Creb1, Fos, Nfkbia, Irf7 51 134 7 51 134 7 IRF7 CRE AP1 NFκB NFκB2
Fbxw11, Creb3, Fos, Nfkbia, Irf7 51 134 7 51 134 7 IRF7 CRE AP1 NFκB NFκB2
Fbxw11, Fos, Nfkbia, Creb5, Irf7 51 134 7 51 134 7 IRF7 CRE AP1 NFκB NFκB2
Fbxw11, Casp3, Nfkbia, Traf6, Map3k3, Map3k7,
Tab1, Ube2v1, Tab3, Tab2, Ube2n
117 239 11 117 239 11 IRF7 AP1 AP12 NFκB NFκB2
Fbxw11, Nfkbia, Traf6, Map3k3, Map3k7, Ecsit,
Tab1, Ube2v1, Tab3, Tab2, Ube2n
117 239 11 117 239 11 IRF7 AP1 AP12 NFκB NFκB2
Atf4, Fos, Ncf2, Irf7, Irf3 28 78 7 28 78 7 ROS ROS2 IRF3 IRF7 CRE AP1
Creb1, Fos, Ncf2, Irf7, Irf3 28 78 7 28 78 7 ROS ROS2 IRF3 IRF7 CRE AP1
Creb3, Fos, Ncf2, Irf7, Irf3 28 78 7 28 78 7 ROS ROS2 IRF3 IRF7 CRE AP1
Fos, Ncf2, Creb5, Irf7, Irf3 28 78 7 28 78 7 ROS ROS2 IRF3 IRF7 CRE AP1
Atf4, Fos, Ncf4, Irf7, Irf3 28 78 7 28 78 7 ROS ROS2 IRF3 IRF7 CRE AP1
Creb1, Fos, Ncf4, Irf7, Irf3 28 78 7 28 78 7 ROS ROS2 IRF3 IRF7 CRE AP1
Creb3, Fos, Ncf4, Irf7, Irf3 28 78 7 28 78 7 ROS ROS2 IRF3 IRF7 CRE AP1
Fos, Ncf4, Creb5, Irf7, Irf3 28 78 7 28 78 7 ROS ROS2 IRF3 IRF7 CRE AP1
Atf4, Ncf2, Nfkbia, Irf7, Irf3 43 109 7 43 109 7 ROS ROS2 IRF3 IRF7 CRE NFκB
Creb1, Ncf2, Nfkbia, Irf7, Irf3 43 109 7 43 109 7 ROS ROS2 IRF3 IRF7 CRE NFκB
Creb3, Ncf2, Nfkbia, Irf7, Irf3 43 109 7 43 109 7 ROS ROS2 IRF3 IRF7 CRE NFκB
Ncf2, Nfkbia, Creb5, Irf7, Irf3 43 109 7 43 109 7 ROS ROS2 IRF3 IRF7 CRE NFκB
Atf4, Ncf4, Nfkbia, Irf7, Irf3 43 109 7 43 109 7 ROS ROS2 IRF3 IRF7 CRE NFκB
Creb1, Ncf4, Nfkbia, Irf7, Irf3 43 109 7 43 109 7 ROS ROS2 IRF3 IRF7 CRE NFκB
Creb3, Ncf4, Nfkbia, Irf7, Irf3 43 109 7 43 109 7 ROS ROS2 IRF3 IRF7 CRE NFκB
Ncf4, Nfkbia, Creb5, Irf7, Irf3 43 109 7 43 109 7 ROS ROS2 IRF3 IRF7 CRE NFκB
Fbxw11, Atf4, Ncf2, Irf7, Irf3 30 75 7 30 75 7 ROS ROS2 IRF3 IRF7 CRE NFκB2
Fbxw11, Creb1, Ncf2, Irf7, Irf3 30 75 7 30 75 7 ROS ROS2 IRF3 IRF7 CRE NFκB2
Fbxw11, Creb3, Ncf2, Irf7, Irf3 30 75 7 30 75 7 ROS ROS2 IRF3 IRF7 CRE NFκB2
Fbxw11, Ncf2, Creb5, Irf7, Irf3 30 75 7 30 75 7 ROS ROS2 IRF3 IRF7 CRE NFκB2
Fbxw11, Atf4, Ncf4, Irf7, Irf3 30 75 7 30 75 7 ROS ROS2 IRF3 IRF7 CRE NFκB2
Fbxw11, Creb1, Ncf4, Irf7, Irf3 30 75 7 30 75 7 ROS ROS2 IRF3 IRF7 CRE NFκB2
Fbxw11, Creb3, Ncf4, Irf7, Irf3 30 75 7 30 75 7 ROS ROS2 IRF3 IRF7 CRE NFκB2
Fbxw11, Ncf4, Creb5, Irf7, Irf3 30 75 7 30 75 7 ROS ROS2 IRF3 IRF7 CRE NFκB2
Fos, Ncf2, Nfkbia, Irf7, Irf3 39 100 6 39 100 6 ROS ROS2 IRF3 IRF7 AP1NFκB
Fos, Ncf4, Nfkbia, Irf7, Irf3 39 100 6 39 100 6 ROS ROS2 IRF3 IRF7 AP1NFκB
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Fbxw11, Fos, Ncf2, Irf7, Irf3 26 66 6 26 66 6 ROS ROS2 IRF3 IRF7 AP1 NFκB2
Fbxw11, Fos, Ncf4, Irf7, Irf3 26 66 6 26 66 6 ROS ROS2 IRF3 IRF7 AP1 NFκB2
Fbxw11, Ncf2, Nfkbia, Irf7, Irf3 45 117 6 45 117 6 ROS ROS2 IRF3 IRF7 NFκB NFκB2
Fbxw11, Ncf4, Nfkbia, Irf7, Irf3 45 117 6 45 117 6 ROS ROS2 IRF3 IRF7 NFκB NFκB2
Atf4, Fos, Ncf2, Nfkbia, Irf3 42 107 7 42 107 7 ROS ROS2 IRF3 CRE AP1NFκB
Creb1, Fos, Ncf2, Nfkbia, Irf3 42 107 7 42 107 7 ROS ROS2 IRF3 CRE AP1NFκB
Creb3, Fos, Ncf2, Nfkbia, Irf3 42 107 7 42 107 7 ROS ROS2 IRF3 CRE AP1NFκB
Fos, Ncf2, Nfkbia, Creb5, Irf3 42 107 7 42 107 7 ROS ROS2 IRF3 CRE AP1NFκB
Atf4, Fos, Ncf4, Nfkbia, Irf3 42 107 7 42 107 7 ROS ROS2 IRF3 CRE AP1NFκB
Creb1, Fos, Ncf4, Nfkbia, Irf3 42 107 7 42 107 7 ROS ROS2 IRF3 CRE AP1NFκB
Creb3, Fos, Ncf4, Nfkbia, Irf3 42 107 7 42 107 7 ROS ROS2 IRF3 CRE AP1NFκB
Fos, Ncf4, Nfkbia, Creb5, Irf3 42 107 7 42 107 7 ROS ROS2 IRF3 CRE AP1NFκB
Fbxw11, Atf4, Fos, Ncf2, Irf3 29 73 7 29 73 7 ROS ROS2 IRF3 CRE AP1 NFκB2
Fbxw11, Creb1, Fos, Ncf2, Irf3 29 73 7 29 73 7 ROS ROS2 IRF3 CRE AP1 NFκB2
Fbxw11, Creb3, Fos, Ncf2, Irf3 29 73 7 29 73 7 ROS ROS2 IRF3 CRE AP1 NFκB2
Fbxw11, Fos, Ncf2, Creb5, Irf3 29 73 7 29 73 7 ROS ROS2 IRF3 CRE AP1 NFκB2
Fbxw11, Atf4, Fos, Ncf4, Irf3 29 73 7 29 73 7 ROS ROS2 IRF3 CRE AP1 NFκB2
Fbxw11, Creb1, Fos, Ncf4, Irf3 29 73 7 29 73 7 ROS ROS2 IRF3 CRE AP1 NFκB2
Fbxw11, Creb3, Fos, Ncf4, Irf3 29 73 7 29 73 7 ROS ROS2 IRF3 CRE AP1 NFκB2
Fbxw11, Fos, Ncf4, Creb5, Irf3 29 73 7 29 73 7 ROS ROS2 IRF3 CRE AP1 NFκB2
Fbxw11, Atf4, Ncf2, Nfkbia, Irf3 48 124 7 48 124 7 ROS ROS2 IRF3 CRE NFκB NFκB2
Fbxw11, Creb1, Ncf2, Nfkbia, Irf3 48 124 7 48 124 7 ROS ROS2 IRF3 CRE NFκB NFκB2
Fbxw11, Creb3, Ncf2, Nfkbia, Irf3 48 124 7 48 124 7 ROS ROS2 IRF3 CRE NFκB NFκB2
Fbxw11, Ncf2, Nfkbia, Creb5, Irf3 48 124 7 48 124 7 ROS ROS2 IRF3 CRE NFκB NFκB2
Fbxw11, Atf4, Ncf4, Nfkbia, Irf3 48 124 7 48 124 7 ROS ROS2 IRF3 CRE NFκB NFκB2
Fbxw11, Creb1, Ncf4, Nfkbia, Irf3 48 124 7 48 124 7 ROS ROS2 IRF3 CRE NFκB NFκB2
Fbxw11, Creb3, Ncf4, Nfkbia, Irf3 48 124 7 48 124 7 ROS ROS2 IRF3 CRE NFκB NFκB2
Fbxw11, Ncf4, Nfkbia, Creb5, Irf3 48 124 7 48 124 7 ROS ROS2 IRF3 CRE NFκB NFκB2
Fbxw11, Fos, Ncf2, Nfkbia, Irf3 44 115 6 44 115 6 ROS ROS2 IRF3 AP1 NFκB NFκB2
Fbxw11, Fos, Ncf4, Nfkbia, Irf3 44 115 6 44 115 6 ROS ROS2 IRF3 AP1 NFκB NFκB2
Atf4, Fos, Ncf2, Nfkbia, Irf7 43 111 7 43 111 7 ROS ROS2 IRF7 CRE AP1NFκB
Creb1, Fos, Ncf2, Nfkbia, Irf7 43 111 7 43 111 7 ROS ROS2 IRF7 CRE AP1NFκB
Creb3, Fos, Ncf2, Nfkbia, Irf7 43 111 7 43 111 7 ROS ROS2 IRF7 CRE AP1NFκB
Fos, Ncf2, Nfkbia, Creb5, Irf7 43 111 7 43 111 7 ROS ROS2 IRF7 CRE AP1NFκB
Atf4, Fos, Ncf4, Nfkbia, Irf7 43 111 7 43 111 7 ROS ROS2 IRF7 CRE AP1NFκB
Creb1, Fos, Ncf4, Nfkbia, Irf7 43 111 7 43 111 7 ROS ROS2 IRF7 CRE AP1NFκB
Creb3, Fos, Ncf4, Nfkbia, Irf7 43 111 7 43 111 7 ROS ROS2 IRF7 CRE AP1NFκB
Fos, Ncf4, Nfkbia, Creb5, Irf7 43 111 7 43 111 7 ROS ROS2 IRF7 CRE AP1NFκB
Fbxw11, Atf4, Fos, Ncf2, Irf7 30 77 7 30 77 7 ROS ROS2 IRF7 CRE AP1 NFκB2
Fbxw11, Creb1, Fos, Ncf2, Irf7 30 77 7 30 77 7 ROS ROS2 IRF7 CRE AP1 NFκB2
Fbxw11, Creb3, Fos, Ncf2, Irf7 30 77 7 30 77 7 ROS ROS2 IRF7 CRE AP1 NFκB2
Fbxw11, Fos, Ncf2, Creb5, Irf7 30 77 7 30 77 7 ROS ROS2 IRF7 CRE AP1 NFκB2
Fbxw11, Atf4, Fos, Ncf4, Irf7 30 77 7 30 77 7 ROS ROS2 IRF7 CRE AP1 NFκB2
Fbxw11, Creb1, Fos, Ncf4, Irf7 30 77 7 30 77 7 ROS ROS2 IRF7 CRE AP1 NFκB2
Fbxw11, Creb3, Fos, Ncf4, Irf7 30 77 7 30 77 7 ROS ROS2 IRF7 CRE AP1 NFκB2
Fbxw11, Fos, Ncf4, Creb5, Irf7 30 77 7 30 77 7 ROS ROS2 IRF7 CRE AP1 NFκB2
Fbxw11, Atf4, Ncf2, Nfkbia, Irf7 49 128 7 49 128 7 ROS ROS2 IRF7 CRE NFκB NFκB2
Fbxw11, Creb1, Ncf2, Nfkbia, Irf7 49 128 7 49 128 7 ROS ROS2 IRF7 CRE NFκB NFκB2
Fbxw11, Creb3, Ncf2, Nfkbia, Irf7 49 128 7 49 128 7 ROS ROS2 IRF7 CRE NFκB NFκB2
Fbxw11, Ncf2, Nfkbia, Creb5, Irf7 49 128 7 49 128 7 ROS ROS2 IRF7 CRE NFκB NFκB2
Fbxw11, Atf4, Ncf4, Nfkbia, Irf7 49 128 7 49 128 7 ROS ROS2 IRF7 CRE NFκB NFκB2
Fbxw11, Creb1, Ncf4, Nfkbia, Irf7 49 128 7 49 128 7 ROS ROS2 IRF7 CRE NFκB NFκB2
Fbxw11, Creb3, Ncf4, Nfkbia, Irf7 49 128 7 49 128 7 ROS ROS2 IRF7 CRE NFκB NFκB2
Fbxw11, Ncf4, Nfkbia, Creb5, Irf7 49 128 7 49 128 7 ROS ROS2 IRF7 CRE NFκB NFκB2
Fbxw11, Fos, Ncf2, Nfkbia, Irf7 45 119 6 45 119 6 ROS ROS2 IRF7 AP1 NFκB NFκB2
Fbxw11, Fos, Ncf4, Nfkbia, Irf7 45 119 6 45 119 6 ROS ROS2 IRF7 AP1 NFκB NFκB2
Fbxw11, Atf4, Fos, Ncf2, Nfkbia 48 126 6 48 126 6 ROS ROS2 CRE AP1 NFκB NFκB2
Fbxw11, Creb1, Fos, Ncf2, Nfkbia 48 126 6 48 126 6 ROS ROS2 CRE AP1 NFκB NFκB2
Fbxw11, Creb3, Fos, Ncf2, Nfkbia 48 126 6 48 126 6 ROS ROS2 CRE AP1 NFκB NFκB2
Fbxw11, Fos, Ncf2, Nfkbia, Creb5 48 126 6 48 126 6 ROS ROS2 CRE AP1 NFκB NFκB2
Fbxw11, Atf4, Fos, Ncf4, Nfkbia 48 126 6 48 126 6 ROS ROS2 CRE AP1 NFκB NFκB2
Fbxw11, Creb1, Fos, Ncf4, Nfkbia 48 126 6 48 126 6 ROS ROS2 CRE AP1 NFκB NFκB2
Fbxw11, Creb3, Fos, Ncf4, Nfkbia 48 126 6 48 126 6 ROS ROS2 CRE AP1 NFκB NFκB2
Fbxw11, Fos, Ncf4, Nfkbia, Creb5 48 126 6 48 126 6 ROS ROS2 CRE AP1 NFκB NFκB2
Atf4, Fos, Nfkbia, Pkcz, Irf7, Irf3 69 174 13 69 174 13 ROS IRF3 IRF7 CRE AP1NFκB
Creb1, Fos, Nfkbia, Pkcz, Irf7, Irf3 69 174 13 69 174 13 ROS IRF3 IRF7 CRE AP1NFκB
Creb3, Fos, Nfkbia, Pkcz, Irf7, Irf3 69 174 13 69 174 13 ROS IRF3 IRF7 CRE AP1NFκB
Fos, Nfkbia, Pkcz, Creb5, Irf7, Irf3 69 174 13 69 174 13 ROS IRF3 IRF7 CRE AP1NFκB
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Fbxw11, Atf4, Fos, Pkcz, Irf7, Irf3 63 156 13 63 156 13 ROS IRF3 IRF7 CRE AP1 NFκB2
Fbxw11, Creb1, Fos, Pkcz, Irf7, Irf3 63 156 13 63 156 13 ROS IRF3 IRF7 CRE AP1 NFκB2
Fbxw11, Creb3, Fos, Pkcz, Irf7, Irf3 63 156 13 63 156 13 ROS IRF3 IRF7 CRE AP1 NFκB2
Fbxw11, Fos, Pkcz, Creb5, Irf7, Irf3 63 156 13 63 156 13 ROS IRF3 IRF7 CRE AP1 NFκB2
Fbxw11, Atf4, Nfkbia, Pkcz, Irf7, Irf3 74 187 12 74 187 12 ROS IRF3 IRF7 CRE NFκB NFκB2
Fbxw11, Creb1, Nfkbia, Pkcz, Irf7, Irf3 74 187 12 74 187 12 ROS IRF3 IRF7 CRE NFκB NFκB2
Fbxw11, Creb3, Nfkbia, Pkcz, Irf7, Irf3 74 187 12 74 187 12 ROS IRF3 IRF7 CRE NFκB NFκB2
Fbxw11, Nfkbia, Pkcz, Creb5, Irf7, Irf3 74 187 12 74 187 12 ROS IRF3 IRF7 CRE NFκB NFκB2
Fbxw11, Fos, Nfkbia, Pkcz, Irf7, Irf3 70 178 11 70 178 11 ROS IRF3 IRF7 AP1 NFκB NFκB2
Fbxw11, Atf4, Fos, Nfkbia, Pkcz, Irf3 73 181 12 73 181 12 ROS IRF3 CRE AP1 NFκB NFκB2
Fbxw11, Creb1, Fos, Nfkbia, Pkcz, Irf3 73 181 12 73 181 12 ROS IRF3 CRE AP1 NFκB NFκB2
Fbxw11, Creb3, Fos, Nfkbia, Pkcz, Irf3 73 181 12 73 181 12 ROS IRF3 CRE AP1 NFκB NFκB2
Fbxw11, Fos, Nfkbia, Pkcz, Creb5, Irf3 73 181 12 73 181 12 ROS IRF3 CRE AP1 NFκB NFκB2
Fbxw11, Atf4, Fos, Nfkbia, Pkcz, Irf7 74 185 12 74 185 12 ROS IRF7 CRE AP1 NFκB NFκB2
Fbxw11, Creb1, Fos, Nfkbia, Pkcz, Irf7 74 185 12 74 185 12 ROS IRF7 CRE AP1 NFκB NFκB2
Fbxw11, Creb3, Fos, Nfkbia, Pkcz, Irf7 74 185 12 74 185 12 ROS IRF7 CRE AP1 NFκB NFκB2
Fbxw11, Fos, Nfkbia, Pkcz, Creb5, Irf7 74 185 12 74 185 12 ROS IRF7 CRE AP1 NFκB NFκB2
Atf4, Fos, Nfkbia, Pkca, Pkcb, Pkcd, Irf7, Irf3 61 135 8 61 135 8 ROS2 IRF3 IRF7 CRE AP1NFκB
Creb1, Fos, Nfkbia, Pkca, Pkcb, Pkcd, Irf7, Irf3 61 135 8 61 135 8 ROS2 IRF3 IRF7 CRE AP1NFκB
Creb3, Fos, Nfkbia, Pkca, Pkcb, Pkcd, Irf7, Irf3 61 135 8 61 135 8 ROS2 IRF3 IRF7 CRE AP1NFκB
Fos, Nfkbia, Pkca, Pkcb, Pkcd, Creb5, Irf7, Irf3 61 135 8 61 135 8 ROS2 IRF3 IRF7 CRE AP1NFκB
Fbxw11, Atf4, Fos, Pkca, Pkcb, Pkcd, Irf7, Irf3 48 101 8 48 101 8 ROS2 IRF3 IRF7 CRE AP1 NFκB2
Fbxw11, Creb1, Fos, Pkca, Pkcb, Pkcd, Irf7, Irf3 48 101 8 48 101 8 ROS2 IRF3 IRF7 CRE AP1 NFκB2
Fbxw11, Creb3, Fos, Pkca, Pkcb, Pkcd, Irf7, Irf3 48 101 8 48 101 8 ROS2 IRF3 IRF7 CRE AP1 NFκB2
Fbxw11, Fos, Pkca, Pkcb, Pkcd, Creb5, Irf7, Irf3 48 101 8 48 101 8 ROS2 IRF3 IRF7 CRE AP1 NFκB2
Fbxw11, Atf4, Nfkbia, Pkca, Pkcb, Pkcd, Irf7, Irf3 67 152 8 67 152 8 ROS2 IRF3 IRF7 CRE NFκB NFκB2
Fbxw11, Creb1, Nfkbia, Pkca, Pkcb, Pkcd, Irf7, Irf3 67 152 8 67 152 8 ROS2 IRF3 IRF7 CRE NFκB NFκB2
Fbxw11, Creb3, Nfkbia, Pkca, Pkcb, Pkcd, Irf7, Irf3 67 152 8 67 152 8 ROS2 IRF3 IRF7 CRE NFκB NFκB2
Fbxw11, Nfkbia, Pkca, Pkcb, Pkcd, Creb5, Irf7, Irf3 67 152 8 67 152 8 ROS2 IRF3 IRF7 CRE NFκB NFκB2
Fbxw11, Fos, Nfkbia, Pkca, Pkcb, Pkcd, Irf7, Irf3 63 143 7 63 143 7 ROS2 IRF3 IRF7 AP1 NFκB NFκB2
Fbxw11, Atf4, Fos, Nfkbia, Pkca, Pkcb, Pkcd, Irf3 66 150 8 66 150 8 ROS2 IRF3 CRE AP1 NFκB NFκB2
Fbxw11, Creb1, Fos, Nfkbia, Pkca, Pkcb, Pkcd, Irf3 66 150 8 66 150 8 ROS2 IRF3 CRE AP1 NFκB NFκB2
Fbxw11, Creb3, Fos, Nfkbia, Pkca, Pkcb, Pkcd, Irf3 66 150 8 66 150 8 ROS2 IRF3 CRE AP1 NFκB NFκB2
Fbxw11, Fos, Nfkbia, Pkca, Pkcb, Pkcd, Creb5, Irf3 66 150 8 66 150 8 ROS2 IRF3 CRE AP1 NFκB NFκB2
Fbxw11, Atf4, Fos, Nfkbia, Pkca, Pkcb, Pkcd, Irf7 67 154 8 67 154 8 ROS2 IRF7 CRE AP1 NFκB NFκB2
Fbxw11, Creb1, Fos, Nfkbia, Pkca, Pkcb, Pkcd, Irf7 67 154 8 67 154 8 ROS2 IRF7 CRE AP1 NFκB NFκB2
Fbxw11, Creb3, Fos, Nfkbia, Pkca, Pkcb, Pkcd, Irf7 67 154 8 67 154 8 ROS2 IRF7 CRE AP1 NFκB NFκB2
Fbxw11, Fos, Nfkbia, Pkca, Pkcb, Pkcd, Creb5, Irf7 67 154 8 67 154 8 ROS2 IRF7 CRE AP1 NFκB NFκB2
Atf4, Fos, Ncf2, Nfkbia, Irf7, Irf3 48 124 8 48 124 8 ROS ROS2 IRF3 IRF7 CRE
AP1NFκB
Creb1, Fos, Ncf2, Nfkbia, Irf7, Irf3 48 124 8 48 124 8 ROS ROS2 IRF3 IRF7 CRE
AP1NFκB
Creb3, Fos, Ncf2, Nfkbia, Irf7, Irf3 48 124 8 48 124 8 ROS ROS2 IRF3 IRF7 CRE
AP1NFκB
Fos, Ncf2, Nfkbia, Creb5, Irf7, Irf3 48 124 8 48 124 8 ROS ROS2 IRF3 IRF7 CRE
AP1NFκB
Atf4, Fos, Ncf4, Nfkbia, Irf7, Irf3 48 124 8 48 124 8 ROS ROS2 IRF3 IRF7 CRE
AP1NFκB
Creb1, Fos, Ncf4, Nfkbia, Irf7, Irf3 48 124 8 48 124 8 ROS ROS2 IRF3 IRF7 CRE
AP1NFκB
Creb3, Fos, Ncf4, Nfkbia, Irf7, Irf3 48 124 8 48 124 8 ROS ROS2 IRF3 IRF7 CRE
AP1NFκB
Fos, Ncf4, Nfkbia, Creb5, Irf7, Irf3 48 124 8 48 124 8 ROS ROS2 IRF3 IRF7 CRE
AP1NFκB
Fbxw11, Atf4, Fos, Ncf2, Irf7, Irf3 35 90 8 35 90 8 ROS ROS2 IRF3 IRF7 CRE AP1
NFκB2
Fbxw11, Creb1, Fos, Ncf2, Irf7, Irf3 35 90 8 35 90 8 ROS ROS2 IRF3 IRF7 CRE AP1
NFκB2
Fbxw11, Creb3, Fos, Ncf2, Irf7, Irf3 35 90 8 35 90 8 ROS ROS2 IRF3 IRF7 CRE AP1
NFκB2
Fbxw11, Fos, Ncf2, Creb5, Irf7, Irf3 35 90 8 35 90 8 ROS ROS2 IRF3 IRF7 CRE AP1
NFκB2
Fbxw11, Atf4, Fos, Ncf4, Irf7, Irf3 35 90 8 35 90 8 ROS ROS2 IRF3 IRF7 CRE AP1
NFκB2
Fbxw11, Creb1, Fos, Ncf4, Irf7, Irf3 35 90 8 35 90 8 ROS ROS2 IRF3 IRF7 CRE AP1
NFκB2
Fbxw11, Creb3, Fos, Ncf4, Irf7, Irf3 35 90 8 35 90 8 ROS ROS2 IRF3 IRF7 CRE AP1
NFκB2
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Fbxw11, Fos, Ncf4, Creb5, Irf7, Irf3 35 90 8 35 90 8 ROS ROS2 IRF3 IRF7 CRE AP1
NFκB2
Fbxw11, Atf4, Ncf2, Nfkbia, Irf7, Irf3 54 141 8 54 141 8 ROS ROS2 IRF3 IRF7 CRE NFκB
NFκB2
Fbxw11, Creb1, Ncf2, Nfkbia, Irf7, Irf3 54 141 8 54 141 8 ROS ROS2 IRF3 IRF7 CRE NFκB
NFκB2
Fbxw11, Creb3, Ncf2, Nfkbia, Irf7, Irf3 54 141 8 54 141 8 ROS ROS2 IRF3 IRF7 CRE NFκB
NFκB2
Fbxw11, Ncf2, Nfkbia, Creb5, Irf7, Irf3 54 141 8 54 141 8 ROS ROS2 IRF3 IRF7 CRE NFκB
NFκB2
Fbxw11, Atf4, Ncf4, Nfkbia, Irf7, Irf3 54 141 8 54 141 8 ROS ROS2 IRF3 IRF7 CRE NFκB
NFκB2
Fbxw11, Creb1, Ncf4, Nfkbia, Irf7, Irf3 54 141 8 54 141 8 ROS ROS2 IRF3 IRF7 CRE NFκB
NFκB2
Fbxw11, Creb3, Ncf4, Nfkbia, Irf7, Irf3 54 141 8 54 141 8 ROS ROS2 IRF3 IRF7 CRE NFκB
NFκB2
Fbxw11, Ncf4, Nfkbia, Creb5, Irf7, Irf3 54 141 8 54 141 8 ROS ROS2 IRF3 IRF7 CRE NFκB
NFκB2
Fbxw11, Fos, Ncf2, Nfkbia, Irf7, Irf3 50 132 7 50 132 7 ROS ROS2 IRF3 IRF7 AP1 NFκB
NFκB2
Fbxw11, Fos, Ncf4, Nfkbia, Irf7, Irf3 50 132 7 50 132 7 ROS ROS2 IRF3 IRF7 AP1 NFκB
NFκB2
Fbxw11, Atf4, Fos, Ncf2, Nfkbia, Irf3 53 139 8 53 139 8 ROS ROS2 IRF3 CRE AP1 NFκB
NFκB2
Fbxw11, Creb1, Fos, Ncf2, Nfkbia, Irf3 53 139 8 53 139 8 ROS ROS2 IRF3 CRE AP1 NFκB
NFκB2
Fbxw11, Creb3, Fos, Ncf2, Nfkbia, Irf3 53 139 8 53 139 8 ROS ROS2 IRF3 CRE AP1 NFκB
NFκB2
Fbxw11, Fos, Ncf2, Nfkbia, Creb5, Irf3 53 139 8 53 139 8 ROS ROS2 IRF3 CRE AP1 NFκB
NFκB2
Fbxw11, Atf4, Fos, Ncf4, Nfkbia, Irf3 53 139 8 53 139 8 ROS ROS2 IRF3 CRE AP1 NFκB
NFκB2
Fbxw11, Creb1, Fos, Ncf4, Nfkbia, Irf3 53 139 8 53 139 8 ROS ROS2 IRF3 CRE AP1 NFκB
NFκB2
Fbxw11, Creb3, Fos, Ncf4, Nfkbia, Irf3 53 139 8 53 139 8 ROS ROS2 IRF3 CRE AP1 NFκB
NFκB2
Fbxw11, Fos, Ncf4, Nfkbia, Creb5, Irf3 53 139 8 53 139 8 ROS ROS2 IRF3 CRE AP1 NFκB
NFκB2
Fbxw11, Atf4, Fos, Ncf2, Nfkbia, Irf7 54 143 8 54 143 8 ROS ROS2 IRF7 CRE AP1 NFκB
NFκB2
Fbxw11, Creb1, Fos, Ncf2, Nfkbia, Irf7 54 143 8 54 143 8 ROS ROS2 IRF7 CRE AP1 NFκB
NFκB2
Fbxw11, Creb3, Fos, Ncf2, Nfkbia, Irf7 54 143 8 54 143 8 ROS ROS2 IRF7 CRE AP1 NFκB
NFκB2
Fbxw11, Fos, Ncf2, Nfkbia, Creb5, Irf7 54 143 8 54 143 8 ROS ROS2 IRF7 CRE AP1 NFκB
NFκB2
Fbxw11, Atf4, Fos, Ncf4, Nfkbia, Irf7 54 143 8 54 143 8 ROS ROS2 IRF7 CRE AP1 NFκB
NFκB2
Fbxw11, Creb1, Fos, Ncf4, Nfkbia, Irf7 54 143 8 54 143 8 ROS ROS2 IRF7 CRE AP1 NFκB
NFκB2
Fbxw11, Creb3, Fos, Ncf4, Nfkbia, Irf7 54 143 8 54 143 8 ROS ROS2 IRF7 CRE AP1 NFκB
NFκB2
Fbxw11, Fos, Ncf4, Nfkbia, Creb5, Irf7 54 143 8 54 143 8 ROS ROS2 IRF7 CRE AP1 NFκB
NFκB2
Fbxw11, Atf4, Fos, Nfkbia, Pkcz, Irf7, Irf3 79 202 13 79 202 13 ROS IRF3 IRF7 CRE AP1 NFκB
NFκB2
Fbxw11, Creb1, Fos, Nfkbia, Pkcz, Irf7, Irf3 79 202 13 79 202 13 ROS IRF3 IRF7 CRE AP1 NFκB
NFκB2
Fbxw11, Creb3, Fos, Nfkbia, Pkcz, Irf7, Irf3 79 202 13 79 202 13 ROS IRF3 IRF7 CRE AP1 NFκB
NFκB2
Fbxw11, Fos, Nfkbia, Pkcz, Creb5, Irf7, Irf3 79 202 13 79 202 13 ROS IRF3 IRF7 CRE AP1 NFκB
NFκB2
Fbxw11, Atf4, Fos, Nfkbia, Pkca, Pkcb, Pkcd, Irf7,
Irf3
72 167 9 72 167 9 ROS2 IRF3 IRF7 CRE AP1 NFκB
NFκB2
Fbxw11, Creb1, Fos, Nfkbia, Pkca, Pkcb, Pkcd, Irf7,
Irf3
72 167 9 72 167 9 ROS2 IRF3 IRF7 CRE AP1 NFκB
NFκB2
Fbxw11, Creb3, Fos, Nfkbia, Pkca, Pkcb, Pkcd, Irf7,
Irf3
72 167 9 72 167 9 ROS2 IRF3 IRF7 CRE AP1 NFκB
NFκB2
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Fbxw11, Fos, Nfkbia, Pkca, Pkcb, Pkcd, Creb5, Irf7,
Irf3
72 167 9 72 167 9 ROS2 IRF3 IRF7 CRE AP1 NFκB
NFκB2
Fbxw11, Atf4, Fos, Ncf2, Nfkbia, Irf7, Irf3 59 156 9 59 156 9 ROS ROS2 IRF3 IRF7 CRE AP1
NFκB NFκB2
Fbxw11, Creb1, Fos, Ncf2, Nfkbia, Irf7, Irf3 59 156 9 59 156 9 ROS ROS2 IRF3 IRF7 CRE AP1
NFκB NFκB2
Fbxw11, Creb3, Fos, Ncf2, Nfkbia, Irf7, Irf3 59 156 9 59 156 9 ROS ROS2 IRF3 IRF7 CRE AP1
NFκB NFκB2
Fbxw11, Fos, Ncf2, Nfkbia, Creb5, Irf7, Irf3 59 156 9 59 156 9 ROS ROS2 IRF3 IRF7 CRE AP1
NFκB NFκB2
Fbxw11, Atf4, Fos, Ncf4, Nfkbia, Irf7, Irf3 59 156 9 59 156 9 ROS ROS2 IRF3 IRF7 CRE AP1
NFκB NFκB2
Fbxw11, Creb1, Fos, Ncf4, Nfkbia, Irf7, Irf3 59 156 9 59 156 9 ROS ROS2 IRF3 IRF7 CRE AP1
NFκB NFκB2
Fbxw11, Creb3, Fos, Ncf4, Nfkbia, Irf7, Irf3 59 156 9 59 156 9 ROS ROS2 IRF3 IRF7 CRE AP1
NFκB NFκB2
Fbxw11, Fos, Ncf4, Nfkbia, Creb5, Irf7, Irf3 59 156 9 59 156 9 ROS ROS2 IRF3 IRF7 CRE AP1
NFκB NFκB2
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Appendix E
Genes used for Network Reconstruction
List of genes in the Core Set (CS) and Predicted Sets (PSs) PS1, and PS2.
Entrez gene ID in parenthesis.
CS (all genes in network)
Atf4 ( 11911 )
Btrc ( 12234 )
Ccl2 ( 20296 )
Ccl4 ( 20303 )
Ccr2 ( 12772 )
Creb1 ( 12912 )
Creb3 ( 12913 )
Cyba ( 13057 )
Cybb ( 13058 )
Fos ( 14281 )
Il1b ( 16176 )
Il6 ( 16193 )
Irf3 ( 54131 )
Irf7 ( 54123 )
Jun ( 16476 )
Map2k4 ( 26398 )
Map2k7 ( 26400 )
Mapk8 ( 26419 )
Myd88 ( 17874 )
Ncf1 ( 17969 )
Ncf2 ( 17970 )
Ncf4 ( 17972 )
Nfkb1 ( 18033 )
Rac1 ( 19353 )
Rela ( 19697 )
Tnf ( 21926 )
Traf6 ( 22034 )
Vav1 ( 22324 )
PS1 Underlined genes are part of the final gene network.
Arf6 ( 11845 )
Arrb2 ( 216869 )
Cd86 ( 12524 )
Hspd1 ( 15510 )
Irak1 ( 16179 )
Irf1 ( 16362 )
Irf4 ( 16364 )
Lyn ( 17096 )
Mapkapk2 ( 17164 )
Nfkbia ( 18035 )
Nr1d1 ( 217166 )
Pdpk1 ( 18607 )
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Peli1 ( 67245 )
Prkce ( 18754 )
Ripk2 ( 192656 )
Rps6ka3 ( 110651 )
Rsad2 ( 58185 )
Tirap ( 117149 )
Tlr1 ( 21897 )
Tlr2 ( 24088 )
Tlr4 ( 21898 )
Tlr7 ( 170743 )
Tnfaip3 ( 21929 )
Tnip1 ( 57783 )
Tnip2 ( 231130 )
Traf3 ( 22031 )
Unc93b1 ( 54445 )
PS2 Underlined genes are part of the final gene network.
Adam8 ( 11501 )
Ahr ( 11622 )
Aim2 ( 383619 )
Axl ( 26362 )
B2m ( 12010 )
Bcap31 ( 27061 )
Bcl10 ( 12042 )
Bcl3 ( 12051 )
Bcl6 ( 12053 )
Bmi1 ( 12151 )
Btk ( 12229 )
C1qa ( 12259 )
C1qb ( 12260 )
C1qc ( 12262 )
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Appendix F
Experimental and simulated gene
trajectories
Shown are the experimental and simulated genes trajectories.
Black: experimental data (LPS condition / TLR4 exitation)
Blue: simulated data using only the gene regulatory network identified in Chap-
ter 3
Red: simulated data using the integrated framework generated in Chapter 4
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